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1. ABSTRACT 
 
The aim of the study was the construction and characterization of a novel, 
fully human immunoRNase (IR). IRs, chimeric proteins made up of a ribonuclease 
(RNase) molecule fused to an antibody moiety, represent a valid alternative to 
immunotoxins (ITs). ITs directed to cell surface molecular targets have shown to 
have a therapeutic potential. However, they also have limitations, mainly 
represented by nonspecific toxicity and by the immunogenicity of their bacterial or 
plant toxins. To circumvent some of these problems, toxins have been replaced by 
mammalian RNases, molecules per se not cytotoxic, which become toxic when 
internalized by target cells. In particular, the use of human RNases, 
physiologically present in extracellular fluids and tissues, has allowed the 
construction of immunoconjugates potentially less immunogenic. Obviously, the 
preparation of fully human IRs is highly desiderable to obtain effective and tumor-
selective, but also immunocompatible immunoagents. 
A novel, fully human IR was prepared in the present study. It is made up 
of human pancreas RNase (HP-RNase), fused to a human single chain variable 
fragment (scFv) directed to the ErbB2 receptor. This scFv, named Erbicin, has 
been isolated in our laboratory from a large human scFv phagemid library. ErbB2, 
a tyrosine kinase receptor, represents one of the most specific tumor associated 
antigens (TAA), since this receptor is overexpressed in clinically significant 
tumors, such as breast, ovary and lung carcinomas. On the other hand, in normal 
tissues it is expressed only in certain epithelial cell types. 
The novel, fully human anti-ErbB2 IR, named hERB-hRNase, was 
successfully expressed in bacterial cells and isolated from the periplasmic fraction. 
The characterization of its biological properties showed that the human IR retains 
the enzymatic activity of the wild-type ribonuclease (HP-RNase) and specifically 
binds to ErbB2-positive cells with high affinity, as the parental scFv. Furthermore, 
our studies showed that the human IR undergoes receptor-mediated endocytosis in 
target cells. In fact, the IR behaves as an immunoprotoxin and upon internalization 
by target cells becomes selectively cytotoxic in a dose-dependent manner at 
nanomolar concentrations. Administered in five doses of 1.5 mg/kg to mice 
bearing an ErbB2-positive tumor, hERB-hRNase induced a dramatic reduction of 
tumor volume. 
The immunoconjugate hERB-hRNase is the first fully human antitumor 
IR produced so far, with a high potential as a poorly immunogenic human drug 
devoid of nonspecific toxicity, directed against ErbB2-positive malignancies. 
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2. BACKGROUND 
 
Conventional anticancer treatments, such as radiation and systemic drugs, 
are characterized by the lack of tumor cell specificity and the appearance of 
multidrug resistance (MDR) phenotype (Biedler and Riehm 1970). 
Immunotherapy represents an alternative and effective strategy to fight cancer, 
mainly based on antibodies specifically directed to cancer cells expressing a tumor 
associated antigen (TAA) (Trikha et al. 2002; Ross et al. 2003). The Food and 
Drug Administration has approved several monoclonal antibodies as therapeutic 
agents to treat tumors, and an increasing number are undergoing clinical 
evaluation (Brekke and Sandlie 2003). Examples of approved antibodies are 
humanized or human-mouse chimeric monoclonal antibodies, such as anti-ErbB2 
trastuzumab (Herceptin) and anti-CD20 rituximab (Rituxan), widely used against 
breast cancer and non-Hodgkin’s lymphoma, respectively (Milenic 2002). To 
enhance their clinical potential, antibodies also have been coupled to cytotoxic 
agents or radionuclides (Allen 2002). 
Immunotoxins (ITs), made up of antibodies or miniantibodies, such as 
single chain variable fragments (scFvs), fused to toxins, have been proposed as 
anticancer drugs during the past two decades (Pastan and FitzGerald 1991; Reiter 
and Pastan 1998). These chimeric proteins combine the potent toxicity of toxins 
with the antigen specificity of antibodies. They have been shown to kill cancer 
cells with IC50 values (the concentration for 50% cytotoxicity) in the 0.01-1 nM 
range (Reiter et al. 1994; Wels et al. 1995). However, obstacles to full success of 
ITs in the treatment of cancer include: 1) immunogenicity due to the murine nature 
of the immunomoieties and the plant or bacterial nature of the toxin moieties; 2) 
high aspecific toxicity; 3) their large size, which hinders their diffusion into bulky 
tumors. 
These three factors have greatly limited the therapeutic potential of ITs 
(Weiner et al. 1989; Schindler et al. 2001), especially because of the occurence of 
vascular leak syndrome (Schnell et al. 2000; Soler-Rodriguez et al. 1993; Baluna 
and Vitetta 1999). Some of these effects have been alleviated by the development 
of humanized antibodies and the use of scFvs (single chain variable fragments), 
consisting of the antigen-binding domains of Ig heavy (VH) and light (VL) chain 
regions connected by a flexible peptide linker (Huston et al. 1988), all encoded by 
a single gene (Fig. 1). scFvs have proved particularly useful, since they can easily 
penetrate solid tumors, fully preserving the specificity of the parental antibody. 
However, the toxins themselves remain a problem. 
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An alternative and more recent strategy in anticancer immunotherapy is 
that based on immunoconjugates in which the toxin is replaced by a ribonuclease 
(RNase) molecule (Rybak and Newton 1999) (Fig. 1). The key to this strategy is 
that mammalian RNases, although per se not cytotoxic, become cytotoxic when 
they are internalized by the target cell, i.e. the cell that displays on its surface the 
epitope recognized by the antibody moiety (Rybak and Newton 1999). This is why 
the most suitable epitopes for the selection of an antibody for these 
immunoconjugates are cell receptors, since the anti-receptor antibody can mimic 
the receptor ligand and be internalized. Thus, these fusion proteins are not ITs but 
rather immunoprotoxins. They have been called immunoRNases (IRs) (De 
Lorenzo et al. 2002a). 
IRs were prepared with various RNases, each fused to a monoclonal 
antibody raised against a cell receptor (De Lorenzo et al. 2002a; Zewe et al. 1997; 
Suwa et al. 1999; Stocker et al. 2003). The first IR was prepared with bovine 
pancreatic RNase A (Newton et al. 1992) fused to an anti-transferrin receptor 
antibody, and shown to be cytotoxic to tumor cells expressing the antigen in the 
200-500 nM range. Another IR was prepared by fusing onconase, an amphibian 
RNase isolated from Rana Pipiens oocytes, with an anti-CD22 monoclonal 
antibody against B-cell lymphoma (Newton et al. 2001). Satisfactory results were 
obtained with this immunoconjugate in the treatment of human lymphomas. IRs 
were also prepared using bovine seminal RNase (BS-RNase). This RNase was 
shown to possess per se a selective anti-tumor activity in vitro and in vivo 
(Matousek 1973; Laccetti et al. 1994; Pouckova et al. 1998; Soucek et al. 1996), 
since it is the only mammalian RNase to be selectively internalized by tumor cells. 
Immunoconjugates were prepared by fusing BS-RNase with a single chain 
variable fragment (scFv) specific for the oncofetal antigen placental alkaline 
phosphatase (Deonarain and Epenetos 1998). 
The immunocompatibility of IRs as anticancer agents can be greatly 
improved by the use of human RNases, as they are physiologically present in 
extracellular fluids and tissues, and are expected to be much less immunogenic 
than xenogeneic proteins, if not immunogenic at all (Fig. 1). Human RNases used 
for the construction of IRs include eosinophil-derived RNase (EDN) (Newton et 
al. 1994), angiogenin (Newton et al. 1996), and human pancreas ribonuclease (HP-
RNase) (Russo et al. 1993). IRs, made up of human RNases fused to an anti-
transferrin receptor scFv, were prepared (Rybak and Newton 1999). These IRs 
were cytotoxic to tumor cells with IC50 values in the 5-20 nM range. However, the 
abundance of the transferrin receptor at the blood-brain barrier (Zewe et al. 1997), 
which can result in the uptake of high amounts of these immunoconjugates by the 
brain, and the non human origin of the scFv set a limit to the use of these reagents 
as therapeutic drugs. 
A scheme of the IRs produced so far is reported in Table 1. 
 9
 
 
 
 
 
ImmunoRNases 
 
TARGET 
 
RNase 
 
AUTHORS 
 
Transferrin receptor 
 
RNase A 
 
Newton et al. 2002 
 
Placental alkaline 
phosphatase 
 
Bovin seminal RNase 
(BS-RNase) 
 
Deonarain and Epenetos 
1998 
 
CD 22 
 
Onconase 
 
Newton and Rybak 2001
 
Transferrin receptor 
 
Angiogenin 
 
Newton et al. 1996 
 
Transferrin receptor 
 
Eosinophil-derived 
RNase (EDN) 
 
Zewe et al. 1997 
 
Transferrin receptor 
 
Human pancreas RNase 
(HP-RNase) 
 
Zewe et al. 1997 
 
ErbB2 receptor 
 
Human pancreas RNase 
(HP-RNase) 
 
De Lorenzo et al. 2002 
Table 1. Scheme of the IRs produced so far. 
Human RNases are indicated in red. 
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An attractive target for IR-based, directed tumor therapy is the ErbB2 
transmembrane receptor. It is a member of the ErbB superfamily of growth factor 
tyrosine kinase receptors (King et al. 1985), homologous to the EGF receptor 
(King et al. 1985, Yamamoto et al. 1986). Typical to other tyrosine kinase 
receptors, ErbB2 bears an extracellular ligand binding domain capable of 
transmitting a signal that results in the activation of the intracellular portion of the 
protein (Klapper et al. 2000). Central to this activation is an intrinsic tyrosine 
kinase catalytic core showing close resemblance between the receptors, but wide 
variety in the flanking sequences enabling diversity of interactions with receptor-
specific effector proteins (Klapper et al. 2000). Receptor activation results in 
phosphorylation of specific tyrosine residues located within the receptor’s 
cytoplasmic region, which leads to the recruitment of phosphotyrosine-binding 
effector proteins, and subsequent simultaneous stimulation of multiple signaling 
pathways (Klapper et al. 2000). The monomeric molecule is inactive but a dimeric 
form is fully active. The EGF-like ligands act as allosteric modifiers by promoting 
rapid receptor dimerization (Yarden and Schlessinger 1987). A specific ligand for 
ErbB2 is still unknown (Klapper et al. 2000). 
A schematic representation of ErbB2 receptor structural features is 
reported in Fig. 2. 
ErbB2 is highly expressed on several tumor cells, especially in breast, 
ovary and lung carcinomas (Slamon et al. 1989; Tagliabue et al. 1991), as well as 
in salivary gland and gastric tumor-derived cell lines (Fukushige et al. 1986; 
Semba et al. 1985). Its overexpression, which occurs most commonly via gene 
amplification, can reach as many as 2x106 molecules/cell. In normal tissues it is 
expressed at low levels, and only in certain epithelial cell types (Press et al. 1990), 
so we can define this receptor as one of the most specific TAA. ErbB2 plays a key 
role in the development of malignancy, since it potentiates and prolongs the signal 
transduction cascades elicited by ligand activation of other ErbB tyrosine kinase 
receptors (Graus-Porta et al. 1997; Ullrich and Schlessinger 1990). Furthermore, 
overexpression of ErbB2 may also increase resistance of tumor cells to host 
defenses through the evasion of immune surveillance exerted by activated 
macrophages (Hudziak et al. 1988). 
The accessibility of ErbB2 on cell surface and its implication in the 
development of malignancy make it an attractive target for immunotherapy, since 
it is internalized upon ligand binding, an event which can be mimicked by an 
antibody directed towards the receptor that can deliver an RNase into ErbB2-
overexpressing tumor cells. Such a strategy has been successfully tested using a 
murine scFv fused to human pancreas RNase (HP-RNase) (Russo et al. 1993). 
This immunoconjugate, named ERB-HPR (De Lorenzo et al. 2002a), was found to 
be active as a ribonuclease and able to bind and selectively kill ErbB2-positive 
cells. However, the non human origin of the scFv sets a limit to the therapeutic 
 12
potential of this IR. The use of antibody and RNase moieties of human origin for 
the preparation of fully human IRs is highly desiderable to obtain effective and 
tumor-selective but also immunocompatible immunoagents. 
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A clear progress in this area of research consisted of the development of 
the antibody humanization technology with the production of humanized versions 
of rodent antibodies (Carter et al. 1992) with reduced immunogenic potential. A 
humanized version of an anti-ErbB2 murine antibody (Herceptin) is currently in 
use for treatment of advanced breast cancer (Milenic 2002). Fully human scFvs 
have recently been generated with the phage display technology through the 
expression of large repertories of antibody variable regions on filamentous phages 
after their fusion to a phage coat protein (Griffiths et al. 1994; Vaughan et al. 
1996; Sheets et al. 1998). Human scFvs specific to ErbB2 have been produced, 
using for their selection the isolated recombinant extracellular domain (Sheets et 
al. 1998; Schier et al. 1995) or more recently breast tumor cells (Poul et al. 2000). 
Given their high affinity for the receptor, these immunoreagents may be 
considered precious tools as delivery vehicles for specifically directing cytotoxic 
agents to antigen-bearing tumor cells. However, none of these exhibit antitumor 
activity. 
Taking advantage of phage display technology, a novel human anti-
ErbB2 scFv (De Lorenzo et al. 2002b) was isolated in our laboratory from a large 
human scFv phagemid library (Griffiths et al. 1994). A double-selection strategy 
was used and performed on live cells either expressing high levels of the receptor 
antigen or virtually lacking the antigen. Such a strategy is represented in Fig. 3. 
The isolated scFv, named Erbicin, specifically binds to ErbB2-positive cells, 
inhibits receptor autophosphorylation, is internalized in target cells, and strongly 
inhibits their proliferation (De Lorenzo et al. 2002b). These biological properties 
make the human scFv Erbicin a very promising immunoagent for the diagnosis of 
specific tumors and also the ideal candidate to deliver cytotoxic molecules 
specifically to ErbB2-overexpressing tumor cells. 
My research project was aimed at the construction and the 
characterization of a fully human antitumor IR made up of the available human 
scFv Erbicin fused to human pancreas RNase (HP-RNase). This IR, to our 
knowledge the first human IR to be produced (De Lorenzo et al. 2004), has been 
termed hERB-hRNase. It has a high potential as a new antitumor drug against 
ErbB2-positive malignancies, being strong and selective as an anticancer agent, 
poorly immunogenic and devoid of nonspecific toxicity. 
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3. AIMS OF THE STUDY 
 
The aim of the study was the construction, isolation and characterization 
of a novel, fully human IR.  
The first step of the research project was the construction of the cDNA 
encoding the chimeric protein, composed by the human anti-ErbB2 scFv Erbicin 
(De Lorenzo et al. 2002b) fused to human pancreas ribonuclease (HP-RNase) 
(Russo et al. 1993). The cDNA was then used to express the immunoconjugate in 
bacterial cells. The recombinant IR was then isolated from the periplasmic space 
following an appropriate purification protocol. 
The second step of the research project was aimed at the characterization 
of the functional properties of the IR. In particular, analyses were performed to test 
the preservation of the enzymatic activity in the fusion protein, as well as the 
ability of the immunoconjugate to recognize and bind with high affinity ErbB2-
positive tumor cells, and to undergo receptor-mediated endocytosis in target cells. 
In vitro experiments were performed to test the effects of the IR on the 
proliferation of a panel of ErbB2-positive and ErbB2-negative tumor cells. In 
parallel experiments, the cytotoxic activity of hERB-hRNase was compared to that 
of Herceptin, a humanized version of an anti-ErbB2 murine antibody, currently in 
use for treatment of advanced breast cancer (Milenic 2002). 
Experiments were then aimed at testing the stability of hERB-hRNase at 
37°C, which is a critical factor for its potential as a therapeutic agent. 
Finally, in vivo studies were performed to test the effects of the IR on the 
growth of tumors induced in mice by inoculation of ErbB2-positive tumor cells. 
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4.  MATERIALS AND METHODS 
 
 
4.1 Bacterial Strains 
 
Escherichia coli strains SF110 (Meerman and Georgiou 1994) and BL21 
(DE3) (purchased from EMD Biosciences, Inc., Novagen Brand, Madison, WI) 
were used. 
 
 
4.2 Expression Vectors 
 
The expression vector pET22b(+) (Novagen) (Fig. 4), containing the 
sequence encoding the human IR hERB-hRNase, was used to transform E. coli 
BL21 (DE3) strain. 
The phagemid expression vector pHEN2 (Fig. 5) (Nissim et al. 1994), 
available in our laboratory, containing the sequence encoding the human IR 
hERB-hRNase, was used to transform E. coli SF110 strain. 
 
 
4.3 Culture Media for Bacterial Strains 
 
LB (Luria-Bertani) and 2x YT media were prepared as described by 
Sambrook and Russel 2001. 
Culture media were supplemented with antibiotics. Ampicillin (100 
µg/ml) and tetracycline (10 µg/ml), both purchased from Sigma Chemical Co. (St. 
Louis, MO), were added to 2x YT medium, used for E. coli SF110 strain 
transformed with the recombinant pHEN2 expression vector. Ampicillin (100 
µg/ml) was added to LB medium, used for E. coli BL21 (DE3) strain transformed 
with the recombinant pET22b(+) expression vector. 
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4.4 Antibodies 
 
The antibodies used in the current study were the following: Herceptin 
(Genentech, South San Francisco, CA); murine mAb 9E10 directed against the 
myc tag protein (Evan et al. 1985); the IgG fraction from a rabbit anti-HP-RNase 
antiserum (Igtech, Salerno, Italy) purified by affinity chromatography of the 
antiserum on protein A-Sepharose CL-4B (Amersham Biosciences AB, Uppsala, 
Sweden); horseradish peroxidase-conjugated anti-His antibody (Qiagen, Valencia, 
CA); horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin antibody 
(Pierce, Rockford, IL); horseradish peroxidase-conjugated rabbit anti-mouse 
immunoglobulin antibody (Pierce); FITC-conjugated sheep anti-rabbit 
immunoglobulin antibody (Dako, Cambridgeshire, UK). 
 
 
4.5 Cell lines and Culture Conditions 
 
The MDA-MB361 (kindly provided by Dr N. Normanno, Cancer Institute 
of Naples), the SKBR3 cell line from human breast tumor (from American Type 
Culture Collection, Rockville, MD) and the A431 cell line from human epidermoid 
carcinoma (from American Type Culture Collection, Rockville, MD) were 
cultured in RPMI 1640 (Gibco BRL, Life Technologies, Paisley, UK). The MDA-
MB453 cell line from human breast tumor (a gift of H. C. Hurst, ICRF, London), 
and the AG12 (TUBO) cell line from a BALB-neu T mouse-derived mammary 
lobular carcinoma (kindly provided by Dr G. Forni, University of Turin, Italy) 
were grown in DMEM (Gibco BRL). Media were supplemented with 10% fetal 
bovine serum (20% for TUBO cells), 2 mM L-glutamine, 50 Units/ml penicillin, 
and 50 µg/ml streptomycin (all from Life Technologies). Cells were grown at 37ºC 
in a humidified atmosphere containing 5% CO2/95% air. All of the cell lines were 
discarded after 3 months and new lines were obtained from frozen stocks. 
 
 
 4.6 Preparation of Bacterial Competent Cells and Transformation 
 
Single clones of SF110 E. coli strain, grown at 37ºC in LB agar 
containing tetracycline (10 µg/ml), were inoculated into 5 ml of 2x YT medium 
containing the same antibiotic and 1% glucose. In the same manner, single clones 
of BL21 (DE3) E. coli strain, grown at 37ºC in LB agar, were inoculated into 5 ml 
of LB medium. 
Cells of both bacterial strains were incubated at 37ºC on a shaker, and 
grown to an O.D.600 of 0.5. At this point, cells (1.5 ml for each transformation) 
were incubated at 0ºC for 10 minutes, and harvested by centrifugation at 5,000 
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rpm for 5 minutes at 4ºC. Cell pellet was then dissolved in 750 µl of ice-cold 50 
mM CaCl2, and incubated for 20 minutes at 0ºC. Following the incubation, cells 
were again harvested by centrifugation at 5,000 rpm for 5 minutes at 4ºC. Cell 
pellet was then dissolved in 150 µl of the same solution (50 mM CaCl2). 
At this point, competent cells (150 µl) were transformed with plasmidic 
DNA and incubated at 4ºC for 40 minutes. Following the incubaton, heat shock 
was performed by incubation of the cells at 42ºC for 2 minutes, followed by 
incubation at 4ºC for 2 minutes. Following the addition of 1 ml of medium (LB or 
2x YT, depending on the bacterial strain), cells were incubated at 37ºC for 1 hour. 
Cells were then harvested by centrifugation at 5,000 rpm for 3 minutes at room 
temperature. Medium (1 ml) was then removed and cell pellet was dissolved in the 
remaining solution (about 100 µl) and plated on LB agar containing tetracycline 
(10 µg/ml) and ampicillin (100µg/ml), in the case of E. coli SF110 strain, or 
ampicillin (100 µg/ml), in the case of BL21 (DE3) E. coli strain. 
 
 
4.7 Construction of the Chimeric cDNA Encoding hERB-hRNase 
 
A cDNA encoding HP-RNase (Russo et al. 1993) was engineered by two 
successive PCR. Upstream primers (termed A and B) were used to incorporate the 
NotI restriction site at the 5’ end, as well as a spacer sequence, whereas a 
downstream primer (C) was employed to introduce a NotI site at the 3’ end. In the 
first reaction, primers B and C were used. 
The sequences of primers A, B and C are reported in Table 2. 
 
 
 
Oligonucleotide 
A 
 
5’-ATAAGAATGCGGCCGCAAGCGGCGGCCCGGAAGGCGG-3’ 
 
Oligonucleotide 
B 
 
5’-GGCCCGGAAGGCGGCAGCAAAGAATCTAGAGCTAAAAA-3’ 
 
Oligonucleotide 
C 
 
5’-ATAAGAATGCGGCCGCAGAGTCTTCAACAGACG-3’ 
 
Table 2. Sequences of the oligonucleotides employed to engineer the cDNA encoding HP-
RNase. 
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The oligonucleotide B sequence encodes the C-terminal half of the 
spacer. The oligonucleotide C sequence contains the NotI restriction site. In the 
second reaction, primers A and C were used. The oligonucleotide A encodes the 
N-terminal half of the spacer preceded by the NotI site sequence.  
PCR reactions were performed in a final volume of 50 µl, using 20 ng of 
plasmidic DNA as template. The reaction mixture contained the 2 primers (20 µM 
each), dNTPs mixture (0.2 mM), MgSO4 (1 mM), amplification buffer (Invitrogen 
Life Technologies, Inc., Carlsbad, CA) and Pfx enzyme from Pyrococcus (5 U) 
(Invitrogen Life Technologies, Inc., Carlsbad, CA). 
Polymerase chain reaction (PCR) was performed as indicated below: 
 
- Denaturation step:   2 minutes at 95º 
- Amplification step (30 cycles):  2 minutes at 95ºC 
2 minutes at 55ºC 
2 minutes at 37ºC 
- Elongation step (1 cycle):  10 minutes at 73ºC 
 
Following the reaction, the amplified fragment was purified using a DNA 
purification system (Promega Biosciences Inc., San Luis Obispo, CA), and 
digested with NotI restriction enzyme (New England Biolabs, Hertfordshire, UK). 
Digestion of 6 µg of amplified fragment with 20 U of NotI restriction enzyme was 
performed by incubation at 37ºC for 2 hours. Following the digestion, the 
fragment was cloned into the corresponding site of pHEN2 vector (Nissim et al. 
1994), downstream to the sequence encoding the available human anti-ErbB2 scFv 
(De Lorenzo et al. 2002b). To this purpose, ligation was performed using a kit 
purchased from Promega Biosciences Inc. (San Luis Obispo, CA). The phagemid 
expression vector pHEN2 was previously digested with NotI restriction enzyme, 
and treated with shrimp alkaline phosphatase (SAP) (Roche Applied Science, 
Indianapolis, IN). Digested vector (4 µg) was incubated with 20 U of SAP at 37ºC 
for 15 minutes. SAP enzyme was then inactivated by incubation at 65ºC for 10 
minutes. 
Following the ligation, the correct directional insertion of the RNase gene 
in the NotI restriction site was assessed by PCR, using the forward primer A in 
combination to a reverse oligonucleotide corresponding to a vector sequence 
positioned downstream to the NotI site (5’-TGAATTTTCTGTATGAGG-3’). 
Sequence analyses confirmed the expected DNA sequence. The 
assembled gene was then cloned in pET22b(+), a T7 promoter based E. coli 
expression vector, in the NcoI/NotI restriction sites. 
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4.8 Expression of hERB-hRNase 
  
Single clones of E. coli SF110 strain, previously transformed with the 
recombinant pHEN2 expression vector, and grown at 37ºC on LB agar containing 
100 µg/ml ampicillin and 10 µg/ml tetracycline, were inoculated into 5 ml of 2x 
YT medium containing the same antibiotics and 1% glucose. In a similar manner, 
single clones of E. coli BL21 (DE3) strain, previously transformed with the 
recombinant expression vector pET22b(+), and grown at 37ºC on LB agar 
containing 100 µg/ml ampicillin, were inoculated into 5 ml of LB medium 
containing the same antibiotic. Following this step, cells of both E. coli strains 
were grown at 37ºC on a shaker to an O.D.600 of 0.6. At this point, cells were 
inoculated into 1 liter of the same medium containing the necessary antibiotics, 
and grown at 37ºC on a shaker to an O.D.600 of 1. Following bacterial growth, the 
expression of hERB-hRNase was induced by addition of isopropyl-β-D-
thiogalactopyranoside (IPTG). IPTG activates both the T7 promoter of pET22b(+) 
vector, and the lac promoter of pHEN2 vector. In the case of SF110 E. coli strain, 
the addition of IPTG was performed after removal of glucose, present in the 
medium during bacterial growth. To this purpose, SF110 E. coli cells were 
harvested by centrifugation at 6,000 rpm for 20 minutes at room temperature, and 
then suspended in glucose-free medium. In both the expression systems, IPTG was 
added to the cultures to a final concentration of 1 mM, and cells were then grown 
at room temperature overnight on a shaker. Following overnight growth, cells were 
harvested by centrifugation at 6,000 rpm for 20 minutes at 4ºC. 
In order to verify hERB-hRNase expression, an aliquot of cell culture (5 
ml) was removed before and after induction with IPTG. Cells of both aliquots 
(induced and not induced) were harvested by centrifugation at 6,000 rpm for 20 
minutes at 4ºC, and suspended in 100 µl of ice-cold phosphate-buffered saline 
(PBS), pH 8.0, containing 1M NaCl and a cocktail of proteases inhibitors (Roche 
Applied Science, Indianapolis, IN). Following an incubation of 30 minutes at 0ºC, 
periplasmic extract was obtained by centrifugation at 12,000 rpm for 15 minutes at 
4ºC, and analyzed by SDS-PAGE 12%, followed by Coomassie staining, Western 
blot analyses with an anti-His and an anti-HP-RNase antibody, and zymogram 
analyses. 
 
 
4.9 Preparation of Periplasmic Extract for the Isolation of hERB-hRNase 
 
In order to obtain the periplasmic extract, cell pellet was dissolved in ice-
cold 50 mM Tris-HCl, pH 7.4, containing 1 mM EDTA, 20% sucrose and a 
cocktail of proteases inhibitors (Roche Applied Science, Indianapolis, IN), and 
incubated for 1 hour on ice. Following the incubation, the periplasmic extract was 
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obtained by centrifugation at 12,000 rpm for 30 minutes at 4°C. At this point, the 
soluble fraction represented the periplasmic extract, whereas the insoluble fraction 
was solubilised with 4 M urea (Bayly et al. 2002), in order to recover a putative 
fraction of hERB-RNase associated to cell membranes. To this purpose, the 
insoluble fraction was dissolved in 4 M urea and TBS 1x (0.25 M Tris-HCl, pH 
8.0, containing 1.4 M NaCl and 27 mM KCl), and incubated for 1 hour at 4ºC on a 
shaker. Samples were then centrifuged at 22,000 x g for 1 hour at 4ºC. A soluble 
fraction containing the IR was thus obtained. 
 
 
4. 10 Purification of hERB-hRNase 
 
Two alternative protocols were used to isolate hERB-hRNase. 
 
 
4.10.1 Isolation of hERB-hRNase by two Steps of Affinity Chromatography 
 
Periplasmic extract was loaded on an immobilized-metal affinity 
chromatography (IMAC) column, using a cobalt-chelating resin (TALON; 
Clontech, Palo Alto, CA). This kind of chromatography is based on the ability of 
the COOH-terminal hexahistidine tag of the recombinant protein to bind Co+2 ions. 
Sample was incubated with the resin for 2 hours at room temperature on a shaker. 
Wash and elution steps were performed according to the manufacturer’s 
instructions. Following the incubation, the resin was washed with 50 mM 
NaH2PO4, pH 7.0, containing 0.3 M NaCl and 20 mM imidazol. Elution step was 
performed in the presence of a high concentration of imidazol (250 mM), which 
compete with hERB-hRNase for the binding to the Co+2 ions of the resin. 
Further purification was achieved by affinity chromatography using 
uridine 2’,5’- and 3’,5’-diphosphate agarose (pUp agarose, Sigma Chemical Co., 
St. Louis, MO). Briefly, the sample was diluted with sodium acetate buffer, pH 
5.8, containing 0.15 M NaCl, and loaded on the column, previously equilibrated in 
0.1 M sodium acetate buffer, pH 5.8, containing 0.15 M NaCl, 10% glycerol and 
0.005% Tween 20. After extensive washing with the equilibrium buffer, the 
protein was eluted in PBS, pH 7.6, containing 0.5 M NaCl, 10% glycerol and 
0.005% Tween 20. The purity of the final preparation was evaluated by SDS-
PAGE 12%, followed by Coomassie staining, Western blot analyses with an anti-
His and an anti-HP-RNase antibody, and zymogram analyses.  
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4.10.2 Isolation of hERB-hRNase by Hydrophobic Interaction 
Chromatography, Followed by Affinity Chromatography  
 
Periplasmic extract was incubated with the MEP HyperCel matrix 
(BioSepra, Cergy-Saint-Christophe, France) for two hours at room temperature. 
This kind of chromatography is based on the ability of the hydrophobic regions of 
the antibody portion of the immunoconjugate to bind 4-mercapto-ethyl-pyridine 
(MEP). After extensive washes with 50 mM Tris-HCl, pH 8.0, two additional 
wash steps were performed: the first with H20, and the second with 25 mM sodium 
caprylate in 50 mM Tris-HCl, pH 8.0. The MEP HyperCel resin was then 
equilibrated in 50 mM Tris-HCl, pH 8.0 before elution of the protein with 50 mM 
sodium acetate, pH 4.0. The sample was immediately adjusted to pH 7.0, diluted 
with BPER buffer (Bacterial Protein Extraction Buffer, Pierce, Rockford, IL), and 
loaded on an immobilized-metal affinity chromatography (IMAC) column by 
using a cobalt-chelating resin (TALON, Clontech, Palo Alto, CA) for achieving 
further purification. Wash and elution steps were performed according to the 
manufacturer’s recommendations (for details see above). The purity of the final 
preparation was evaluated by SDS-PAGE 12%, followed by Coomassie staining, 
Western blot analyses with an anti-His and an anti-HP-RNase antibody, and 
zymogram analyses. 
 
 
4.10.3 Isolation of hERB-hRNase from the insoluble fraction of bacterial cells 
 
As previously described, a considerable amount of expressed hERB-
hRNase is present in the insoluble fraction obtained from bacterial cells. Such 
immunoconjugate was efficiently recovered by solubilisation with urea (Bayly et 
al. 2002). The recovered IR was isolated by using the hydrophobic interaction 
chromatography (HIC) described above, followed by the affinity chromatography 
based on uridine 2’,5’- and 3’,5’-diphosphate agarose (pUp agarose, Sigma 
Chemical Co., St. Louis, MO) (for details see above). 
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4.11 Gel Electrophoresis (SDS-PAGE) 
 
SDS-PAGE was performed as described by Laemmli 1970. 
 
 
4.11.1 Coomassie Staining 
 
Following gel electrophoresis, gel was incubated for 30 minutes at room 
temperature in 20% isopropanol, containing 10% acetic acid, and 0.1% Coomassie 
Brilliant Blue R250 (Applichem, Darmstadt, Germany). Following the incubation, 
gel was treated with 20% ethanol, containing 7% acetic acid. Such a solution was 
replaced by water when protein bands were detectable. 
 
 
4.11.2 Western Blot Analyses 
 
Following gel electrophoresis, proteins were transferred to PVDF 
membranes (Immobilon-P, Millipore, Billerica, MA) at 25 V overnight at 4°C. At 
this point, membranes were incubated in a blocking solution (5% non-fat milk in 
PBS buffer, containing 0.1% Tween 20) at room temperature for 1 hour. 
Membranes were then washed with PBS buffer containing 0.1% Tween 20, and 
incubated with the IgG fraction from a rabbit anti-HP-RNase antiserum (Igtech, 
Salerno, Italy), purified by affinity chromatography of the antiserum on protein A-
Sepharose CL-4B (Amersham Pharmacia Biotech., Uppsala, Sweden), diluted 
1:1000, or with murine mAb 9E10 directed against the myc tag protein (Evan et al. 
1985) diluted 1:1000, or with horseradish peroxidase-conjugated anti-His antibody 
(Qiagen, Valencia, CA) diluted 1:1000. Primary antibodies were all diluted in PBS 
buffer containing 0.1% Tween 20 and 5% non-fat milk, and incubated with the 
membranes at room temperature for 1 hour on a shaker. Membranes were then 
washed with PBS buffer containing 0.1% Tween 20, and incubated with a 
horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin antibody 
(Pierce, Rockford, IL), or with a horseradish peroxidase-conjugated rabbit anti-
mouse immunoglobulin antibody (Pierce, Rockford, IL). Both the secondary 
antibodies were diluted 1:5000 in PBS buffer, containing 0.1% Tween 20 and 5% 
non-fat milk. Membranes were incubated with the secondary antibodies for 1 hour 
at room temperature on a shaker. Membranes were then washed with PBS buffer 
containing 0.1% Tween 20. Detection by enzyme-linked chemiluminescence 
(enhanced chemiluminescence: ECL) was performed according to the 
manufacturer’s instructions (Super Signal®West-Pico Chemiluminescent 
Substrate, Pierce, Rockford, IL), using a Phosphorimager. 
 
 26
4.11.3 RNase Activity 
 
RNase zymograms, carried out on SDS-PAGE electropherograms, were 
performed as described previously (Blank et al. 1982). Briefly, following 
electrophoresis, gel was incubated for 30 minutes in 50 mM Tris-HCl, pH 7.4, 
containing 25% isopropanol and then equilibrated in 50 mM Tris-HCl, pH 7.4. Gel 
was then incubated at 37ºC for 10 minutes in the same buffer, containing 4 mg/ml 
RNA. Following the incubation, gel was washed with the equilibrium buffer and 
incubated for 15 minutes at room temperature in a solution of 0.2% toluidine blue, 
containing 0.1% acetic acid. Following the coloration step, gel was washed several 
times with water. At the end of the procedure, proteins endowed with enzymatic 
activity were visualized as white bands on a dark background. Bovine seminal 
ribonuclease (BS-RNase) (100-200 ng) was used as a positive control. 
 
 
4.12 RNase Activity Assays 
 
RNase activity was tested using a modified version of the procedure 
described by Bartholeyns et al. 1977, based on assaying acid-soluble products of 
RNA degradation. Yeast RNA (8mg/ml) was incubated for 30 minutes at 37°C 
with the enzyme under test in the reaction buffer (0.05 M Tris-HCl, pH 8.0, 
containing 0.15 M NaCl and 0.05 mg/ml RNase-free BSA). The reaction was 
stopped, and undegraded RNA was precipitated by addition of one volume of cold 
10% perchloric acid, containing 0.25% uranyl acetate. After 15 minutes on ice, the 
A260 of the supernatant, diluted 1:20 with distilled water, was determined. A blank 
reaction was performed in the absence of the enzyme. In this assay, one unit of 
enzymatic activity is defined as the amount of enzyme that generates an increase 
of 1 absorbance unit at 260 nm. 
 
 
4.13 Binding Assays 
 
ErbB2-positive SKBR3, MDA-MB361, MDA-MB453 and AG12 
(TUBO) cells, and ErbB2-negative A431 control cells, harvested in non-
enzymatic dissociation solution (Sigma, St. Louis, MO), were washed with PBS 
and transferred to U-bottom microtiter plates (1x105 cells per well). After 
blocking with PBS containing 6% bovine serum albumin (BSA), the plates were 
incubated with purified immunoagents in ELISA buffer (PBS/BSA 3%) for 90 
minutes. After centrifugation and removal of supernatants, harvested cells were 
washed twice in 200 µl of ELISA buffer, suspended in 100 µl of the same buffer 
and incubated for 1 hour with either rabbit anti-HP-RNase IgGs (for hERB-
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hRNase detection), or with murine anti-myc mAb (for scFv detection), followed 
by peroxidase-conjugated anti-rabbit or anti-mouse IgGs (Pierce, Rockford, IL), 
respectively, according to the source of the primary antibody. After 1 hour, the 
plates were centrifuged, washed with ELISA buffer, and reacted with 3,3’,5,5’-
tetramethylbenzidine (TMB) (Sigma, St. Louis, MO). The reaction was stopped 
by addition of 1N HCl. Binding values were determined from the absorbance at 
450 nm, and reported as the mean of at least three determinations (standard 
deviation ≤ 5%). 
 
 
4.14 Internalization of hERB-hRNase 
 
Cells grown on coverslips to 60% confluency were incubated with the 
immunoagent (20 µg/ml) for 16 hours at 37°C. Cells were then washed, fixed and 
permeabilized as described elsewhere (Becerril et al. 1999). Intracellular IR was 
detected with a rabbit anti-HP-RNase antibody, followed by FITC-conjugated 
sheep antirabbit antibody. Optical confocal sections were taken using a confocal 
microscope (LSM 510; Zeiss, Oberkochen, Germany). 
 
 
4.15 Cytotoxicity Assays 
 
Cells were seeded in 96-well plates (150 µl/well); SKBR3, MDA-
MB361, AG12 (TUBO) and MDA-MB453 cells were seeded at a density of 
1.5x104/well; A431 cells were seeded at a density of 5x103/well. Proteins under 
test were added, and after 72 hours cell counts were determined in triplicate using 
the trypan blue exclusion test. Cell survival was expressed as percentage of viable 
cells in the presence of the protein under test, with respect to control cultures 
grown in the absence of the protein. 
 
 
4.16 Stability of the IR 
 
The stability of hERB-hRNase was determined by incubating the IR at a 
concentration of 0.04 mg/ml in either human or murine serum at 37°C for 24 or 48 
hours. Following the incubation, the samples were tested using the analytical tests 
described above: Western blot analyses, RNase activity assays, and binding assays 
(see above). 
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4.17 In Vivo Antitumor Activity 
 
All of the experiments were performed with 6-week old female 
Balb/cAnNCrlBR mice (Charles River laboratories, Wilmington, MA). AG12 
(TUBO) cells (5x105) were suspended in 0.2 ml sterile PBS and injected 
subcutaneously (day 0) in the right paw. At day 10, tumors were clearly detectable 
(at least 15 mm3 in volume). At day 11, hERB-hRNase, dissolved in PBS, was 
administered 5 times at 72 hours intervals peritumorally or intraperitoneally to two 
groups of five mice at doses of 1,5 mg/kg of body weight. Equimolar doses of 
native HP-RNase or anti-ErbB2 scFv were administered peritumorally to other two 
groups as controls. Another group of control animals was treated with identical 
volumes of sterile PBS. At day 45, blood samples were taken and tested to obtain 
the main hematological parameters. During the treatment period, tumor volumes 
(V) were measured and calculated using the formula of rotational ellipsoid 
V=AxB2/2 (A is axial diameter and B is rotational diameter). All of the mice were 
maintained at the animal facility of the Department of Cellular and Molecular 
Biology and Pathology, University of Naples “Federico II”. The experiments on 
animals described here were conducted in accordance with accepted standards of 
animal care and in accordance with the Italian regulations for the welfare of 
animals used in studies of experimental neoplasia. The School of Medicine 
Institutional Committee on animal care approved the study. 
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5. RESULTS AND DISCUSSION 
 
 
5.1 Construction of the Chimeric cDNA Encoding hERB-hRNase 
 
A cDNA encoding human pancreas ribonuclease (HP-RNase) (Russo et 
al. 1993) was available in our laboratory, inserted in the expression vector 
pET22b(+). It was engineered by two successive PCR (polymerase chain reaction) 
reactions which added a spacer sequence encoding a peptide of 11 residues 
designed to separate the RNase and scFv moieties in the fusion protein. It is known 
that the insertion of a spacer peptide is important to obtain a stable and 
biologically active immunoconjugate (Newton et al. 1996). During the two 
successive PCR reactions, upstream primers were used to incorporate the NotI 
restriction site at the 5’ end, as well as the spacer sequence, whereas a downstream 
primer was employed to introduce a NotI restriction site at the 3’ end (see 
Materials and Methods section for details). The PCR fragment was then digested 
and cloned into the corresponding restriction site of the phagemid expression 
vector pHEN2 (Nissim et al. 1994), downstream to the available sequence 
encoding the available human anti-ErbB2 scFv Erbicin (De Lorenzo et al. 2002b). 
The correct directional insertion of the RNase gene was assessed by PCR (see 
Materials and Methods section for details). Sequence analyses confirmed the 
expected DNA sequence. The cloning strategy is reported in Fig. 6.  
The resulting construct encodes the immunoRNase (IR), henceforth called 
hERB-hRNase, whose structure is shown in Fig. 7 (De Lorenzo et al. 2004). It 
includes the scFv Erbicin at the NH2-terminal end, followed by HP-RNase. A 
linker peptide of 15 residues (SSGGGGSGGGGSGGS) is interposed between VH 
and VL chains of the scFv, whereas a spacer peptide of 11 residues 
(AAASGGPEGGS) is inserted between the antibody fragment and the 
ribonuclease. Two COOH-terminal tags are located downstream to the 
ribonuclease: 1) a hexahistidine tag, useful for the isolation of the IR; 2) a myc tag, 
useful for its identification by Western blot analyses. 
The assembled gene was then cloned in pET22b(+), a T7 promoter based 
Escherichia coli expression vector. This vector was chosen since it has been 
successfully used in our laboratory for the expression at satisfactory yields of other 
proteins, mainly ribonucleases. The resulting construct had the same structure of 
the one previously described (Fig. 7), with the only difference that the sequence 
encoding the myc tag is missing. It is important to mention that both the 
expression vectors, pET22b(+) and pHEN2, are equipped with an upstream pel B 
signal sequence, for the expression of hERB-hRNase as a soluble protein in the 
periplasmic space.  
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5.2 Expression of hERB-hRNase 
 
Both the recombinant expression vectors pET22b(+) and pHEN2 were 
used to express hERB-hRNase in E. coli, with the purpose to compare the IR 
expression levels. 
Cultures of E. coli BL21 (DE3) and SF110 were transformed with the 
recombinant expression vectors pET22b(+) and pHEN2, respectively. E. coli 
BL21 (DE3) cells were then grown at 37°C in LB medium containing ampicillin. 
Resistance to ampicillin is given by the recombinant vector pET22b(+), thus 
allowing to select transformed cells. On the other hand, E. coli SF110 cells were 
grown at 37°C in 2x YT medium containing 1% glucose, tetracycline and 
ampicillin, until the exponential phase of growth was reached. Resistance to 
tetracycline is a feature of SF110 E. coli strain, whereas resistance to ampicillin is 
given by the expression vector pHEN2, thus allowing to select transformed cells. 
In both cases, cells were grown until the exponential phase of growth was reached. 
The expression of hERB-hRNase was induced by addition of isopropyl-β-D-
thiogalactopyranoside (IPTG). IPTG activates both the T7 promoter of pET22b(+) 
vector, and the lac promoter of pHEN2 vector. In the case of SF110 E. coli strain, 
the addition of IPTG was performed after removal of glucose, present in the 
medium during bacterial growth. In both the expression systems, IPTG was added 
to the cultures to a final concentration of 1 mM, and cells were then grown at room 
temperature overnight. Cells were then harvested by centrifugation. The IR was 
expected to be directed to the periplasmic space, because of the presence of the 
upstream pel B signal sequence in both the recombinant expression vectors, 
pET22b(+) and pHEN2. However, exogenous proteins, mainly if toxic, may be 
sequestered in inclusion bodies, when expressed at high levels in bacterial cells. 
For this reason, both periplasmic extracts and insoluble fractions of bacterial cells 
were prepared and analyzed by SDS-PAGE, followed by Western blot analyses 
with an anti-His and an anti-HP-RNase antibody. The results, obtained with both 
the expression vectors, were similar. In both cases, an immunoreactive band of the 
expected size, approximately Mr 46,000, was present in the periplasmic extracts, 
as well as in insoluble fractions. No bands were instead detected in the samples 
prepared from not induced cells. Such a result is reported for the expression vector 
pET22b(+) in Fig. 8, showing the analysis of the periplasmic extract with an anti-
HP-RNase antibody. 
In order to test the enzymatic activity of the IR present in the periplasmic 
space, a zymogram (Blank et al. 1982) was developed using yeast RNA as a 
substrate. An active band, corresponding to the size expected for hERB-hRNase 
(46,000 Da), was detected only in the samples prepared from induced bacteria, 
suggesting that the recombinant IR retains in the periplasmic space its enzymatic 
activity. Such a result is reported in Fig. 8 for the expression vector pET22b(+). 
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Since with the recombinant expression vector pET22b(+) the expression 
levels of hERB-hRNase were about 30% higher than those obtained using the 
expression vector pHEN2, further analyses were performed using the pET22b(+) 
based expression system. 
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5.3 Purification of hERB-hRNase 
 
Two alternative protocols were used to isolate hERB-hRNase from the 
periplasmic space. 
 
 
5.3.1 Isolation of hERB-hRNase by two Steps of Affinity Chromatography 
 
The isolation of the IR was achieved by two steps of affinity 
chromatography. The first step is based on the ability of the COOH-terminal 
hexahistidine tag of the recombinant protein to bind Co+2 ions. The periplasmic 
extract was loaded on an immobilized-metal affinity chromatography (IMAC) 
column, using a cobalt-chelating resin (see Materials and Methods section for 
details). At the end of the chromatography, the selected sample was analyzed by 
SDS-PAGE, followed by Coomassie staining, Western blot analyses with an anti-
HP-RNase antibody and an anti-His antibody, and zymogram. The latter was 
performed to test the ribonuclease activity of the immunoconjugate. The results are 
shown in Fig. 9. The resin selected few molecular species from the material 
present in the periplasmic fraction. Among these, only one immunoreactive band 
of the expected size, approximately Mr 46,000, was detectable by Western blot 
analyses, and demonstrated to be enzymatically active by zymogram (Fig. 9). 
Further purification was achieved by a second affinity chromatoghraphy 
based on uridine 2’,5’- and 3’,5’-diphosphate agarose (pUp), which is able to bind 
to the active site of enzymatically active ribonucleases. This selection criterion 
was chosen to allow the isolation of immunoconjugate molecules containing an 
enzymatically active ribonuclease moiety, as inactive IRs are not able to bind the 
resin. After extensive washing with the equilibrium buffer, the protein was eluted 
in phosphate-buffered saline (PBS) containing 0.5 M NaCl (for details see 
Materials and Methods section). This buffer was chosen since it is compatible with 
the growth of eukaryotic cells, thus allowing the direct use of the purified IR in 
biological assays. 
At the end of the second chromatographic step, the sample was analyzed 
by SDS-PAGE, followed by Coomassie staining, Western blot analyses with an 
anti-His and an anti-HP-RNase antibody, and zymogram (Fig. 9). The results 
indicated that the recombinant protein was homogeneous and endowed with 
ribonuclease activity. 
The described protocol allowed the isolation of about 150 µg of purified 
IR from 2 liters of cultured cells. These results are quite satisfactory if one takes in 
consideration the difficulties to express chimeric proteins, composed by two 
moieties, which have to assume their correct folding. 
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5.3.2 Isolation of hERB-hRNase by Hydrophobic Interaction 
Chromatography (HIC), Followed by Affinity Chromatography  
 
An alternative protocol was used to isolate the IR from the periplasmic 
space. In such purification protocol, the first step was a hydrophobic interaction 
chromatography (HIC), based on the ability of the hydrophobic regions of the 
antibody portion of the immunoconjugate to bind 4-mercapto-ethyl-pyridine 
(MEP) HyperCel matrix (see Materials and Methods section for details). The 
sample selected by this kind of chromatography was immediately neutralized, and 
loaded on an immobilized metal-affinity chromatography (IMAC) column, using 
the previously described cobalt-chelating resin. The purity of the final preparation 
was evaluated by SDS-PAGE, followed by Coomassie staining, Western blot 
analyses with an anti-His and an anti-HP-RNase antibody, and zymogram to test 
the enzymatic activity of the purified IR (Fig. 10). The results indicated that the 
recombinant protein was homogeneous and endowed with ribonuclease activity. 
The protein was then dialyzed against phosphate-buffered saline (PBS), 
containing 0.16 M NaCl, as this buffer is compatible with the growth of eukaryotic 
cells, thus allowing the direct use of the IR in biological assays. 
Both the described protocols of purification are valid to achieve purity. 
However, the latter protocol allows the isolation of slightly higher amounts of IR, 
about 200 µg of recombinant protein from 2 liters of cultured cells. This procedure 
was thus preferred to the other to isolate hERB-hRNase. 
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5.4 Isolation of hERB-hRNase from the Insoluble Fraction of Bacterial Cells 
 
As previously described, a considerable amount of expressed hERB-
hRNase is also present in the insoluble fraction obtained from bacterial cells. Such 
a fraction of expressed IR was efficiently recovered by solubilisation with urea 
(Bayly et al. 2002), and analyzed by SDS-PAGE, followed by Coomassie staining, 
and Western blot analyses with an anti-His and an anti-HP-RNase antibody. The 
results are shown in Fig. 11. The solubilised sample appeared to contain different 
molecular species. Among them, only one was found to be immunoreactive to an 
anti-HP-RNase antibody. This band corresponded to the expected size (46,000 
Da). Furthermore, an active band of the same molecular mass was visualized by 
zymogram analyses (Fig. 11), suggesting that the solubilisation procedure did not 
affect the enzymatic activity of the IR. 
The recovered IR was then isolated by using the hydrophobic interaction 
chromatography (HIC) described above, followed by the affinity chromatography 
based on uridine 2’,5’- and 3’,5’-diphosphate (pUp) agarose, which is able to bind 
to the active site of enzymatically active ribonucleases (see above). Such a second 
step of purification was chosen to select the molecules of immunoconjugate with 
an enzymatically active ribonuclease portion, since the enzymatic activity of a 
fraction of IR molecules could be affected by solubilisation with urea. The 
obtained sample was then analyzed as above (Fig. 11). The results indicated that 
although the recombinant protein was present, it was not homogeneous (Fig. 11), 
since contaminant bands were detectable, requiring further purification, with an 
expected loss of protein. For this reason, the isolation of hERB-hRNase from the 
insoluble fraction of bacterial cells was considered to be impracticable. 
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5.5 Analysis of the Ribonucleolytic Activity of hERB-hRNase 
 
The enzymatic activity of the purified IR was further tested with the acid-
insoluble RNA precipitation assay (Bartholeyns et al. 1977), by which the 
chimeric protein was found to have a specific activity of 950 ± 25 units/nmol. This 
value is the mean of data obtained with several preparations of the recombinant 
fusion protein (De Lorenzo et al. 2004). Since the specific activity of wild-type 
HP-RNase, tested in the same experimental conditions, was found to be 
approximately 1100 ± 20 units/nmol, we can conclude that the IR retains about 
90% of the activity of the parental RNase (De Lorenzo et al. 2004). This result is 
of great interest, since most of the IRs prepared so far (Rybak and Newton 1999; 
Deonarain and Epenetos 1998) showed a consistent loss of enzymatic activity with 
respect to the native RNase. 
 
 
5.6 Analysis of the Ability of hERB-hRNase to Specifically Recognize ErbB2 
Receptor 
 
The ability of the IR to specifically recognize ErbB2 receptor was 
evaluated by ELISA assays (see Materials and Methods section for details). The 
assays were performed using the following cell lines: SKBR3 cells, from human 
breast carcimoma, which express ErbB2 receptor at high levels, and A431 cells, 
from human epidermoid carcinoma, which express ErbB2 receptor at low levels, 
but are characterized by high expression levels of ErbB1 EGF receptor, belonging 
to the same ErbB family. It is worth noting that the use of intact cells, instead of 
the isolated antigen, allows the analysis of the ability of the immunoconjugate to 
bind the extracellular portion of ErbB2 receptor, in its native conformation. 
The results of ELISA assays, shown in Fig. 12, indicate that hERB-
hRNase binds with high affinity to SKBR3 cells, whereas no significant binding to 
A431 cells was detected. This clearly shows that the immunoconjugate is able to 
discriminate between ErbB2-positive and ErbB2-negative tumor cells, as well as 
among different receptors belonging to the same family. The apparent binding 
affinity of the IR for the ErbB2 receptor (i.e., the concentration corresponding to 
half-maximal saturation) was found to be 4.5 nM, almost identical to that obtained 
with the parental scFv Erbicin (4 nM; Fig. 12) (De Lorenzo et al. 2004). Such a 
result clearly shows that the ability of the scFv Erbicin to recognize ErbB2 
receptor is fully retained by the IR, and that the presence of the ribonuclease 
moiety in the immunoconjugate does not modify either the affinity of the scFv for 
ErbB2 or its ability to discriminate between ErbB2-positive and ErbB2-negative 
tumor cells. 
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ELISA assays were also performed using the following cell lines: MDA-
MB361 cells, derived from human breast carcinomas, characterized by high 
expression levels of ErbB2 receptor; MDA-MB453 cells, derived from human 
breast carcinomas, and AG12 (TUBO) cells, from a BALB-neu T mouse-derived 
mammary lobular carcinoma (Rovero et al. 2000), both characterized by a lower 
level of ErbB2 expression, in comparison with SKBR3 and MDA-MB361 cells. 
The results of these assays, reported in Fig. 13, clearly show lower levels of ErbB2 
immunoreactivity for MDA-MB453 and TUBO cells, compared with those 
obtained for SKBR3 and MDA-MB361 cells. These results are in agreement with 
previously reported data. In fact, the level of ErbB2 is reported six-fold lower in 
MDA-MB453 cells, compared with SKBR3 and MDA-MB361 cells (De Lorenzo 
et al. 2002a; Merlin et al. 2002). Thus, these results clearly indicate a positive 
correlation between ErbB2 expression levels on a particular cell type and the 
extent of binding of hERB-hRNase to those cells (De Lorenzo et al. 2004). 
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5.7 Internalization of hERB-hRNase by Target Cells 
 
The human anti-ErbB2 scFv Erbicin undergoes receptor-mediated 
endocytosis in SKBR3 cells (De Lorenzo et al. 2002b). Experiments were aimed at 
testing whether the scFv retains this biological property in the fusion protein, thus 
providing a useful vehicle to deliver the RNase molecule into the cytosol of target 
cells. To this purpose, tumor target cells were incubated with hERB-hRNase for 16 
hours at 37ºC. After extensive washes, cells were fixed and permeabilized as 
described previously (De Lorenzo et al. 2002b). Internalized IR was visualized 
with an anti-HP-RNase antibody, followed by sheep antirabbit FITC-conjugated 
antibody. A strong intracellular staining was visualized by confocal microscopy in 
SKBR3 cells treated with hERB-hRNase (Fig. 14B), whereas no signal was 
detected in untreated SKBR3 cells (Fig. 14A) (De Lorenzo et al. 2004). 
 
 
 44
5.8 Cytotoxic Effects of hERB-hRNase on Tumor Cells 
 
Purified hERB-hRNase was tested for cytotoxic activity on ErbB2-
positive and ErbB2-negative tumor cells. The cytotoxicity assays were performed 
using the following cell lines: 1) SKBR3 and MDA-MB361 cells, derived from 
human breast carcinomas, characterized by high expression levels of ErbB2 
receptor; 2) MDA-MB453 cells, from human breast carcinoma, and AG12 
(TUBO) cells, from a BALB-neu T mouse-derived mammary lobular carcinoma 
(Rovero et al. 2000), characterized by a lower level of ErbB2 expression, with 
respect to SKBR3 and MDA-MB361 cells; 3) A431 cells, from human epidermoid 
carcinoma, characterized by very low levels of ErbB2 expression, but high levels 
of ErbB1 EGF receptor, belonging to the same ErbB family. 
Cells were plated in the absence or in the presence of increasing amounts 
of hERB-hRNase. Following an incubation of 72 hours at 37ºC, cell survival was 
measured by counting trypan blue-excluding cells and expressed as percentage of 
viable cells in the presence of the immunoconjugate, with respect to control 
cultures grown in the absence of the protein. The results of the assays are reported 
in Fig. 15. The IR was found to be cytotoxic in a dose-dependent manner on all of 
the antigen-positive cell lines tested, whereas no effects were observed on the 
proliferation of A431 cells. The values of IC50 (i.e., the concentration capable of 
reducing cell viability by 50%) were found to be 12.5, 47, 52, and 60 nM for 
SKBR3, MDA-MB361, MDA-MB453, and TUBO cells, respectively (De Lorenzo 
et al. 2004). 
These results clearly indicate that the IR is able to finely discriminate 
between ErbB2-positive and ErbB2-negative cells and to selectively induce the 
death of target cells. Moreover, no effects on cell survival were detected when 
native HP-RNase was tested on ErbB2-positive cells at doses up to 20-fold higher 
than the highest dose of RNase present in the IR samples tested on cell cultures 
(data not shown). This clearly indicates that the RNase moiety has no effect on cell 
proliferation, unless driven inside the cells by the antibody moiety. It should be 
also noted that the scFv alone was found to inhibit the proliferation of SKBR3 
cells with an IC50 value of 200 nM (De Lorenzo et al. 2002b) (data not shown). 
This means that the IR, for which an IC50 value of 12.5 nM was obtained, is much 
more effective as an anticancer agent than the isolated antibody moiety. The 
increased cytotoxic potential can only be attributed to the additional toxic action of 
the internalized RNase. 
Furthermore, it is of interest to notice that the stronger cytotoxicity of 
hERB-hRNase on SKBR3 and MDA-MB361 cells compared with that observed 
on MDA-MB453 and AG12 (TUBO) cells is related to the different ErbB2 
expression levels on these cell lines, assessed as described above. Thus, these 
results clearly indicate a strong positive correlation between ErbB2 expression 
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levels on a particular cell type, the extent of binding of hERB-hRNase to those 
cells, and their sensitivity to IR cytotoxic action. 
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Further studies were performed to compare the cytotoxic activity of 
hERB-hRNase and that of Herceptin, a humanized version of an anti-ErbB2 
murine antibody, currently in use for treatment of advanced breast cancer (Milenic 
2002). The results of these assays are reported in Fig. 16. Interestingly, in our 
hands the antiproliferative effects of Herceptin, tested for 72 hours on the 
previously described cell lines (SKBR3, MDA-MB453, TUBO and A431), were 
much weaker than those obtained with identical amounts of hERB-hRNase. 
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5.9 Stability of hERB-hRNase 
 
The stability of immunoagents at 37ºC is a critical factor for their 
potential as therapeutic agents. The stability of hERB-hRNase in human or murine 
serum at 37°C for up to 48 hours was analyzed by monitoring its integrity both as 
a protein and as functional bioeffector. Following an incubation in serum for 24 or 
48 hours at 37°C, the percentage of undegraded and enzymatically active IR was 
determined by Western blot and zymogram analyses. By using a Phosphorimager, 
the intensity of the electrophoretic bands obtained with treated hERB-hRNase was 
expressed as the percentage of the signal given by the untreated protein. After 24 
or 48 hours the percentage of undegraded and enzymatically active hERB-hRNase 
was 100 + 5% (De Lorenzo et al. 2004) (Fig. 17). 
The binding properties of the IR after incubation in serum were assessed 
by ELISA assays on ErbB2-positive cells and expressed as the concentration 
corresponding to half-maximal saturation (Fig. 17). The results showed that the 
protein, incubated in human or murine serum, conserved a value of half-maximal 
saturation of 5 nM, virtually identical to that measured for the protein before 
incubation (see above) (De Lorenzo et al. 2004). 
Finally, hERB-hRNase was found to fully retain its cytotoxic activity 
after incubation at 37°C for up to 48 hours. The IC50 values of the incubated 
samples, tested on SKBR3 cells (see above), were within ± 10% of the values 
measured before incubation (Fig. 17) (De Lorenzo et al. 2004). 
These results clearly indicate that the IR is stable under the examined 
physiologic-like conditions. 
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5.10 In vivo Antitumor Activity of hERB-hRNase 
 
The ErbB2-positive tumor cell line AG12 (TUBO), from a BALB-neu T 
mouse-derived mammary lobular carcinoma (Rovero et al. 2000), was used for in 
vivo studies. TUBO cells were used to induce the formation of tumors in 
BALB/cAnNCrIBR mice. The IR was administered five times at intervals of 72 
hours, peritumorally or intraperitoneally, at doses of 1.5 mg/kg of body weight. 
Control animals were treated with identical volumes of sterile phosphate-buffered 
saline (PBS). A dramatic reduction in tumor volume was observed when hERB-
hRNase was injected peritumorally (Fig. 18). Similar results were obtained when 
the protein was administered systemically by intra-peritoneal injections. This 
suggests that the protein is stable in the bloodstream and is able to permeate tumor 
masses. Contrarily, equimolar doses of the anti-ErbB2 scFv Erbicin and native HP-
RNase, injected peritumorally, showed no significant effects on tumor growth 
(Fig. 18). Thus, these results clearly indicate that the effects on the growth of 
TUBO tumors can be attributed to the fusion protein as a whole. Moreover, during 
the period of treatment the animals did not show signs of wasting or other visible 
signs of toxicity, and their main haematological parameters were those of normal 
mice (data not shown). 
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6. CONCLUSIONS 
In the present study, we report the construction, characterization and 
antitumor activity of a novel, fully human IR (De Lorenzo et al. 2004). Such IR is 
composed by the human pancreas ribonuclease (HP-RNase) and a human single 
chain variable fragment (scFv) directed to the ErbB2 receptor (De Lorenzo et al. 
2002b). ErbB2 is an attractive tumor target because of its specific localization on 
many tumor cells of different origin, its extracellular accessibility, and its high 
expression levels in many carcinomas (Slamon et al. 1989; Klapper et al. 2000).  
The novel fully human IR, named hERB-hRNase, was found to retain the 
enzymatic activity of native RNase and to bind to target cells as selectively and 
effectively as the parental, free scFv. 
The fully human IR acts as an immunoprotoxin. This means that it is the 
ability of the scFv to be internalized by ErbB2-overexpressing cells, a feature fully 
preserved in the fusion protein, which allows the RNase to enter the cytosol and 
kill target cells. This was confirmed by experiments showing that HP-RNase is not 
per se a cytotoxic agent, neither in vitro nor in vivo. On the other hand, previous 
studies showed that the scFv alone is able to inhibit the proliferation of ErbB2-
positive cells (De Lorenzo et al. 2002b). Here, we demonstrate that the IR is a 
more effective anticancer drug. Such a result can only be attributed to the 
additional toxic action of the internalized RNase. 
Interestingly, the comparison between the cytotoxic effects of hERB-
hRNase and those of Herceptin, a humanized version of an anti-ErbB2 murine 
antibody, currently in use for treatment of advanced breast cancer (Milenic 2002), 
indicated that the antiproliferative effects of Herceptin were much weaker than 
those obtained with the same amount of hERB-hRNase. 
Furthermore, hERB-hRNase was found to be stable for at least 48 hours 
when incubated at 37ºC in human or murine serum. Such a feature of the IR 
enhances its potential as a promising antitumor drug. Even more interesting are the 
results of in vivo assays of hERB-hRNase antitumor action carried out on mice 
inoculated with TUBO ErbB2-positive tumor cells, which produce tumors similar 
to the alveolar-type human lobular mammary carcinomas (Di Carlo et al. 1999). 
Treatment of mice inoculated with TUBO cells with only five doses of hERB-
hRNase (1.5 mg/kg body weight) strongly inhibited tumor growth. These results 
can only be attributed to the fusion protein as a whole, as the two moieties, the 
anti-ErbB2 scFv and HP-RNase, when administered separately to tumor bearing 
mice, were not found to be effective in inhibiting tumor growth. 
To our knowledge, hERB-hRNase is the first fully human IR to be 
constructed and tested with satisfactory results in vitro and in vivo. Its fully human 
nature, combined with its stability and its selective cytotoxic action on target cells, 
could make it a precious tool in the therapy of human mammary carcinomas. 
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1. ABSTRACT 
 
The ABC (ATP binding cassette) family of membrane transport proteins 
includes the best known mediators of resistance to anticancer drugs, such as the 
ABC transporters ABCB1 (MDR1/P-gp), ABCC1/MRP1, and ABCG2/MXR. 
However, although ABC transporters overexpression appears to be a major cause 
of failure in the treatment of cancer, acquired resistance to multiple anticancer 
drugs may also be multifactorial, involving alteration of detoxification processes, 
apoptosis, DNA repair and drug uptake. 
The human prostate cancer cell line RC0.1 has been derived from the 
parental sensitive cell line DU145 by continuous exposure to the drug rubitecan 
(9-nitro-camptothecin), an inhibitor of topoisomerase I, now in phase III clinical 
trials. Several factors have been proposed to explain the phenotype of 
camptothecin resistance in RC0.1 cell line. Microarray analyses, performed using a 
novel ABC-ToxChip, indicated the overexpression of the ABC transporter MRP2 
in the resistant cell line RC0.1. In order to establish the role of MRP2 in 
camptothecin resistance, different strategies were used in the present study to 
inhibit this ABC transporter. The inhibition of MRP2 expression was obtained by 
RNA interference technology, whereas the inhibition of its biological activity was 
achieved using the inhibitor MK571. In both cases, the resistance phenotype of 
RC0.1 tumor cells was not reverted. This indicated that MRP2 does not play a 
crucial role in the resistance mechanism. To explain MRP2 overexpression, we 
hypothesized that this represents an early adaptation of the cells to the drug, 
providing the background for the evolution of different resistance mechanisms. 
The expression profile of the 48 ABC transporters has been characterized 
in a panel of 60 diverse cancer cell lines (the NCI-60), used by the National 
Cancer Institute (NCI) to screen for anticancer activity. By correlating the 
expression results with the growth inhibitory profiles of 1,429 candidate anticancer 
drugs tested against the cells, transporters able to confer resistance to anticancer 
drugs have been identified. In particular, 28 compounds were predicted to be less 
active in cells that expressed large amounts of MRP2. Such a prediction has been 
confirmed in the present study. Furthermore, the analysis of the chemical 
structures of the 28 identified MRP2 substrates led to the identification of common 
structural features, such as a cyclopentanone ring, an element structurally related 
to the cyclopentenone ring of prostaglandins. This observation led us to 
hypothesize a new role for MRP2 transporter, such as its involvement in the 
transport of cyclopentenone prostaglandins. Prostaglandins are involved in a wide 
variety of physiological and pathophysiological processes, but the mechanism of 
prostaglandin release from cells is not completely understood. Here we 
demonstrate an effective involvement of MRP2 in the transport of the 
cyclopentenone prostaglandin 15-deoxy-∆12,14-prostaglandin J2 (15-d-PGJ2). 
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2. BACKGROUND 
 
 
2.1 Multidrug Resistance (MDR) and ATP-Binding Cassette (ABC) 
Transporters 
 
Chemotherapy is still one of the most effective ways to treat metastatic 
tumors. Unfortunately, even when multiple agents are used simultaneously, the 
effectiveness of chemotherapy is limited by the multidrug resistance of cancer 
cells, a phenotype that makes tumor cells resistant to structurally and 
mechanistically unrelated drugs. Resistance to natural-product hydrophobic drugs, 
sometimes known as classical multidrug resistance (MDR), is generally associated 
with the decreased cellular accumulation of anti-cancer drugs and the elevated 
expression of an ATP-dependent drug-efflux pump, termed P-glycoprotein (P-gp), 
the MDR1 gene product (Gottesman et al. 2002). 
Intrinsic or primary resistance is characteristic of cancers originating from 
tissues constitutively expressing high levels of P-gp, such as the epithelia of the 
kidney, liver and intestine, the endothelial cells of the brain, ovary, testis, the 
adrenal cortex and placenta (Gottesman et al. 2002). Since P-gp is also expressed 
in hematopoietic stem cells and other circulating blood cells, intrinsic resistance is 
also found in several hematological malignancies (Gottesman et al. 2002). These 
localizations are consistent with the concept that P-gp plays a major role in the 
normal uptake and excretion of many differential drugs and also serves as blood-
brain, blood-testis, blood-ovary, and blood-fetus barriers for cytotoxic drugs. 
Furthermore, cells may increase P-gp expression as a consequence of a chronic 
environmental stress. This has been shown in experiments performed applying 
heat shock, or partial hepatectomy in various models (Chin et al. 1990; 
Thorgeirsson et al. 1987; Marino et al. 1990). In addition, molecular events 
occurring during malignant transformation (such as mutations in p53) may be 
sufficient to produce increased MDR1 expression (Chin et al. 1992; Zastawny et 
al. 1993; Thottassery et al. 1997). More importantly, due to their inherent genetic 
instability and heightened frequency of mutation, cancer cells are frequently 
heterogeneous with respect to MDR1 expression and such cells have a selective 
advantage during adaptation to stress, such as hypoxia or inflammation. As a result 
of these mechanisms, a significant portion of malignant cells may be already 
prepared for defense against chemotherapy at the time of diagnosis. In addition, 
cells may increase MDR1 expression in direct response to drug exposure (Szakács 
et al. 2004b). 
Classical multidrug resistance P-gp mediated is due to increased drug 
efflux that lowers intracellular drug concentrations. Drugs that are affected by this 
kind of multidrug resistance include vinblastine and vincristine (Vinca Alkaloids), 
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doxorubicin and daunorubicin (Anthracyclines), the RNA transcription inhibitor 
actinomycin-D and the microtubule-stabilizing drug paclitaxel (Ambudkar et al. 
1999). 
However, resistance can also be mediated by reduced drug uptake. In fact, 
water-soluble drugs or agents that enter the cell by means of endocytosis, might 
fail to accumulate without evidence of increased efflux. Examples include the 
antifolate methotrexate, nucleotide analogues, such as 5-fluorouracil and 8-
azaguanine, and cisplatin (Shen et al. 2000; Shen et al. 1998). Multidrug resistance 
can also result from activation of coordinately regulated detoxifying systems, such 
as DNA repair and the cytochrome P450 mixed-function oxidases. Indeed, 
coordinate induction of the multidrug transporter P-gp and cytochrome P4503A 
has been observed (Schuetz et al. 1996). This type of multidrug resistance can be 
induced after exposure to any drug. It has been shown that certain orphan nuclear 
receptors, such as SXR, might be involved in mediating this global response to 
environmental stress (Synold et al. 2001). 
Finally, resistance can result from defective apoptotic pathways. This 
might occur as a result of malignant transformation; for example, in cancers with 
mutant or non-functional p53 (Lowe et al. 1993). Alternatively, cells might 
acquire changes in apoptotic pathways during exposure to chemotherapy, such as 
changes in cell-cycle machinery, which activate checkpoints and prevent initiation 
of apoptosis. An important principle in multidrug resistance is that cancer cells are 
genetically heterogeneous. Although the process that results in uncontrolled cell 
growth in cancer favours clonal expansion, tumor cells that are exposed to 
chemotherapeutic agents will be selected for their ability to survive and grow in 
the presence of cytotoxic drugs. These cancer cells are likely to be genetically 
heterogeneous because of the mutator phenotype. Thus, in any population of 
cancer cells, that is exposed to chemotherapy, more than one mechanism of 
multidrug resistance can be present. This phenomenon has been called 
multifactorial multidrug resistance (Gottesman et al. 2002). 
In Fig. 1 a schematic representation of the mechanisms responsible for 
MDR is reported. 
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P-gp, also known as ABCB1, belongs to the superfamily of ATP-binding 
cassette (ABC) transporters. ABC transporters are integral membrane proteins that 
transport a wide variety of substrates across cell membranes, including metabolic 
products, lipids, sterol and xenobiotics such as chemotherapeutic drugs. They 
share sequence and structural homology. Their functional significance is suggested 
by the observation that they form one of the largest protein families, found in 
various cellular membranes of organisms, from bacteria to mammals. So far, 48 
human ABC genes have been identified and divided into 7 distinct subfamilies 
(ABCA-ABCG) on the basis of their sequence homology and domain organization 
(Dean et al. 2001).  
P-gp is a broad-spectrum multidrug efflux pump that has 12 
transmembrane regions and 2 ATP-binding sites (Chen et al. 1986) (Fig. 2). The 
transmembrane regions bind hydrophobic drugs that are either neutral or positively 
charged, and are probably presented to the transporter directly from the lipid 
bilayer (Ambudkar et al. 1999). Two ATP hydrolysis events, which do not occur 
simultaneously, are needed to transport one drug molecule (Senior and Bhagat 
1998). Binding of substrate to the transmembrane regions stimulates the ATPase 
activity of P-gp, causing a conformational change that releases substrate to either 
the outer leaflet of the membrane (from which it can diffuse into the medium) or 
the extracellular space (Ramachandra et al. 1998). Hydrolysis at the second ATP 
site seems to be required to re-set the transporter so that it can bind substrate again, 
completing one catalytic cycle (Sauna ZE and Ambudkar SV 2000). 
P-gp efficiently removes cytotoxic drugs and many commonly used 
pharmaceuticals from the lipid bilayer. Its broad substrate specificity presumably 
reflects a large, polymorphous drug-binding domain or domains within the 
transmembrane segments. As P-gp binds many different hydrophobic compounds, 
it has been easy to find potent P-gp inhibitors. Two inhibitors that are used in the 
laboratory and in clinical trials that attempted to reverse drug resistance are the 
calcium channel blocker verapamil and the immunosuppressant cyclosporin A 
(Gottesman et al. 2002). 
Since P-gp is not expressed in all multidrug-resistant cells, a search for 
other efflux pumps led to the discovery of the multidrug-resistance associated 
protein 1 (MRP1, or ABCC1) (Cole et al. 1993). MRP1 is an ABC transporter 
similar to P-gp in structure, with the exception of an amino-terminal extension that 
contains five membrane-spanning domains attached to a P-gp-like core (Fig. 2). 
MRP1 recognizes neutral and anionic hydrophobic natural products, and transports 
glutathione, or other, conjugates of these drugs, or, in some cases (such as for 
vincristine) co-transports unconjugated glutathione (Loe et al. 1998; Jedlitschky et 
al. 1996; Muller et al. 1994). The discovery of MRP1 stimulated a genomic search 
for homologues, leading to the discovery of eight additional members of the 
ABCC subfamily of transporters, six of which have been studied in some detail 
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(Borst et al. 2000). Like MRP1, some of these MRPs have the five-transmembrane 
amino-terminal extension (ABCC2, ABCC3 and ABCC6, also named MRP2, 
MRP3, and MRP6), whereas others do not. Several MRP family members 
transport drugs in model systems and therefore have the potential to confer drug 
resistance (Borst et al. 2000). 
Some anticancer drugs, such as mitoxantrone, are poor substrates for 
MDR1 and MRP1. Selection for mitoxantrone resistance resulted in the 
identification of multidrug-resistant cells that produce a more distant member of 
the ABC transporter family, ABCG2, also known as MXR (mitoxantrone-
resistance gene), BCRP (breast cancer resistance protein) or ABC-P (ABC 
transporter in placenta) (Miyake et al. 1999; Doyle et al. 1998; Allikmets et al. 
1998). This transporter is thought to be a homodimer of two half-transporters, each 
containing an ATP-binding domain at the amino-terminal end of the molecule and 
six transmembrane segments (Fig. 2). 
In Fig.2 a schematic representation of the structural features of the ABC 
transporters known to confer resistance is represented. 
Other ABC family members have been associated with drug resistance. 
For example, the bile salt export protein (BSEP, also known as ABCB11) is 
expressed at high levels in liver cells, and in transfection experiments it confers 
low-level resistance to paclitaxel (Childs et al. 1998). MDR3 (sometimes called 
MDR2), a phosphatidylcholine FLIPPASE that is closely related to P-gp, normally 
transports phospholipids into bile, but can transport paclitaxel and vinblastine 
(Smit et al. 1993; Zhou et al. 1999; Borst et al. 2000). Furthermore, ABCA2 is 
overexpressed in estramustine-resistant cells (Laing et al. 1998; Vulevic et al. 
2001). Estramustine is a nitrogen mustard derivative of oestradiol, so ABCA2, 
expressed intracellularly in endosomal/lysosomal vesicles, might partecipate in 
steroid transport (Gottesman et al. 2002). By their ability to transport nucleoside 
analogues, ABCC3/MRP3 and ABCC5/MRP5 are proteins that are thought to 
cause certain forms of drug resistance (Reid et al. 2003a). Finally, 
ABCC11/MRP8 has recently been associated with anti-cancer drug export (Guo et 
al. 2003; Szakács et al. 2004a). 
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Although many ABC transporters have been identified as drug-resistance 
proteins, they are all expressed in normal tissues (Gottesman et al. 2002). ABC 
transporters have an important role in regulating central nervous system 
permeability. The brain is protected against blood-born toxins by the blood-brain 
barrier, and the blood-cerebrospinal fluid barrier. At the level of the blood-brain 
barrier, P-gp, located on the luminal surface of endothelial cells, plays an 
important role in preventing the penetration of cytotoxins across the endothelium 
(Schinkel et al. 1996; Xie et al. 1999). MRP proteins such as MRP1 are localized 
to the basolateral membrane of the choroid plexus, where they serve to pump the 
metabolic waste products of blood-cerebrospinal fluid barrier into the blood (Rao 
et al. 1999). In a similar manner, ABC transporters seem to protect testicular tissue 
and the developing fetus, since P-gp and MRP1 transporters have been found to be 
expressed in testis (Gottesman et al. 2002). On the other hand, P-gp is also 
localized in placenta (Cordon-Cardo et al. 1990), as the half-transporter ABCG2 
(Jonker et al. 2000; Maliepaard et al. 2001). MRP1 and other isoforms might also 
be involved in protecting fetal blood from toxic organic anions and in excreting 
glutathione/glucuronide metabolites into the maternal circulation (St-Pierre et al. 
2000). 
Whereas ABC transporters are expressed in the brain, testis and placenta 
to protect them from cytotoxins, the liver, gastrointestinal tract and kidney use 
these transporters to excrete toxins, thus protecting the entire organism. Examples 
are the presence of P-gp in the apical membranes of hepatocytes, where it 
transports toxins into bile (Schinkel et al. 1997), as well as the presence of MRP3 
in the basolateral surface of hepatocytes, where it transports organic anions from 
liver back into the bloodstream (Scheffer et al. 2000). In addition, the ABC 
transporter MRP2 (cMOAT) has been found to be expressed on the apical surface 
of hepatocytes, where it transports bilirubin-glucuronide and other organic anions 
into bile (Konig et al. 1999). In the gastrointestinal tract, P-gp is localized in apical 
membranes of mucosal cells, where it extrudes toxins, forming a first line of 
defence (Gottesman et al. 2002). Additionally, P-gp actively secretes 
intravenously administered drugs into the gastrointestinal tract (Sparreboom et al. 
1997). In contrast to P-gp, MRP1 is located in the basolateral membrane of 
mucosa cells, and therefore transports substrates into the interstitium and the 
bloodstream, rather than across the apical surface into the intestinal lumen (Evers 
et al. 1996). MRP2, on the other hand, is localized in the canalicular membrane of 
hepatocytes and the apical surface of epithelial cells, and has a primary role in the 
excretion of bilirubin-glucuronide. Studies indicated that MRP2 was capable of 
mediating drug efflux, suggesting that this transporter, like P-gp, might also 
regulate drug bioavailability (Dietrich et al. 2001). 
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2.2 Screening for ABC Transporters Involved in MDR 
 
Tools, such as the oligo-based, cDNA-based microarrays or SAGE (Serial 
analysis of gene expression, Velculescu et al. 1995) are relevant methodologies to 
screen for multifactorial mechanisms of drug resistance. Although microarrays 
make possible the screening of thousands of genes in the same matrix, attempts 
aiming to address anticancer drug resistance have been biased in their 
interpretation by microarrays bearing a low number of ABC transporter 
superfamily probes (Lamendola et al. 2003). 
At the beginning of my stage at the National Institutes of Health (NIH), in 
the laboratory directed by Dr M. Gottesman, I was involved in studies directed to 
the design and the application of a dedicated ABC-ToxChip. In this system, a 
comprehensive set of detoxifying genes was complemented with probes 
specifically matching 36 of the 48 ABC transporters. Instead of using the short 25-
mer probe-technology (Affimetrix, Santa Clara, CA), not optimized for detecting 
infrequent transcripts, a combination of 70-mer oligo probes and 200-500 bp 
fragments was used. This strategy offers higher sensitivity due to the longer 
complementary sequence. 
We used such a dedicated ABC-ToxChip to compare the transcriptional 
profiles of the parental prostate cancer cell line DU145 and its 9-nitro-
camptothecin-selected derivative cell line RC0.1 (Annereau et al. 2004). 
Camptothecin derivatives such as CPT-11 (Irinotecan) or Hycamtin (Topotecan) 
are increasingly used in anti-tumor therapy against colon or lung cancers (Kudoh 
et al. 1998). 9-nitro-camptothecin has recently been used in phase II studies for 
pancreatic cancer and is now in phase III clinical trials (Pantazis et al. 2003). The 
camptothecin resistant cell line RC0.1 derived from the parental sensitive cell line 
DU145 by continuous exposure to the drug 9-nitro-camptothecin. Many factors, 
such as specific mutations in topoisomerase I gene and a general alteration of 
apoptotic regulation have been proposed to explain the phenotype of drug 
resistance in the prostate cancer cell line RC0.1 (Reinhold et al. 2003; Urasaki et 
al. 2001; Chatterjee et al. 2001). 
Our results indicated that the resistance phenotype of RC0.1 cell line is 
accompanied by the differential expression of the ABC transporter ABCC2/MRP2, 
as well as that of enzymes regulating glutathione metabolism (Annereau et al. 
2004). In fact, among the 20,000 genes, ABCC2/MRP2 shows a strong variation 
of the expression levels associated with 9-nitro-camptothecin resistance. 
First named the canalicular multispecific organic anion transporter 
(cMOAT), ABCC2/MRP2 is a 190 kDa phosphoglycoprotein localized in the 
canalicular (apical) membrane of hepatocytes. It is involved in the transport of 
organic anions, including sulfated and glucuronidated bile salts. Overexpression of 
MRP2 has been suggested to confer resistance to anti-cancer drugs such as 
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cisplatin, anthracyclines, and methotrexate, and animal models have shown 
reduced hepatic transport of camptothecins (Horikawa et al. 2002). 
We were also able to confirm the microarray results by quantitative real-
time RT-PCR analyses. These showed that among the 47 ABC transporters, 
ABCC2/MRP2 is overexpressed in RC0.1 resistant cell line, whereas the 
expression of the other members of the superfamily was found to be unchanged 
(Annereau et al. 2004). The obtained results were confirmed by Western blot 
analyses as well (Annereau et al. 2004). 
On the basis of these results, my research project was directed to the 
analysis of the role of the ABC transporter ABCC2/MRP2 in camptothecin 
resistance. To this purpose, experiments were performed to analyze the effects of 
MRP2 inhibition on the resistance phenotype of RC0.1 tumor cell line (see Results 
section). 
Moreover, in the early phase of my stage at the NIH, I was involved in 
studies directed to determine which ABC transporters play a role in drug resistance 
of cancer cells. To this purpose, we characterized the expression profile of the 48 
ABC transporters in a panel of cancer cells (Szakács et al. 2004a) whose 
molecular characteristics have been cataloged. We chose a panel of 60 human 
cancer cell lines (the NCI-60), which have been used by the Developmental 
Therapeutics Program (DTP) of the National Cancer Institute (NCI) to screen for 
more than 100,000 chemical compounds since 1990. Included among the 60 cell 
lines are leukemias, melanomas, and cancers of ovarian, breast, prostate, lung, 
renal, colon, and central nervous system. Patterns of drug activity across the cell 
lines and patterns of cell sensitivity across the set of tested drugs have been shown 
to contain detailed information on mechanisms of action and resistance (Paul et al. 
1989; Weinsten et al. 1992). In addition to this pharmacological characterization, 
the NCI-60 cells have been more extensively profiled at the DNA, mRNA, protein 
and functional levels than any other set of cells in existence.  
The main goal of this study was the identification of the relationship 
between ABC transporters expression levels and sensitivity to drugs or drug 
candidates. The addressed question was which of the ABC transporters do (and 
which do not) confer resistance or sensitivity to various classes of agents. To this 
purpose, the expression profile of the 48 ABC transporters in the NCI-60 cell lines 
was measured by real-time RT-PCR, since reproducible and quantitative 
correlations between expression and sensitivity were required (Szakács et al. 
2004a). The results of RT-PCR analyses allowed the construction of a clustered 
image map (“heat map”) (Weinstein et al. 1997) that offers a visual summary of 
the patterns of ABC transporters expression across the 60 cell lines (Szakács et al. 
2004a). Such image map is reported in Fig. 3. Quantitative analyses showed that 
the pattern of expression is mostly characteristic of the tissue of origin for 
melanoma cells, as 9 of the 10 melanoma cells cluster together (Szakács et al. 
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2004a). The database provides valuable information on the expression patterns of 
both known and currently uncharacterized ABC transporters (Szakács et al. 
2004a). Some of them are expressed ubiquitously, whereas others are selectively 
expressed in particular cell types. Furthermore, the expression of ABC transporters 
appears to be independent of sequence-homology categories (Szakács et al. 
2004a). 
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The identification of transported molecules should help to understand the 
physiological mechanisms and specificities of ABC transporters. By correlating 
the results of ABC transporters expression with the growth inhibitory profiles of 
1,429 candidate anticancer drugs tested against the cells, transporters able to 
confer resistance to anticancer agents were identified (Szakács et al. 2004a). 
Pearson’s correlation coefficients were calculated for a total of 68,592 
relationships (48 genes x 1,429 compounds) (Szakács et al. 2004a). One striking 
result was the identification of at least one compound whose toxicity appears to be 
potentiated, rather than antagonized, by P-gp (ABCB1/MDR1) (Szakács et al. 
2004a). Of the 1,429 compounds analyzed in the study, 28 were shown to be less 
active in cells that expressed large amounts of ABCC2/MRP2 (Szakács et al. 
2004a). In order to verify this finding, dose-response curves of control and 
ABCC2-transfected cells were obtained upon treatment with one of these 
compound (NSC641281), available from DTP (Developmental Therapeutics 
Program). In sharp contrast to the control (sham-transfected) cells, ABCC2-
overexpressing cells were found to be extremely resistant to NSC641281, 
reinforcing the suggestion that this compound is an ABCC2/MRP2 substrate 
(Szakács et al. 2004a).  
My research project (see Aims of the study) was aimed at the 
identification of putative substrates for the ABC transporter ABCC2/MRP2. As 
shown in the Results section, prostaglandins were identified as potential substrates.  
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2.3 Prostaglandins, as a New Class of Compounds Interacting with ABC 
Transporters 
 
Prostaglandins are key mediators in the regulation of many physiological 
processes. They are involved in inflammatory responses and tumorigenesis, and 
their synthesis and metabolism are tightly regulated (Funk 2001). The first step in 
prostaglandin synthesis is the production of arachidonic acid, which is released 
from membrane lipid primarily by cytosolic phospholipase A2 (Funk 2001). 
Arachidonic acid is then oxidized to the intermediate prostaglandin H2 (PGH2) by 
PGH synthases, also known as cyclooxygenase (COX)-1 and –2, and the recently 
identified COX-3 (Warner and Mitchell 2002). These enzymes are known 
clinically as the targets of aspirin and other nonsteroidal anti-inflammatory drugs 
(NSAIDS) (Vane 2000). 
Several recent studies have shown a link between COX-2 expression and 
carcinogenesis. Prostaglandins are overproduced by a variety of tumors, leading to 
the suggested prophylactic use of COX-2 inhibitors to decrease the incidence of 
colon cancer (Prescott and Fitzpatrick 2000; Gupta and Dubois 2001). After COX-
mediated synthesis, PGH2 is further converted by tissue-specific prostaglandin 
synthases into PGE2, PGF2α, PGD2, prostacyclin, or thromboxane B2, the 
biologically active molecules. 
Prostaglandins are formed and secreted by most cells, and act as 
autocrine- or paracrine-signaling molecules. In many cases they exert their effects 
extracellularly via interaction with a family of G protein-coupled membrane 
receptors (Breyer and Breyer 2000), although some prostaglandins interact with 
the nuclear hormone receptor peroxisomal proliferator-activated receptor γ 
(PPARγ) (Harris et al. 2002). The localized action of prostaglandins requires their 
efficient release, reuptake, and metabolism to initiate and terminate signaling. The 
uptake of prostaglandins is mediated by many organic anion transporters (OAT); 
one of the best characterized is the prostaglandin transporter (PGT) (Schuster 
2002). It is thought to mediate prostaglandin uptake via an exchange mechanism, 
with lactate acting as the counter-ion (Chan et al. 2002). In contrast, the release of 
prostaglandins after their synthesis, a process essential for their activity, is still 
unknown. Although poorly membrane permeable, primary prostaglandins such as 
PGE2 are widely assumed to diffuse passively from the cell. 
However, it is known that the proinflammatory leukotriene LTC4, a 
prostanoid, is transported by the multidrug resistance proteins MRP1 (Jedlitschky 
et al. 1994; Leier et al. 1994; Muller et al. 1994) and MRP2 (Cui et al. 1999). 
Besides MRP1-/- mice show an impaired response to inflammatory stimuli, 
associated with decreased LTC4 secretion (Wijnholds et al. 1997). Furthermore, 
the metabolically inactive glutathione conjugate of PGA1 (PGA1-GS) is 
transported by both MRP1 (Akimaru et al. 1996; Ishikawa et al. 1998; Evers et al. 
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1997) and MRP2 (Evers et al. 1998). MRP1 also transports the glutathione 
conjugate of the synthetic prostaglandin ∆7-PGA1 methyl ester (Akimaru et al. 
1996). The primary prostaglandin PGE2, however, was not found to be a substrate 
of MRP1 (Evers et al. 1997). A recent study showed that in inside-out membrane 
vesicles derived from insect cells or HEK 293 cells, the ABC tranporter 
ABCC4/MRP4 catalyzes the time- and ATP- dependent uptake of prostaglandin E1 
(PGE1) and PGE2 (Reid et al. 2003b). In contrast, MRP1, MRP2, MRP3, and 
MRP5 do not transport PGE1 or PGE2. The MRP4-mediated transport of PGE1 and 
PGE2 displays saturation kinetics, with Km values of 2.1 and 3.4 µM, respectively. 
Furthermore, PGF1α, PGF2α, PGA1, and thromboxane B2 are high-affinity 
inhibitors of MRP4 and so presumably substrates (Reid et al. 2003b). In the same 
way, several nonsteroidal anti-inflammatory drugs are potent inhibitors of MRP4 
at concentrations that do not inhibit MRP1. In cells expressing the prostaglandin 
transporter PGT, the steady-state accumulation of PGE1 and PGE2 is reduced 
proportional to MRP4 expression (Reid et al. 2003b). Inhibition of MRP4 by an 
MRP4-specific RNA interference construct reversed this accumulation deficit 
(Reid et al. 2003b). Thus, MRP4 can release prostaglandins from cells and some 
nonsteroidal anti-inflammatory drugs, in addition to inhibiting prostaglandins 
synthesis, might also act by inhibiting this release. 
Among prostaglandins, cyclopentenone prostaglandins, such as 
prostaglandin J2 (PGJ2), ∆12-prostaglandin J2 (∆12-PGJ2), 15-deoxy-∆12,14-
prostaglandin J2 (15-d-PGJ2), prostaglandin A1 (PGA1) and prostaglandin A2 
(PGA2) influence a variety of cellular processes including growth and 
differentiation, gene expression, apoptosis and inhibition of inflammatory 
signaling pathways (Kliewer et al. 1995; Atsmon et al. 1990a; Honn and Marnett 
1985; Clay et al. 2000; Clay et al. 1999; Forman et al. 1995; Rovin et al. 2002). 
15-deoxy-∆12,14-prostaglandin J2 (15-d-PGJ2), a terminal product of prostaglandin 
D2 metabolism, is among the most potent cyclopentenone prostaglandinds. This 
prostaglandin has attracted considerable attention because of its antitumor 
activities including the ability to inhibit growth and induce apoptosis in several 
cancer cell lines (Clay et al. 2000; Clay et al. 1999; Harris and Phipps 2002; Eibl 
et al. 2001; Shimada et al. 2002; Padilla et al. 2002). Additionally, 15-d-PGJ2 
influences the expression of several genes and has anti-inflammatory effects 
(Kliewer et al. 1995; Yamazaki et al. 2002; Rossi et al. 2000; Straus et al. 2000; 
Ricote et al. 1998; Jiang et al. 1998). In addition to its potential pharmacological 
utility, the physiological relevance of 15-d-PGJ2 is supported by recent findings 
showing that it is produced in cells and tissues including activated macrophages, 
where 15-d-PGJ2 is made and secreted (Shibata et al. 2002) and human breast 
tissue (Badawi and Badr 2003). Its biological effects are mediated by both 
peroxisomal proliferator-activated receptor γ (PPARγ)-independent and PPARγ-
dependent mechanisms (Clay et al. 1999; Forman et al. 1995; Rossi et al. 2000; 
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Straus et al. 2000; Shibata et al. 2002; Dussault and Forman 2000; Oliva et al. 
2003). 
Many PPARγ-independent effects are believed to involve the formation 
of 15-d-PGJ2/protein adducts (Rossi et al. 2000; Oliva et al. 2003; Castrillo et al. 
2000; Cernuda-Morollon et al. 2001) via reactions between protein thiols and the 
α,β-unsaturated ketone on 15-d-PGJ2 (Atsmon et al. 1990a; Atsmon et al. 1990b; 
Paumi et al. 2003; Bogaards et al. 1997). Formation of these adducts inactivates or 
modifies the function of the target protein resulting in the observed biological 
effects (Rossi et al. 2000; Oliva et al. 2003; Castrillo et al. 2000; Cernuda-
Morrolon et al. 2001). Indeed, the inhibition of cell proliferation by 
cyclopentenone prostaglandins has been attributed to the presence of this α,β-
unsaturated carbonyl in a variety of tumor models (Atsmon et al. 1990b; Honn and 
Marnett 1985). Moreover, previous studies have indicated that this electrophilic 
center of 15-d-PGJ2 and other cyclopentenone prostaglandins is a target for the 
Michael addition of glutathione (Atsmon et al. 1990a; Atsmon et al. 1990b; 
Bogaards et al. 1997; Ohno and Hirata 1993; Parker and Ankel 1992). 15-d-PGJ2 
is also a ligand for the nuclear receptor PPARγ. Activation of PPARγ by binding 
of this or other ligands facilitates PPARγ/retinoid X receptor heterodimer 
formation, recruitment of transcriptional coeffectors, and binding of the 
PPARγ/retinoid X receptor complex to its PPAR responsive elements (Kliewer et 
al. 1995; Forman et al. 1995; Dussault and Forman 2000; Kodera et al. 2000; 
Chawla et al. 2001; Krey et al. 1997). Consequently, ligand binding to PPARγ is 
associated with the altered expression of a variety of genes including those 
involved in adipocyte differentiation, cell proliferation, and lipid and glucose 
homeostasis (Dussault and Forman 2000; Chawla et al. 2001; Hihi et al. 2002). 
PPARγ is upregulated in cancer cells including those from colon and breast, and it 
has been suggested that the ligands of PPARγ may be useful in the treatment of 
some cancers (Honn and Marnett 1985; Clay et al. 2000; Clay et al. 1999; 
Shimada et al. 2002; Padilla et al. 2002; Elstner et al. 1998). 15-d-PGJ2 
cytotoxicity and activation of PPARγ-dependent transcription are attenuated by 
expression of the glutathione conjugate efflux transporters, MRP1/ABCC1 and 
MRP3/ABCC3 (Paumi et al. 2003). This attenuation is glutathione-dependent and 
is associated with the formation of the glutathione conjugate of 15-d-PGJ2, 15-d-
PGJ2-SG, and its MRP-dependent efflux (Paumi et al. 2003). 
These observations appear to be in agreement with a putative role of the 
ABC transporter ABCC2/MRP2 in the transport of cyclopentenone prostaglandins. 
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3. AIMS OF THE STUDY 
 
The main goal of the present study was the analysis of the role played by 
the ABC transporter ABCC2/MRP2 in multidrug resistance (MDR). 
In the first part of my study, experiments were performed to clarify the 
role of ABCC2/MRP2 in camptothecin resistance. The model of study was 
represented by the human prostate cancer cell line RC0.1, derived from the 
parental sensitive cell line DU145 by continuous exposure to the drug Rubitecan 
(9-nitro-camptothecin). 9-nitro-camptothecin is now in phase III clinical trials 
(Pantazis et al. 2003). Many factors have been proposed to explain the phenotype 
of drug resistance in the resistant cell line RC0.1 (Reinhold et al. 2003; Urasaki et 
al. 2001; Chatterjee et al. 2001). Since microarray analyses indicated high 
expression levels of MRP2 in RC0.1 cell line (Annereau et al. 2004), experiments 
were here performed to analyze the meaning of MRP2 overexpression associated 
with resistance. To this purpose, different strategies were used to inhibit this ABC 
transporter, such as the use of MK571, a compound that is known to strongly 
inhibit MRP2 by interacting with its substrate binding site (Chen et al. 1999), and 
RNA interference (RNAi) technology. In both cases, experiments were then 
performed to analyze the effects of MRP2 inhibition on the resistance phenotype 
of RC0.1 tumor cell line. 
In the second part of my study, experiments were performed to analyze a 
putative involvement of ABCC2/MRP2 in the transport of cyclopentenone 
prostaglandins. Previous studies indicated 28 anticancer drugs as putative 
substrates of ABCC2/MRP2 (Szakács et al. 2004a). Experiments performed in the 
present study showed an effective involvement of MRP2 in their transport. The 
analysis of the chemical structures of the 28 identified MRP2 substrates indicated 
the presence of common structural features, such as a cyclopentanone ring, an 
element structurally related to the cyclopentenone ring of prostaglandins. This 
observation led us to assume a role of ABCC2/MRP2 in the transport of this class 
of prostaglandins. This hypothesis is in agreement with recent findings indicating 
the involvement of other ABC transporters in the transport of prostaglandins (Reid 
et al. 2003b; Paumi et al. 2003), and with the observation that the mechanism of 
prostaglandins release from cells is not completely understood. Cyclopentenone 
prostaglandins are known to influence a variety of cellular processes, such as 
growth and differentiation, gene expression, apoptosis and inhibition of 
inflammatory signaling pathways (Rovin et al. 2002; Forman et al. 1995; Kliewer 
et al. 1995). In order to verify the involvement of MRP2 in the transport of this 
class of biological molecules, experiments were perfomed to analyze the effects of 
cyclopentenone prostaglandins on the growth and the resistance phenotype of 
control (sham-transfected) and ABCC2-transfected cells. 
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4. MATERIALS AND METHODS 
 
 
4.1 Cell Lines and Culture Conditions 
 
DU145 cell line (Stone et al. 1978) and its 9-nitro-camptothecin-
derivative RC0.1 cell line were a generous gift from Dr P. Pantazis (University of 
Miami, Coral Gables, FL). They were cultured in RPMI 1640 (Life Technologies, 
Gaithersburg, MD) medium. Resistance phenotype of RC0.1 cell line was 
maintained by passage in 9-nitro-camptothecin-containing medium (0.1 µM) every 
three months. 
Control and ABCC2-transfected Madin-Darby canine kidney cell lines 
(MDCKII) were a generous gift from Dr Balasz Sarkadi (Budapest). Control and 
MRP1-transfected human embryonic kidney cell lines (HEK 293) were a generous 
gift from Dr Suresh V. Ambudkar (NCI, NIH, Bethesda, USA) (Muller et al. 
2002). These four cell lines were grown in Dulbecco’s modified Eagle’s medium 
(Life Technologies, Gaithersburg, MD). 
MCF-7 and MCF-7MDR cell lines, available in Dr Gottesman’s 
laboratory, were grown in Dulbecco’s modified Eagle’s medium (Life 
Technologies, Gaithersburg, MD). Resistance phenotype of MCF-7MDR cell line, 
due to P-gp overexpression, was maintained by culturing cells in colchicine-
containing medium (60 ng/ml). 
All of the cell lines were cultured in media supplemented with 10% fetal 
bovine serum (Hyclone Inc. Logan, UT), 2 mM L-glutamine (Life Technologies, 
Gaithersburg, MD), 50 Units/ml penicillin (Life Technologies, Gaithersburg, MD), 
and 50 µg/ml streptomycin (Life Technologies, Gaithersburg, MD). Cells were 
grown at 37°C in a humidified atmosphere containing 5% CO2/95% air. All of the 
cell lines were discarded after 3 months and new lines were obtained from frozen 
stocks. 
 
 
4.2  Antibodies, Drugs and Chemicals 
 
The antibodies used in the current study were the following: murine 
monoclonal antibody M2-III-6 directed against an internal epitope COOH-terminal 
(aa 1339-1541) of human MRP2 protein (Alexis, San Diego, CA); murine 
monoclonal antibody C219 (Alexis, San Diego, CA) directed against human P-gp; 
murine polyclonal antibody directed against human and rat GAPDH (Research 
Diagnostic Inc., Flanders, NJ); horseradish peroxidase-conjugated goat antimouse 
immunoglobulin antibody (Jackson ImmunoResearch Laboratories, # IR-115-035-
164). 
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The compounds designated by NSC numbers were obtained from the 
Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, 
Division of Cancer Treatment and Diagnosis, National Cancer Institute, National 
Institutes of Health, Bethesda, MD, USA. The compounds NSC641281, 
NSC645145, NSC618059 and NSC626878 were dissolved in dimethyl sulfoxide 
(DMSO) at the following concentrations: 52 mM (NSC641281), 260 mM 
(NSC645145), 213 mM (NSC618059) and 54 mM (NSC626878). 
Colchicine, camptothecin and dimethyl sulphoxide (DMSO) were 
purchased from Sigma Chemical Co. (St. Louis, MO). The drug rubitecan (9-nitro-
camptothecin) was purchased from LKT Laboratories (St. Paul, MN, # C0156). 
The compound MK571 was purchased from Alexis (San Diego, CA). 
Cyclopentenone prostaglandins, such as prostaglandin J2 (PGJ2), ∆12-
prostaglandin J2 (∆12-PGJ2), 15-deoxy-∆12,14-prostaglandin J2 (15-d-PGJ2), 
prostaglandin A1 (PGA1) and prostaglandin A2 (PGA2) were purchased from 
Cayman Chemical (Ann Arbor, MI). They were dissolved in dimethyl sulfoxide 
(DMSO) at the following concentrations (as indicated by the manufacturer): 10 
mg/ml (PGJ2), 100 mg/ml (∆12-PGJ2), 20 mg/ml (15-d-PGJ2), 50 mg/ml (PGA1), 
50 mg/ml (PGA2). 
 
 
4.3 siRNA Preparation and Transfection 
 
The 4 short interfering RNA (siRNA) sequences targeting human 
ABCC2/MRP2 corresponded to the following coding regions relative to the start 
codon: 
1) 1560-1578 (5’-GAATCAAGATCCTGAAATA-3’); 
2) 3682-3700 (5’-GAACCTGACTGTCTTCTTT-3’); 
3) 1222-1240 (5’-TATCATGGCTTCTGTATAT-3’); 
4) 3115-3133 (5’-CTACGGAGCTCTGGGATTA-3’). 
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The siRNA duplexes with the sense and antisense sequences represented 
in Table 1 were used. 
 
 
Sequences of the 4 siRNA duplexes targeting human ABCC2/MRP2 
siRNA duplex 1 5’-GAAUCAAGAUCCUGAAAUAdTdT-3’ (sense) 
3’-dTdTCUUAGUUCUAGGACUUUAU-5’ (antisense) 
siRNA duplex 2 5’- GAACCUGACUGUCUUCUUUdTdT-3’ (sense) 
3’-dTdTCUUGGACUGACAGAAGAAA-5’ (antisense) 
siRNA duplex 3 5’-UAUCAUGGCUUCUGUAUAUdTdT-3’ (sense) 
3’-dTdTAUAGUACCGAAAGACAUAUA-5’ (antisense) 
siRNA duplex 4 5’-CUACGGAGCUCUGGGAUUAdTdT-3’ (sense) 
3’-dTdTGAUGCCUCGAGACCCUAAU-5’ (antisense) 
Table1: Sequences of the 4 siRNA duplexes targeting the human ABC transporter 
            ABCC2/MRP2. For each siRNA  the  sense  and  antisense  sequences  are 
            represented. 
 
The siRNA sequence targeting MDR1 corresponded to the coding region 
79-99 (5’-AAGGAAAAGAAACCAACTGTC-3’) relative to the start codon (Wu 
et al. 2003). The siRNA duplex with the following sense and antisense sequences 
was used:  
5’-GGAAAAGAAACCAACUGUCdTdT-3’ (sense) and  
3’-dTdTCCUUUUCUUUGGUUGACAG-5’ (antisense). 
Cells of the different cell lines in exponential phase of growth were plated 
in six-well plates at a density of 5x105 cells/well and grown for 24 hours. The 
number of cells was chosen to allow the cells to be 30-50% confluent the day of 
transfection. At the time of plating and during the transfection, antibiotics were not 
added to the culture medium. Cells were then incubated for 24 hours at 37°C in a 
humidified 5% CO2. After 24 hours, cells were transfected with siRNA (pool of 4 
MRP2-specific siRNAs: 100 nM, 25 nM each; P-gp siRNA: 200 nM, as described 
by Wu et al. 2003) using oligofectamine and OPTI-MEM I serum-reduced 
medium (Invitrogen Life Technologies, Inc., Carlsbad, CA), according to the 
manufacturer’s instructions. Briefly, oligofectamine reagent (3 µl) was diluted in 
serum-reduced medium to a final volume of 15 µl and incubated at room 
temperature for 5-10 minutes. Diluted oligofectamine was then mixed to diluted 
siRNA duplexes and incubated at room temperature for 15-20 minutes. Following 
the incubation, the solution was added to the cells, previously washed with serum-
reduced medium. Cells were then incubated for 4 hours at 37°C in a humidified 
5% CO2. Following the incubation, serum was added to the cells without removing 
the transfection mixture. Silencing was examined 24-72 hours after the 
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transfection in the case of MRP2, and 24 hours after the transfection in the case of 
P-gp. Control cells were treated with oligofectamine and serum-reduced medium 
(mock). 
 
 
4.4 Western Blot Analyses 
 
Cells were washed twice with cold PBS containing a cocktail of proteases 
inhibitors (Roche Applied Science, Indianapolis, IN), scraped off the dishes, and 
collected by centrifugation at 500 x g for 10 minutes at 4°C. Cell pellets were then 
dissolved in a lysis buffer containing 10 mM Tris-HCl, pH 8.0, 0.1% Triton X-100 
(v/v), 10 mM MgSO4, 2 mM CaCl2, 2 mM DTT, a cocktail of proteases inhibitors 
(Roche Applied Science, Indianapolis, IN) and 20 µg/ml micrococcal DNase 
(Sigma Chemical Co., St. Louis, MO). Samples were then incubated at 37°C for 5 
minutes, quickly frozen in dry ice, thawed in cold water and sonicated in a bath 
sonicator (3 times for 1 minute, with 30 seconds intervals of incubation on ice). 
Protein concentration was determined using a Bradford assay (Bio-Rad, Hercules, 
CA). Samples were then mixed with Novex Tris-Glycine SDS sample buffer 
(Invitrogen, Carlsbad, CA). Identical amounts (50 µg of protein) of cell lysates 
were loaded on Novex 4–20% Tris-glycine gels (Invitrogen, Carlsbad, CA) and 
transferred to nitrocellulose membranes (Invitrogen, Carlsbad, CA) at 200 mAmps 
for 2 hours at 4°C. At this point, membranes were incubated in a blocking solution 
(20% non-fat milk in PBS buffer containing 0.5% Tween 20) at room temperature 
for 1 hour and washed with PBS buffer containing 0.5% Tween 20. Membranes 
were then incubated with a murine monoclonal anti-MRP2 antibody M2-III-6 
(Alexis, San Diego, CA) diluted 1:200, or a murine monoclonal anti-P-gp antibody 
C219 (Alexis, San Diego, CA) diluted 1:2000, or a murine polyclonal anti-
GAPDH antibody (Research Diagnostic Inc., Flanders, NJ) diluted 1:2000. For 
details about antibodies see above. Primary antibodies were all diluted in PBS 
buffer containing 0.5% Tween 20 and 5% non-fat milk, and incubated with the 
membranes at room temperature overnight on a shaker. Membranes were then 
washed with PBS buffer containing 0.5% Tween 20 and incubated with a 
horseradish peroxidase-conjugated goat antimouse immunoglobulin antibody 
(Jackson ImmunoResearch Laboratories, # IR-115-035-164), diluted 1:5000 in 
PBS buffer containing 0.5% Tween 20 and 5% non-fat milk. Membranes were 
incubated with the secondary antibody for 1 hour at room temperature on a shaker. 
Detection by enzyme-linked chemiluminescence (enhanced chemiluminescence: 
ECL) was performed according to the manufacturer’s instructions (Amersham, 
Piscataway, NJ). 
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4.5 Analysis of Drug Sensitivity 
 
Cell survival was measured by the MTT [3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium] assay. Exponentially growing cells were trypsinized, 
harvested, and 5x103 cells in 100 µl of culture medium were inoculated into each 
well of a 96 well plate. A different number of cells was plated just in the case of 
DU145 and RC0.1 cell lines. In fact, because of the differences in duplication time 
and size of the two cell lines, 1x103 cells (RC0.1) and 2.5x103 cells (DU145) in 
100 µl of culture medium were inoculated into each well of a 96 well plate, thus to 
reach equal levels of confluency (20-30%) after 24 hours. After overnight 
incubation, serially diluted drug was added in 100 µl of culture medium to give the 
indicated final concentration. Cells were then incubated for 72 hours at 37ºC in 5% 
CO2. Following the incubation, the MTT assays were performed as indicated by 
the manufacturer (Molecular Probes, Eugene, OR).  
Briefly, the medium was removed and 100 µl of fresh medium red 
phenol-free (Iscove’s Modified Dulbecco’s Medium, Life Technologies, 
Gaithersburg, MD), containing 10 µl of MTT (12 mM in PBS, Molecular Probes), 
were added to each well and the cells were incubated for an additional 4 hours at 
37°C in 5% CO2. After aspiration of the culture medium, the resulting formazan 
precipitate was dissolved with 150 µl of isopropanol/0.1 N HCl. Plates were then 
placed on a shaker for 5 minutes in the dark and the formation of the soluble MTT 
purple dye was immediately monitored by measuring the optical density at 570 nm 
using a 96 well plate reader (SpectroMax 250, Molecular Devices Inc., city, state). 
In order to examine the effects of the compounds MK571 and 15-d-PGJ2, 
used as MRP2 inhibitors, cells were preincubated without or with MK571 (20 
µM), or 15-d-PGJ2 (2.37 µM) for 24 hours and then incubated with various 
concentrations of drugs in the presence and in the absence of MK-571 (20 µM) or 
15-d-PGJ2 (2.37 µM). 
In order to assess whether siRNA-directed suppression of MRP2 
sensitized RC0.1 resistant cells to camptothecins, mock-treated and si-RNA-
treated cells were trypsinized 24 hours after the transfection, performed in 6 well 
plates, and transferred into 96 well plates. The same number of mock-treated and 
siRNA-treated cells (1x103) was inoculated into each well of a 96 well plate. 
Following overnight incubation, serially diluted drug was added in 100 µl of 
culture medium to give the indicated final concentration. The drug (camptothecin 
or 9-nitro-camptothecin) was thus added to the culture medium 48 hours after the 
treatment with MRP2-specific siRNAs. After 72 hours from drug addition, MTT 
assays were performed as decribed above to evaluate cell viability. 
Cell survival was expressed as the percentage of viable cells in the 
presence of the compound under test, with respect to control cultures grown in the 
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absence of the tested compound. The values reported in each figure represent the 
average of the values obtained in 3 independent experiments. 
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5. RESULTS AND DISCUSSION 
 
 
5.1 Overexpression of the ABC Transporter ABCC2/MRP2 in the 
Resistant Tumor Cell Line RC0.1 
 
In this study the human prostate resistant cancer cell line RC0.1, derived 
from the parental sensitive cell line DU145 by continuous exposure to 0.1 µM 
rubitecan (9-nitro-camptothecin) (Chatterjee et al. 1996), was used. This cell line 
presents a peculiar profile of multidrug resistance (Reinhold et al. 2003), since it 
has been reported to be resistant to camptothecin (Oberlies and Kroll 2004) and its 
analogues, NB-506 (an inhibitor of topoisomerase I) (Meng et al. 2003) and 
cisplatin (Ho et al. 2003). RC0.1 cells have been reported to be also sensitive to 
drugs known to be exported by ABC transporters, such as ABCB1/MDR1 or 
ABCC1/MRP1 (Chatterjee et al. 2001). 
Many factors have been proposed to explain the phenotype of drug 
resistance in RC0.1 cell line (Reinhold et al. 2003; Urasaki et al. 2001). Among 
them, the effects of specific mutations in topoisomerase I gene which would 
prevent the binding of camptothecin and its analogues, and a general alteration of 
apoptotic regulation. Topoisomerase I enzyme has recently been investigated as a 
new target for chemotherapy (Cabanillas 1999; Kantarjian 1999). In higher 
eukaryotes, it is an essential enzyme that catalyzes the relaxation of negative 
supercoils during DNA processing, including replication, transcription, and repair. 
The natural product camptothecin targets the topoisomerase I/DNA covalent 
complex, a catalytic intermediate, by reversibly blocking topoisomerase I-
mediated religation of the DNA strand and release of free topoisomerase I (Hsiang 
et al. 1985). In the presence of camptothecin, topoisomerase I remains covalently 
linked to one strand of the DNA, and thus leaves the DNA as a single-stranded 
nicked DNA linked to the protein. These lesions are cytotoxic and trigger 
apoptotic cell death (Shao et al. 1999; Strumberg et al. 2000). However, it is worth 
noting that topoisomerase I mutations can explain resistance to camptothecin and 
its analogues in some experimental models (Pommier et al. 1999; Chen and Liu 
1994; Beck et al. 1997; Nieves-Neira and Pommier 1999), but they have not been 
implicated in clinical resistance to camptothecins. 
In order to compare mRNA expression profiles of DU145 and RC0.1 
cells, microarray and quantitative RT-PCR analyses were performed (Annereau et 
al. 2004). The ABC transporter ABCC2/MRP2 was found to be overexpressed in 
the resistant cell line RC0.1, whereas the expression of other members of the ABC 
superfamily was found to be unchanged (Annereau et al. 2004). Since mRNA 
levels may not reflect protein expression, due to modulation of translation or 
inhibition of protein processing, MRP2 expression was analyzed also at the protein 
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level. To this purpose, total proteins were extracted from cells of both cell lines, 
DU145 and RC0.1, and analyzed by SDS-PAGE, followed by Western blot 
analyses with an anti-MRP2 antibody. The results indicated that the protein 
expression follows the pattern predicted by RNA analyses (Annereau et al. 2004). 
The ABC transporter MRP2 was found to be up-regulated in the resistant cell line, 
whereas the signal for MRP2 was not detectable in the case of the parental 
sensitive cell line DU145 (Fig. 4). In these experiments the use of an antibody able 
to recognize the housekeeping protein glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) allowed a direct comparison of the expression levels (Fig. 4). 
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5.2 Analysis of the Effect of the MDR-reversing Agent MK571 on the 
Resistance Phenotype of RC0.1 Tumor Cell Line 
 
In order to establish the role of the ABC transporter MRP2 in maintaining 
the resistance phenotype of RC0.1 tumor cells, the cytotoxicity of the drug 
camptothecin and its derivative 9-nitro-camptothecin was evaluated in the 
presence of MK571, a compound that is known to strongly inhibit MRP2 by 
interacting with its substrate binding site (Chen et al. 1999). Dose-response curves 
of DU145 and RC0.1 cells were performed to examine the cytotoxic effect of 
MK571. When cells were incubated in the presence of MK571, it was found to be 
not toxic for either cell lines at a concentration of 20 µM (data not shown). Dose-
response curves of DU145 and RC0.1 cells were then obtained upon treatment 
with increasing concentrations of the drugs (camptothecin or 9-nitro-
camptothecin) in the presence and absence of 20 µM MK571. The results of the 
MTT assays are shown in Fig. 5. Unexpectedly, the presence of the inhibitor 
MK571 did not revert the resistance phenotype of RC0.1 tumor cells. 
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5.3 Inhibition of MRP2 Protein Expression by RNA Interference 
 
An alternative strategy was used to evaluate the role of the ABC 
transporter MRP2 in the resistance phenotype of RC0.1 tumor cells to the drug 9-
nitro-camptothecin. To this purpose, the expression of MRP2 was inhibited using 
the RNA interference (RNAi) technology. RNAi is a conserved biological 
response to double-stranded RNA fragments, which results in sequence-specific 
gene silencing (Hannon 2002). Physiologically, RNAi is initiated by specific 
double-stranded RNA (dsRNA) fragments generated by RNase III Dicer enzyme 
that is responsible for the processing of long dsRNAs into small interfering RNAs 
(siRNAs). These siRNAs are incorporated into a protein complex that recognizes 
and cleaves its target mRNAs (Nykanen et al. 2001) (Fig. 6). Introduction of 
dsRNAs into mammalian cells does not result in efficient Dicer-mediated 
generation of siRNAs and therefore does not induce RNAi (Ui-Tei et al. 2000). 
The requirement for Dicer in maturation of siRNAs can be bypassed by 
introducing synthetic 21-nucleotides siRNA duplexes that inhibit expression of 
transfected or endogenous genes in a variety of mammalian cells (Elbashir et al. 
2001). 
A pool of 4 specific siRNAs, whose sequence is shown in Fig. 7, was 
used to inhibit the expression of MRP2. Their homology to different regions of 
MRP2 mRNA sequence is indicated in Fig. 7. 
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Both DU145 and RC0.1 tumor cells were transfected with the pool of 4 
siRNAs, used at a concentration of 25 nM each. Following the transfection, the 
expression of the ABC transporter MRP2 was analyzed at the protein level. Total 
proteins were extracted and analyzed by SDS-PAGE, followed by Western blot 
analyses with an anti-MRP2 antibody. The results obtained are shown in Fig. 5. 
The expression of the ABC transporter MRP2 was found to be significantly 
inhibited in RC0.1 cells after 24 and 48 hours from the transfection as compared to 
the controls (mock-treated cells), with higher inhibition values at 48 hours. At 72 
hours instead, the level of expression of MRP2 appeared to have been restored 
(Fig. 8). On the other hand, a signal for MRP2 was instead not detectable in 
DU145 cells (data not shown), as expected from MRP2 low expression levels in 
this cell line. 
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To further confirm the specificity of siRNA-mediated silencing of MRP2, 
experiments were performed to test the effects of the pool of 4 MRP2-specific 
siRNAs on the expression of the ABC transporter P-glycoprotein (P-gp), the 
product of the ABCB1 (or MDR1) gene. To this purpose, RNAi experiments were 
performed using the human breast cancer cell lines MCF-7 and MCF-7MDR. The 
resistant cell line MCF-7MDR, characterized by high levels of expression of P-gp, 
derived from the parental sensitive cell line MCF-7 by transduction with MDR1 
cDNA (Clark et al. 1992). Both MCF-7 and MCF-7MDR tumor cells were 
transfected with the pool of 4 MRP2-specific siRNAs, used at a concentration of 
25 nM each. Following the transfection, the expression of the ABC transporter P-
gp was analyzed at the protein level after 24 hours from the treatment. Total 
proteins were extracted and analyzed by SDS-PAGE, followed by Western blot 
analyses with an anti-Pgp antibody. The results indicated that (see Fig. 9) the 
MRP2-specific siRNAs did not affect P-gp expression in MCF7-MDR cells. Thus, 
we can conclude that MRP2 is a specific target of the siRNAs pool, since the 
expression of the homologous protein P-gp was not affected by the treatment with 
these siRNAs. In order to have a positive control for this experiment, MCF-7 and 
MCF-7MDR cells were also transfected with a siRNA duplex known to inhibit the 
expression of P-gp (Wu et al. 2003). This siRNA was used at a concentration of 
200 nM. Following the transfection, Western blot analyses were performed after 
24 hours from the treatment, as described above. The expression of P-gp was 
found to decrease in siRNA-treated cells as compared to mock-treated cells (Fig. 
9). 
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5.4 Analysis of the Effects of siRNA-mediated MRP2 Silencing on the 
Resistance Phenotype of RC0.1 Tumor Cell Line 
 
In order to assess whether siRNA-directed suppression of MRP2 
sensitized RC0.1 resistant cells to the drug 9-nitro-camptothecin, the drug 
sensitivity of siRNA-treated RC0.1 cells was compared to that of the mock-treated 
cells. To this purpose, 48 hours after the treatment with MRP2-specific siRNAs, 
the drug (camptothecin or 9-nitro-camptothecin) was added to the culture medium. 
This time interval was chosen since at 48 hours the strongest inhibition of MRP2 
expression was observed. After 72 hours from drug addition, MTT assays were 
performed to evaluate cell viability. The results of these experiments indicated that 
the resistance of RC0.1 cells to the drugs camptothecin and 9-nitro-camptothecin 
was not affected by silencing MRP2 expression (Fig. 10). 
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Thus, the results obtained from MRP2 inhibition experiments (Fig. 5), as 
well as from MRP2 silencing experiments (Fig. 10), indicated the absence of any 
correlation between the high expression levels of MRP2 in RC0.1 cell line and its 
resistance phenotype. We can speculate that the high expression levels of MRP2 
possibly represent an early adaptation of cells to the drug, followed by the 
evolution of different resistance mechanisms, such as mutations in the 
topoisomerase I gene. 
These observations are in agreement with the results obtained by 
microarray analyses, which indicated that mRNA expression profiles are 
significantly different in RC0.1 cells with respect to DU145 cells. In particular, 
these analyses indicated the overexpression of the enzyme gamma-
glutamylcysteine synthetase (GSC), also known as glutamate cysteine ligase, in 
the resistant cell line RC0.1 (Annereau et al. 2004). GSC is a key enzyme in 
glutathione metabolism. In contrast, despite its general up-regulation in cancer 
cells, the expression of the enzyme glutathione S-transferase pi (GST-Pi), 
catalyzing the conjugation of glutathione to electrophilic carcinogens, was found 
to be significantly reduced in RC0.1 cells (Annereau et al. 2004). Since the ABC 
transporter MRP2 is known to transport GSH-S-conjugates (e.g., leukotriene C4 
and 2,4-dinitrophenyl-S-GSH), oxidized glutathione (GSSG), glucuronide 
conjugates (e.g., glucuronidated bilirubin and bile salts), and sulfate conjugates of 
certain bile acids (e.g., 3-sulfatolithocholytaurine) (Muller et al. 1994), these 
observations seem to suggest a “metabolic switch” in RC0.1 cells responsible for 
the resistance phenotype. 
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5.5 Identification of New Substrates for the ABC Transporter 
ABCC2/MRP2 
 
In previous studies we identified 28 anticancer drugs as putative 
substrates of the ABC transporter MRP2 (Szakács et al. 2004a). Four of these were 
available from DTP (Developmental Therapeutics Program) and named as follows: 
NSC641281; NSC645145; NSC618059; NSC626878. Their chemical structures 
are represented in Fig. 11. 
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Dose-response curves of wild-type (MDCK parental) and ABCC2-
transfected (MDCKII cMOAT) Madin-Darby canine kidney cells were obtained 
upon treatment with the four compounds. In all the experiments, ABCC2-
overexpressing cells were found to be more resistant to the four drugs as compared 
to control cells, as indicated by the results of MTT assays (Fig. 12). This clearly 
indicated the involvement of the ABC transporter MRP2 in the transport of these 
drugs. The strongest evidence was obtained in the case of compound NSC641281, 
since ABCC2-overexpressing cells proved to be extremely resistant to this 
compound, reinforcing the suggestion that NSC641281 is an ABCC2/MRP2 
substrate (Szakács et al. 2004a). 
To test the specificity of the involvement of MRP2 in the transport of the 
four identified compounds, dose-response curves were performed using control 
(HEK 293 parental) and MRP1-transfected human embryonic kidney cells (HEK 
293). ABCC1/MRP1 is an ABC transporter homologous to MRP2, belonging to 
the same subfamily (ABCC). Control and MRP1-transfected cells were found to 
be equally sensitive to compounds NSC641281, NSC645145 and NSC618059 
(Fig. 10), suggesting that the efflux of these compounds is MRP1 independent, but 
specifically requires MRP2 involvement. However, MRP1-transfected cells were 
found to be slightly more resistant to compound NSC626878 as compared to 
control cells (Fig. 13). This suggested a putative role of MRP1 in the transport of 
this compound. 
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5.6 Identification of the Cyclopentenone Prostaglandin 15-Deoxy-∆12,14-
Prostaglandin J2 (15-d-PGJ2) as a New Substrate of the ABC 
Transporter MRP2 
 
Cyclopentenone prostaglandins, such as prostaglandin J2 (PGJ2), ∆12-
prostaglandin J2 (∆12-PGJ2), 15-deoxy-∆12,14-prostaglandin J2 (15-d-PGJ2), 
prostaglandin A1 (PGA1) and prostaglandin A2 (PGA2) influence a variety of 
cellular processes, including growth and differentiation, gene expression, apoptosis 
and inhibition of inflammatory signaling pathways (Rovin et al. 2002; Forman et 
al. 1995; Kliewer et al. 1995). The chemical structures of the 5 cyclopentenone 
prostaglandins are reported in Fig. 14. 
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The analysis of the chemical structures of the 28 predicted substrates of 
MRP2 evidenced common structural features. As shown in Fig. 15, 7 of the 28 
predicted substrates of MRP2 share a common structural element, represented by a 
cyclopentanone ring, structurally related to the cyclopentenone ring of 
prostaglandins. These compounds are evidenced by a green box in Fig. 15. 
Based on this observation, a role of MRP2 in the efflux of cyclopentenone 
prostaglandins was hypothesized. 
In Fig. 15, the 4 compounds available from DTP (Developmental 
Therapeutics Program) are represented in red. Among them, NSC626878 is the 
only compound containing a cyclopentanone ring. This compound was also 
indicated as a putative substrate of both MRP1 and MRP2 (see above). 
To test our hypothesis, dose-response curves of control (MDCK parental) 
and ABCC2-transfected (MDCKII cMOAT) cells were obtained upon treatment 
with the five above mentioned cyclopentenone prostaglandins. The results of the 
MTT assays are reported in Fig. 16. Control and MRP2-transfected cells were 
found to be equally sensitive to the cytotoxic action of ∆12-prostaglandin J2 (∆12-
PGJ2), prostaglandin A1 (PGA1) and prostaglandin A2 (PGA2). On the contrary, 
MRP2-overexpressing cells were found to be more resistant to prostaglandin J2 
(PGJ2) and 15-deoxy-∆12,14-prostaglandin J2 (15-d-PGJ2) as compared to control 
cells (Fig. 13). Since PGJ2 is an intermediate of the synthesis of 15-d-PGJ2, the end 
product of the metabolic pathway (Straus and Glass 2001), the obtained results 
suggested a role of MRP2 in the transport of the cyclopentenone prostaglandin 15-
d-PGJ2. 
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Further analyses were performed using the cyclopentenone prostaglandin 
15-d-PGJ2 as an inhibitor of the ABC transporter MRP2. To this purpose, control 
(MDCK parental) and MRP2-transfected (MDCKII cMOAT) cells were exposed 
to the identified MRP2 substrate NSC641281 (see above), in the absence and 
presence of 15-d-PGJ2 at the highest concentration previously found to be not 
toxic for both cell lines (2.37 µM). In the presence of 15-d-PGJ2 the resistance of 
MRP2-transfected cells (MDCKII cMOAT) to the drug NSC641281 was 
completely reverted, since they became as sensitive as control cells (Fig. 17). 
These results clearly indicated that compound NSC641281 and 
prostaglandin 15-d-PGJ2 compete for the same target, MRP2. This is a clear 
evidence of a new role of MRP2 transporter, i.e. its involvement in the efflux of 
cyclopentenone prostaglandin 15-d-PGJ2. 
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To test the specificity of the ABC transporter MRP2 in the transport of 
15-d-PGJ2, dose-response curves were performed using control (HEK 293 
parental) and MRP1-transfected human embryonic kidney cells (HEK 293). As 
mentioned before, MRP1 is an ABC transporter belonging to the same subfamily 
(ABCC) of MRP2. Dose-response curves of control and MRP1-transfected HEK 
293 cells were obtained upon treatment with the above mentioned cyclopentenone 
prostaglandins. Control and MRP1-transfected cells were found to be equally 
sensitive to the cytotoxic action of cyclopentenone prostaglandins (Fig. 18). These 
results allowed us to exclude a role of MRP1 in the transport of cyclopentenone 
prostaglandin 15-d-PGJ2, which seems to be specifically related to MRP2. 
However, it is worth noting that there is a discrepancy between these 
results and recent findings indicating that MRP1, as well as MRP3, are able to 
modulate the biological effects of 15-d-PGJ2 in a glutathione-dependent manner 
(Paumi et al. 2003). 
To this purpose, further experiments will be performed to clarify the role 
of the ABC transporter MRP1 in the transport of cyclopentenone prostaglandins. 
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6. CONCLUSIONS 
 
In the first part of my study, the role of the ABC transporter 
ABCC2/MRP2 in camptothecin resistance was analyzed. Microarray analyses, 
performed with a novel ABC-ToxChip (Annereau et al. 2004), indicated high 
levels of MRP2 expression in the camptothecin-resistant prostate tumor cell line 
RC0.1, derived from the parental sensitive cell line DU145 by continuous 
exposure to the drug 9-nitro-camptothecin. Following this observation, 
experiments were here performed to clarify the role of MRP2 in the resistance 
phenotype of RC0.1 tumor cell line. Inhibition of this ABC transporter by specific 
RNA interference constructs or by the inhibitor MK571 did not revert the 
resistance phenotype of RC0.1 cell line. Thus, the obtained results demonstrated 
that MRP2 overexpression is not directly related to the resistance phenotype. This 
observation is in agreement with data indicating the presence of specific mutations 
in topoisomerase I gene and a general alteration of apoptotic regulation in the 
prostate cancer cell line RC0.1 (Reinhold et al. 2003; Urasaki et al. 2001; 
Chatterjee et al. 2001). We can speculate that more than one mechanism is 
involved in resistance phenotype of RC0.1 tumor cell line, and that the elevated 
expression of MRP2 represents only one of the adaptation mechanisms of cells to 
the drug. 
By further experiments, I was able to identify a new physiological role of 
the ABC transporter ABCC2/MRP2, i.e. its involvement in the transport of the 
cyclopentenone prostaglandin 15-deoxy-∆12,14prostaglandin J2 (15-d-PGJ2). 
Among cyclopentenone prostaglandins, 15-d-PGJ2 has attracted considerable 
attention because of its antitumor activities (Clay et al. 2000; Clay et al. 1999; 
Harris and Phipps 2002; Eibl et al. 2001; Shimada et al. 2002; Padilla et al. 2002).  
Prostaglandins are though to exit cells by passive diffusion, but such a 
mechanism is incompatible with their water solubility, which clearly suggests the 
necessity of an active process. In this contest, the idea of an involvement of ABC 
transporters in prostaglandins efflux is really interesting. Such an observation is in 
agreement with recent findings indicating that the ABC transporter MRP4 is 
involved in the efflux of prostaglandins PGE1 and PGE2 (Reid et al. 2003b), and 
that MRP1 and MRP3 are able to modulate the biological effects of 15-d-PGJ2, in 
a glutathione-dependent manner (Paumi et al. 2003). 
The results obtained in the present study clearly indicated a specific 
involvement of ABCC2/MRP2 in the transport of 15-d-PGJ2, whereas other 
cyclopentenone prostaglandins appear not to interact with this ABC transporter. 
Such a result broadens the physiological substrate specificity of MRP2, and 
suggests a putative interaction between cyclopentone prostaglandins and other 
MRP subfamily members of ABC transporters. 
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Antineoplastic Ribonucleases Selectively Kill
Thyroid Carcinoma Cells Via Caspase-Mediated
Induction of Apoptosis
DANIELA SPALLETTI-CERNIA, ROSANNA SORRENTINO, SONIA DI GAETANO, ANGELA ARCIELLO,
CORRADO GARBI, RENATA PICCOLI, GIUSEPPE D’ALESSIO, GIANCARLO VECCHIO,
PAOLO LACCETTI, AND MASSIMO SANTORO
Istituto di Endocrinologia ed Oncologia Sperimentale del Consiglio Nazionale delle Ricerche (CNR), Dipartimento di
Biologia e Patologia Cellulare e Molecolare, Universita` di Napoli Federico II (D.S.-C., R.S., C.G., G.V., M.S.), 80131 Naples,
Italy; Dipartimento di Chimica Biologica, Universita` di Napoli Federico II (S.D.G., A.A., R.P., G.D., P.L.), 80134 Naples,
Italy; and Istituto di Biostrutture e Bioimmagini-CNR (S.D.G.), 80134 Naples, Italy
Bovine seminal ribonuclease (BS-RNase), a natural dimeric
homolog of bovine pancreatic RNase (RNase A), and HHP2-
RNase, an engineered dimeric form of human pancreatic
RNase (HP-RNase), are endowed with powerful antitumor ef-
fects. Here we show that BS- and HHP2-RNases, but not mo-
nomeric RNase A, induce apoptosis of human thyroid carci-
noma cell lines. RNase-induced apoptosis was associated with
activation of initiation caspase-8 and -9. This was followed by
activation of executioner caspase-3, leading to the proteolytic
cleavage of poly(ADP-ribose) polymerase. The caspase in-
hibitor Z-Val-Ala-Asp-(OMe)-fluoromethylketone protected
thyroid cancer cells from BS-RNase-induced apoptosis.
RNase-triggered apoptosis and caspase activation were ac-
companied by reduced phosphorylation of Akt/protein kinase
B (PKB), a serine-threonine kinase that when phosphorylated
is able to deliver survival signals to cancer cells. BS-RNase
antitumor effects in nude mice were accompanied by caspase
activation and apoptosis. Because of the high selectivity of
apoptotic effects for malignant cells, BS- and HHP2-RNase are
promising tools for the treatment of aggressive thyroid
cancer. (J Clin Endocrinol Metab 88: 2900–2907, 2003)
APPROXIMATELY 20,000 NEW cases of thyroid carci-noma are diagnosed each year in the United States,
and 1,300 patients die of the disease. The biological behavior
of thyroid carcinoma varies from indolent microcarcinomas
to poorly differentiated carcinoma, which is associated with
significant morbidity and mortality, and anaplastic carci-
noma, one of the most aggressive human malignancies. At
diagnosis, most anaplastic carcinoma patients have distant
metastases, primarily in lung, bone, and liver. Doxorubicin,
alone or combined with cisplatin, is the most widely used
therapeutic agent, but it does not improve survival in ana-
plastic carcinoma patients (1, 2). Thus, although radioactive
iodine is beneficial in cases of differentiated tumors, more
effective chemotherapeutic agents are needed for aggressive
thyroid cancers.
Bovine seminal ribonuclease (BS-RNase) from bull semen
and Onconase (Onconase is a registered trademark of Al-
facell, Inc., Bloomfield, NJ) from frog eggs (Rana pipiens) are
selectively toxic for cancer cells (3). BS-RNase, the only
dimeric RNase in the vertebrate superfamily (for a review,
see Ref. 4), is not toxic for normal cells grown in vitro, nor
does it exert appreciable toxic effects when administered in
vivo to experimental animals (5), whereas it is very cytotoxic
for a number of tumor cells of different origins (3). BS-RNase
exerts remarkable antitumor effects in syngeneic and xeno-
transplant models (6), and antimetastatic activity (5). Onco-
nase is currently being tested in phase II clinical trials (7).
Conjugation of ribonucleases with polymers or antibodies
results in increased stability and specificity. Onconase linked
to a monoclonal antibody (anti-CD22) is a potent immuno-
toxin against B cell lymphoma (8).
The binding of BS-RNase to a component of the extracel-
lular matrix (9, 10) or of Onconase to an unidentified cell
surface receptor (11) is followed by endocytosis, transloca-
tion to the cytosol, degradation of RNA (rRNA or tRNA by
BS-RNase and Onconase, respectively), and suppression of
protein synthesis. The cytosolic ribonuclease inhibitor (cRI)
tightly binds to internalized RNases, blocking their cytotoxic
activity. Thus, only RNases that can evade cRI are capable of
exerting a cytotoxic action (11–15). The resistance of BS-
RNase to cRI inhibition depends on the dimeric structure of
the enzyme (12, 13, 15). On the other hand, Onconase, the frog
RNase, is inhibited by frog, but not mammalian, cRI.
We recently transformed human pancreatic RNase (HP-
RNase), a monomeric noncytotoxic RNase, into a dimeric
RNase (designated HHP-RNase). This was achieved by re-
placing four of its amino acid residues (Q28, K31, K32, and
N34) with the corresponding residues (L28, C31, C32, and
K34) from BS-RNase. HHP-RNase was selectively cytotoxic
for malignant cell lines (16). A second generation dimeric
mutant of HP-RNase, designated HHP2-RNase, obtained by
introducing another mutation (E111G), was more cytotoxic
Abbreviations: BS-, Bovine seminal; cRI, cytosolic ribonuclease in-
hibitor; fmk, fluoromethylketone; HDF, human diploid fibroblasts;
HP-, human pancreatic; PARP, poly(ADP-ribose) polymerase; PI3K,
phosphoinositide 3-kinase; pNA, p-nitroanilide; RNase, ribonuclease;
zVADfmk, Z-Val-Ala-Asp-(OMe)-fluoromethylketone; Akt/PKB,
protein kinase B.
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than HHP-RNase (17). Given their human origin, HP-RNase
dimeric variants are very promising anticancer agents be-
cause their effects are less likely to be curtailed by the host
immune response.
Onconase and RC-RNase (a cytotoxic ribonuclease from
Rana catesbeiana) promote apoptosis of HeLa (18) and MCF-7
breast cancer cells (19), respectively, and BS-RNase induces
apoptosis of human neuroblastoma (20) and thyroid tumor
cells (16, 21, 22). Two major apoptotic pathways, triggered by
mitochondria and cell surface receptors, respectively, have
been identified. The mitochondrial pathway is involved in
the apoptotic response to DNA-damaging agents, for exam-
ple, conventional cancer chemotherapeutics and radiation
(for a review, see Ref. 23). Caspases, aspartate-specific cys-
teine proteases, are key effectors of apoptosis (for a review,
see Ref. 24). The initiation caspase of mitochondria-driven
apoptosis is caspase-9; the initiation caspase of the cell sur-
face-triggered apoptosis is caspase-8. In turn, caspase-8 and
-9 directly activate executioner caspase-3 (for a review, see
Ref. 24).
We have studied BS-RNase- and HHP2-RNase-induced
apoptosis in four thyroid carcinoma cell lines. Our results
demonstrate that the two RNases kill thyroid carcinoma cells
by engaging both the mitochondrial and the cell surface-
initiated apoptotic machinery and suggest that Akt/protein
kinase B (PKB) is a target of apoptotic RNase cell signaling.
Materials and Methods
RNases
BS-RNase was purified from bovine seminal vesicles as reported
previously (25). HHP2-RNase was generated and purified as previously
described (17). RNase A was purchased from Sigma-Aldrich Corp. (St.
Louis, MO).
Cell lines
NPA and ARO cells (26), a gift from J. A. Fagin, derive from human
papillary and anaplastic thyroid carcinomas, respectively. CAL62 (27),
a gift from J. Gioanni, and KAT4 (28), a gift from K. B. Ain, were
established from human thyroid anaplastic carcinomas. All of these cell
lines are tumorigenic when injected into nude mice (26–28). HDF are
normal human diploid fibroblasts, and they were gifts from P. Dotto and
C. Missero. All cell lines were grown in DMEM supplemented with 10%
fetal calf serum (Life Technologies, Inc., Paisley, PA), penicillin (50
U/ml), and streptomycin (50 g/ml; Sigma-Aldrich Corp.).
Analysis of apoptosis
For fluorescence microscopy analysis, 104 cells were plated on cov-
erglasses in 24-well plates. Twenty-four hours after plating, RNases
were added to a final concentration of 1.8 m. Seventy-two hours later,
adherent cells and those present in the medium were fixed for 20 min
in 3.7% formaldehyde, washed in PBS, permeabilized for 5 min in 0.1%
Triton X-100, and stained for 30 min with Hoechst 33258 (Sigma-Aldrich
Corp.) at a concentration of 0.5 g/ml in PBS. The stained cells were
observed under an epifluorescent microscope (Axiovert 2, Carl Zeiss,
New York, NY) interfaced with the image analyzer software KS300 (Carl
Zeiss), and photographed.
For a time-dependent analysis of apoptotic DNA fragmentation, cells
were plated in 96-well plates (1 103/well in 100l medium). After 24 h,
each RNase was added to the culture medium (to a final concentration
of 1.8 m) for times ranging from 15 min to 72 h. Apoptosis was mea-
sured in quadruplicate samples using the Cell Death Detection ELISA
Plus kit (Roche, Mannheim, Germany). This photometric sandwich en-
zyme immunoassay determines cytoplasmic histone-associated DNA
fragments (mono- and oligonucleosomes) upon induction of cell death.
Briefly, a mixture of biotin-labeled antihistone and peroxidase-conju-
gated anti-DNA antibodies was added to the cell lysates and placed in
a streptavidin-coated microtiter plate. During incubation, the antihis-
tone antibody binds to the histone component of the apoptotic nucleo-
somes and simultaneously captures the immunocomplex to the strepta-
vidin-coated plates via its biotinylation. Meanwhile, the anti-DNA
antibody reacts with the DNA component of the nucleosomes. The
amount of nucleosomes was determined spectrophotometrically at 405
nm with 2,2-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) as a sub-
strate of peroxidase (Microplate reader, Bio-Rad Laboratories, Inc., Mu-
nich, Germany).
Determination of caspase activation
Cells were treated with RNases for various times. At the end of each
treatment, caspases-3, -8, and -9 activities were tested with colorimetric
protease assay kits (Alexis Biochemicals, San Diego, CA), in which the
chromophore p-nitroanilide (pNA) is detected spectrophotometrically
(at 400 or 405 nm) after cleavage from the labeled substrate. The caspase-
3/CPP32, the Flice/caspase-8, and the caspase-9/Mch6 kits assay the
activity of caspase-3, which recognizes the Asp-Glu-Val-Asp (DEVD)
sequence; the activity of caspase-8, which recognizes the Ile-Glu-Thr-
Asp (IETD) sequence; and the activity of caspase-9, which recognizes
the Leu-Glu-His-Asp (LEHD) sequence, respectively. The increase in
caspase activity was determined by comparing the absorbance of pNA
from a treated sample vs. an untreated control. The results from three
independent experiments were averaged for each time point.
Caspase inhibitors
Caspase inhibitors (Alexis Biochemicals, San Diego, CA) irreversibly
bind to the caspase active sites because the peptide recognition sequence
is linked to a fluoromethylketone (fmk). To increase cell permeability,
their aspartic acid residues are esterified with methyl groups. Z-Val-
Ala-Asp-(OMe)-fluoromethylketone (zVADfmk; 50 m; added every
24 h) was used as a general upstream caspase inhibitor for the in vivo
DNA fragmentation assay. Z-Ile-Glu-Thr-Asp(OMe)-fluoromethyl-
ketone, Z-Leu-Glu(OMe)-His-Asp(OMe)-fluoromethylketone, and Z-
Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-fluoromethylketone (to a final
concentration of 10 m) were used as caspase-8, -9, and -3 selective
inhibitors, respectively.
Immunoblot
Protein lysates (100 g) were electrophoresed through 7.5% sodium
dodecyl sulfate-polyacrylamide gel, transferred to Immobilon mem-
branes (Bio-Rad Laboratories, Inc.), and analyzed by immunoblot. An-
tipoly-(ADP-ribose) polymerase (anti-PARP) antibodies (1:2000) were
purchased from Roche Molecular Biochemicals. Anti-Akt and antiphos-
pho-Akt (Ser473), specific for the active Akt phosphorylated at serine 473,
antibodies were obtained from Cell Signaling (Beverly, MA). Immuno-
reactive bands were visualized using the enhanced chemiluminescence
detection reagents (Amersham Pharmacia Biotech, Arlington Heights,
IL) according to the manufacturer’s protocol.
Tumorigenicity in nude mice
ARO cells (2  106/mouse) were inoculated sc into the right dorsal
portion of 6-wk-old male BALB/c /mice (The Jackson Laboratory, Bar
Harbor, ME). BS-RNase (20 g/g body weight) or vehicle (PBS) was
injected in the peritumor area starting 1 d after cell implantation for a
total of six injections (at 72-h intervals). Tumors were harvested 14 d after
cell implantation and weighed. Apoptotic rate and caspase-9 and -3
activity were measured as described above. No mouse showed signs of
wasting or other signs of toxicity. Animals were maintained at the
Dipartimento di Biologia e Patologia Cellulare e Molecolare Animal
Facility. All manipulations were performed under isoflurane gas anes-
thesia and were conducted in accordance with Italian regulations for
experimentation on animals.
Statistical analysis
A t test was used to evaluate the statistical significance of the results.
Analyses were performed with the BMDP New System statistical pack-
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age version 1.0 for Microsoft Corp. Windows (BMDP Statistical Soft-
ware, Los Angeles, CA).
Results
BS-RNase and HHP2-RNase induce apoptosis of thyroid
carcinoma cells
We previously demonstrated that dimeric RNases (16) are
very cytotoxic for NPA, a highly tumorigenic human thyroid
carcinoma cell line. To identify the mode of thyroid cell
death, we treated NPA cells and HDF with BS-RNase and
HHP2-RNase. Noncytotoxic RNase A and HP-RNase were
used as controls. After treatment (1.8 m for 72 h), cells were
examined for the presence of apoptotic nuclear bodies by
fluorescence microscopy after Hoechst 33258 staining. Cells
were cytospun to analyze both adherent and detached cells;
the experiments were performed in triplicate; at least 200
cells were counted for each assay. BS-RNase and HHP2-
RNase treatment caused relevant apoptosis of NPA cells
(25–30  5%); apoptotic cells showed typical condensed
chromatin and apoptotic bodies (Fig. 1A). In contrast, apo-
ptosis was not detected (2%) with RNase A (Fig. 1A) or
HP-RNase (not shown). More importantly, apoptosis was
not detected (5%) in HDF cells treated with BS-RNase or
HHP2-RNase (data not shown and see below).
PARP cleavage, a sensitive marker of caspase-mediated
apoptosis, resulted in the disappearance of the 116-kDa full-
size PARP band (p116PARP) monitored by Western blot.
p116PARP levels decreased in NPA cells after 24 h of BS-
RNase treatment (Fig. 1B); after 72 h, most of the full-size
PARP had disappeared. Differently, BS-RNase treatment did
not affect the amount of p116PARP in HDF cells (Fig. 1B).
We used an ELISA-based assay to quantitate apoptosis. As
shown in Fig. 1C, apoptotic nucleosomes were detected after
treatment of NPA cells with both cytotoxic ribonucleases; the
greatest effects occurred at 24 h (BS-RNase) and 48 h (HHP2-
RNase). As expected, apoptotic nucleosomes were not de-
tected in HDF cells (Fig. 1C). To determine whether these
findings also applied to other thyroid carcinoma cell lines, we
measured apoptosis in highly tumorigenic anaplastic ARO,
CAL62, and KAT4 cells after treatment for various times.
These anaplastic cell lines were even more sensitive than
NPA cells to the proapoptotic effects of HHP2-RNase (Fig. 2)
and BS-RNase (not shown).
BS-RNase and HHP2-RNase trigger caspase cascades in
thyroid cancer cells
To assess the role of caspases in RNase-induced apoptosis,
we analyzed the kinetics of caspase activation in the four
FIG. 1. NPA cell apoptosis induced by cytotoxic RNases. A, NPA cells were exposed for 72 h to the indicated RNases or were left untreated ().
Cells were fixed and stained with Hoechst 33258 to reveal nuclear signs of apoptosis and photographed (360). Insets, Apoptotic nuclei (2400).
B, NPA and HDF cells were treated with BS-RNase for the indicated times. Protein lysates were immunoblotted with anti-PARP and antitubulin
for normalization. C, NPA and HDF cells were treated with the indicated RNases for times ranging from 15 min to 72 h. At the end of each
treatment, DNA fragmentation was measured with the Cell Death Detection ELISA Plus kit. Values are the mean  SD of quadruplicate
determinations of three independent experiments.
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thyroid cancer cell lines using substrates specific for
caspase-8, -9, and -3. In these assays the spectrophotometric
detection of pNA chromophore, cleaved from the specific
synthetic substrate, is a measure of caspase activity. Selective
inhibitors of the three caspases served as a control of spec-
ificity. Caspase-8 activity increased significantly at 5 min and
peaked at 30 min in NPA cells treated with BS-RNase (Fig.
3A). Its activity slowly declined thereafter, but was still sig-
nificantly enhanced at 48 h. Similar kinetics were observed
in HHP2-RNase-treated NPA cells (Fig. 3A). The extent of
caspase-8 activation in the three anaplastic cell lines was, on
the average, even greater than that in NPA cells (Fig. 3A).
Caspase-9 activity began to increase at 6 h and peaked at 24 h
in BS-RNase-treated NPA cells, whereas it peaked at 3–6 h
after treatment with HHP2-RNase in all four cancer cell lines
(Fig. 3B). Consistent with its downstream role, caspase-3
activity started to increase later than caspase-8 and -9 activ-
ities, with a peak at 24–48 h depending on the RNase tested
and on the cell line (Fig. 3C). There was no caspase activation
in HDF cells treated with either BS-RNase or HHP2-RNase.
No apoptosis was detected in cells treated with RNase A.
A general caspase inhibitor protects thyroid cancer cells
from BS-RNase-induced cell death
If RNase-induced apoptosis is a caspase-dependent pro-
cess, DNA fragmentation should be partially or fully pre-
vented in cells cotreated with RNases and caspase inhibitors.
To address this question, we cotreated NPA cells with BS-
RNase and zVADfmk (to a final concentration of 50 m), a
general upstream inhibitor of caspases. The inhibitor
was replenished daily when the treatment exceeded 24 h.
zVADfmk significantly decreased RNase-induced DNA
fragmentation (Fig. 4). Similarly, HHP2-RNase-induced ap-
optosis of CAL62 cells was significantly decreased by zVAD-
fmk treatment (not shown). However, apoptosis was re-
duced, but not abrogated, upon caspase inhibition.
Cytotoxic RNases decrease Akt/PKB phosphorylation
The serine/threonine protein kinase Akt/PKB (hereafter
Akt) has emerged as a key factor in tumorigenesis (29). Akt
is a downstream effector of phosphoinositide 3-kinase
(PI3K). Amplification of PI3K and Akt family genes, loss of
function mutations of the PTEN phosphatase (which nega-
tively regulates the PI3K/Akt pathway), and gain of function
mutations of upstream activators of Akt (e.g. oncogenic ras
and receptor tyrosine kinases) are frequent features of hu-
man cancer, including thyroid carcinomas (30–32). Akt af-
fects such important cancer cell functions as growth and
survival. In particular, by phosphorylating Bad and
caspase-9, Akt obstructs caspase activation and protects can-
cer cells from apoptosis (29). We examined Akt activation by
immunoblot with antibodies specific for the activated form
of Akt phosphorylated at serine 473 in NPA and Cal62 thy-
roid cancer cells treated with HHP2-RNase. RNase treatment
caused a slow, but significant, decrease in Akt activation
levels; at 24 h of treatment, Akt phosphorylation was ap-
proximately 3-fold lower than that in untreated cells, as
measured by phosphorimaging (Fig. 5).
In vivo BS-RNase antitumor effects are associated with
induction of apoptosis
We determined whether the proapoptotic effects of
RNases could be detected in vivo in mice bearing tumors
induced by thyroid neoplastic cells. Nude mice were inoc-
ulated with 2  106 ARO cells sc. Starting 24 h after cells
injection, five mice were treated with six injections (at 72-h
intervals) of BS-RNase (20 g/g body weight) in the peri-
tumoral area. Another group of five control mice was treated
with PBS. Consistent with in vitro cytotoxic effects of BS-
RNase, the average tumor weight of RNase-treated animals
was 0.06  0.01 g, whereas untreated tumors reached 0.4 
0.02 g 14 d after cell injection. Tumor tissues were harvested,
and apoptotic rate and caspase activation were measured as
described above. As shown in Fig. 6, apoptosis was signif-
icantly (P 0.02) increased (8-fold) in tumors treated with
BS-RNase compared with vehicle-treated tumors. Moreover,
the activity of downstream caspase-9 and -3 increased sig-
nificantly (P  0.02 and P  0.009, respectively) in tumors
treated with BS-RNase.
Discussion
Cytotoxic RNases are a nonmutagenic alternative to
conventional DNA-damaging cancer therapy. We show
that BS-RNase and HHP2-RNase readily kill thyroid car-
cinoma cells by apoptosis. No apoptosis was observed
FIG. 2. DNA fragmentation of thyroid carcinoma cells treated with
HHP2-RNase. The various cell lines were treated with HHP2-RNase
for 0, 24, or 48 h. At the end of each treatment, DNA fragmentation
was measured with the Cell Death Detection ELISA Plus kit. Values
are expressed as the fold increase in apoptosis and are the mean 
SD of quadruplicate determinations of three independent experi-
ments.
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when the same cells were treated with monomeric RNases.
Furthermore, no apoptosis was observed upon RNase
treatment of normal human diploid fibroblasts, which con-
firms the selectivity of cytotoxic RNases for malignant
cells. Importantly, induction of apoptosis was also ob-
served when tumors induced by thyroid carcinoma cells in
FIG. 3. Caspase activation. Time course of caspase-8 (A), caspase-9 (B), and caspase-3 (C) substrate hydrolysis in cells exposed to RNases.
Caspase activity was also measured in the presence of the caspase-8 inhibitor Z-Ile-Glu-Thr-Asp(OMe)-fluoromethylketone (zIETDfmk), the
caspase-9 inhibitor Z-Leu-Glu(OMe)-His-Asp(OMe)-fluoromethylketone (zLEHDfmk), or the caspase-3 inhibitor Z-Asp(OMe)-Glu(OMe)-Val-
Asp(OMe)-fluoromethylketone (zDEVDfmk) to prove specificity. Each point represents the mean  SD of three determinations from three
independent experiments.
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nude mice were treated in vivo with BS-RNase. The thyroid
carcinoma cell lines studied lack functional p53 (26, 33)
(Spalletti-Cernia, D., unpublished observations) and are
thus resistant to chemotherapeutic drugs such as doxo-
rubicin. Consequently, by inducing cell death regardless
of p53 status, cytotoxic RNases have an advantage over
current therapeutic protocols for advanced human thyroid
carcinomas that frequently carry inactivated p53 (26).
Both BS-RNase and HHP2-RNase induced robust
caspase activation in the carcinoma cells. RNase-mediated
apoptosis was dependent on caspase activation, and cell
treatment with zVADfmk significantly reduced DNA frag-
mentation. However, the constant presence of apoptotic
cells despite zVADfmk probably indicates that other path-
ways, in addition to caspase activation, transduce the ap-
optotic signals of RNases. The kinetics of caspase activa-
tion after RNase treatment of thyroid cancer cells are
consistent with a model in which caspase-8 activation is an
upstream event, followed by activation of caspase-9 and
then caspase-3. Caspase-8 mediates cytochrome c release
from mitochondria by activating Bid (a proapoptotic Bcl-2
family member) that, in turn, triggers caspase-9 activation
(34). Alternatively, caspase-9 may be activated indepen-
dently of caspase-8. Whatever the case, the capability of
BS- and HHP2-RNases of inducing two distinct caspase
cascades probably accounts for their pronounced pro-
apoptotic effect and may hinder the development of re-
sistance of cancer cells.
Caspase-8 is typically activated by the engagement of cell
surface proteins of the TNF receptor superfamily, such as
Fas. Neoplastic thyroid cells are killed by caspase-8, whereas
they are resistant to FasL (35). This is probably due to short-
lived protein inhibitor(s) acting upstream from caspase-8,
because treatment with protein synthesis inhibitors rescues
sensitivity to Fas ligand (35). We did not detect Fas or Fas
ligand overexpression after cell treatment with RNases (not
shown). However, it is feasible that cytotoxic RNases act
downstream from Fas in neoplastic thyroid cells by blocking
the synthesis of the putative caspase-8 inhibitor(s). Our re-
sults differ from those of Iordanov and colleagues (19), who
found activation of caspase-9, -3, and -7, but not of caspase-8,
upon treatment of HeLa cells with Onconase. These discrep-
ancies may be due to the different phenotypes of the cell lines
and the different RNases used. The mode of RNase delivery
may also determine which caspase cascades are activated.
Indeed, although we simply added RNase to the culture
medium, exploiting the natural capability of cancer cells to
internalize cytotoxic RNases, Iordanov and colleagues (19)
FIG. 4. BS-RNase-mediated NPA cell apoptosis depends on caspase
activation. Cells growing in 96-well plates were either untreated (time
zero) or treated with BS-RNase for different times without () or with
(f) zVADfmk. Apoptosis was measured as the mean  SD of quadru-
plicate determinations of three independent experiments with the
Cell Death Detection ELISA Plus kit.
FIG. 5. RNase-mediated apoptosis is accompanied by reduced Akt
phosphorylation. NPA and CAL62 cells were treated with HHP2-
RNase for the indicated times. Protein lysates were immunoblotted
with antiphospho-Akt (pAKT) and anti-Akt for normalization.
FIG. 6. In vivo induction of apoptosis
by BS-RNase. Nude mice were inocu-
lated with 2  106 ARO cells sc and
treated with six injections of BS-RNase
or PBS as a control. Tumor tissues from
RNase-treated () and PBS-treated ()
mice were harvested, and triplicate de-
terminations of apoptotic rate with the
Cell Death Detection ELISA Plus kit (A)
and caspase-9 (B) and -3 (C) activation
were performed. The mean  SD are
shown.
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used lipofectin-mediated delivery of Onconase. Lipofectin
treatment is very efficient because it skips one of the rate-
limiting steps in RNase action, i.e. transport across the cell
membrane. However, it might have perturbed the normal
engagement of the RNase with the cell surface, thus modi-
fying the caspase response.
The very rapid caspase-8 activation in thyroid cancer cells
(starting as early as 5 min post-RNase and peaking at 30 min)
suggests that either the cellular routing (membrane binding-
endocytosis-cytosolic penetration-RNA hydrolysis-transla-
tion inhibition) of RNases is very rapid, or that RNases trig-
ger intracellular signaling events soon after being engaged at
the cell surface.
Cellular RNA degradation is probably a key step in the
process of RNase-mediated cell death. Although the inhibi-
tion of protein synthesis per se could lead to apoptosis, ev-
idence suggests that RNase-induced cell death does not en-
tirely result from the inhibition of protein synthesis. Indeed,
inhibitors of protein synthesis, such as cycloheximide, re-
quire much higher levels of translational inhibition, and they
do so with slower kinetics compared with RNases. Thus, it
is likely that apoptosis results not only from protein synthesis
inhibition, but also from cell signaling events such as c-Jun
N-terminal kinase activation (36) or Akt dephosphorylation
(this paper). The therapeutic specificity of RNases remains
enigmatic. Endocytosis or cellular routing rates of RNases
may differ between malignant and nonmalignant cells. Al-
ternatively, malignant cells might be more sensitive than
normal cells to the toxic effects of RNA hydrolysis. Whatever
the case, we show that there is a major difference between
malignant and normal cells upstream from the cellular
events leading to apical caspases (-8 and -9) activation. In
addition, our data suggest that the down-modulation of Akt
is at least one of the mechanisms leading to thyroid cell death.
Because they obstruct Akt, which is frequently activated in
thyroid cancer, and because they kill thyroid cancer cells
regardless of p53 status, BS-RNase and HHP2-RNase are
promising novel chemotherapeutic agents for aggressive
thyroid cancers.
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ABSTRACT
We report the preparation and characterization of a novel, fully human
antitumor immunoRNase (IR). The IR, a human RNase and fusion pro-
tein made up of a human single chain variable fragment (scFv), is directed
to the ErbB-2 receptor and overexpressed in many carcinomas. The
anti-ErbB-2 IR, named hERB-hRNase, retains the enzymatic activity of
the wild-type enzyme (human pancreatic RNase) and specifically binds to
ErbB-2-positive cells with the high affinity (Kd  4.5 nM) of the parental
scFv. hERB-hRNase behaves as an immunoprotoxin and on internaliza-
tion by target cells becomes selectively cytotoxic in a dose-dependent
manner at nanomolar concentrations. Administered in five doses of 1.5
mg/kg to mice bearing an ErbB-2-positive tumor, hERB-hRNase induced
a dramatic reduction in tumor volume. hERB-hRNase is the first fully
human antitumor IR produced thus far, with a high potential as a poorly
immunogenic human drug devoid of nonspecific toxicity, directed against
ErbB-2-positive malignancies.
INTRODUCTION
Immunotherapy is of great interest today as an effective strategy to
manage cancer and as an alternative to chemotherapy. The Food and
Drug Administration has approved several monoclonal antibodies as
therapeutic agents to manage tumors, and an increasing number are
undergoing clinical evaluation (1). Examples of approved antibodies
are humanized or human-mouse chimeric monoclonal antibodies,
such as anti-ErbB-2 trastuzumab (Herceptin) and anti-CD20 ritux-
imab (Rituxan), widely used against breast cancer and non-Hodgkin’s
lymphoma, respectively (2). To enhance their clinical potential, anti-
bodies also have been coupled to cytotoxic agents or radionuclides
(3).
Immunotoxins (ITs), made up of antibodies or miniantibodies [sin-
gle chain variable fragment (scFv)] fused to toxins, have been pro-
posed as anticancer drugs during the past 2 decades (4, 5). These
chimeric proteins combine the potent toxicity of toxins with the
antigen specificity of antibodies. However, the murine nature of the
immunomoieties, the plant or bacterial nature of the toxin moieties,
and their high toxicity have greatly limited the therapeutic potential of
ITs (6, 7), especially because of the occurrence of vascular leak
syndrome (8–10). Although the development of humanized antibod-
ies has alleviated some of these effects, the toxins themselves remain
a problem.
An alternative, more recent strategy in anticancer immunotherapy is
that based on immunoconjugates in which an RNase substitutes for
the toxin (11). Mammalian RNases are not toxic to cells unless
internalized; thus, these fusion proteins are not ITs but rather immu-
noprotoxins. We have proposed (12) to call them immunoRNases
(IRs). IRs have been prepared with various RNases, each fused to a
monoclonal antibody raised against cell receptors (12–15). However,
the IRs prepared thus far have a limited interest for immunotherapy,
given the nonhuman origin of the antibody moiety used and the choice
of the targeted receptors, such as the epidermal growth factor or the
transferrin receptor (16, 17).
Because of its preferential expression in tumor cells (18) and its
extracellular accessibility, an attractive target for immunotherapy is
ErbB-2, a transmembrane tyrosine kinase receptor that is overex-
pressed on many carcinoma cells of different origin (19, 20), with a
key role in the development of malignancy (21, 22). Furthermore,
activated ErbB-2 is readily internalized, an event that can be mim-
icked by an antibody directed toward the receptor. Thus, an anti-
ErbB-2 antibody can deliver an RNase into ErbB-2-overexpressing
tumor cells. Such a strategy has been successfully tested using a
murine scFv fused to a human RNase (12).
The use of antibody and RNase moieties of human origin for the
preparation of fully human IRs is highly desirable to obtain effective
and tumor-selective but also immunocompatible immunoagents.
Fully human scFvs recently have been generated with the phage
display technology through the expression of large repertoires of
antibody variable regions on filamentous phages after their fusion to
a phage coat protein (23–25). Taking advantage of this powerful
technique, we have isolated a novel human anti-ErbB-2 scFv (26)
from a large phage display library (23) through a double-selection
strategy performed on live cells. This scFv specifically binds to
ErbB-2-positive cells, inhibits receptor autophosphorylation, is inter-
nalized in target cells, and strongly inhibits their proliferation (26).
We report here the construction and characterization of a fully
human antitumor IR made up of the available human anti-ErbB-2
scFv (26) and a human RNase, which we have termed hERB-hRNase.
This IR, to our knowledge the first human IR to be produced, may
prove to be a valuable anticancer agent for therapy of ErbB-2-
overexpressing carcinomas.
MATERIALS AND METHODS
Antibodies and Cell Cultures. The antibodies used in the current study
were the following: murine monoclonal antibody 9E10 directed against the
myc tag protein (27), the IgG fraction from a rabbit anti-human pancreas
RNase (HP-RNase) antiserum (Igtech, Salerno, Italy) purified by affinity
chromatography of the antiserum on protein A-Sepharose CL-4B (Amersham
Pharmacia Biotech, Piscataway, NJ), horseradish peroxidase-conjugated anti-
His antibody (Qiagen, Valencia, CA), horseradish peroxidase-conjugated goat
antirabbit immunoglobulin antibody (Pierce, Rockford, IL), horseradish
peroxidase-conjugated rabbit antimouse immunoglobulin antibody (Pierce),
and FITC-conjugated sheep antirabbit immunoglobulin antibody (Dako,
Glostrup, Denmark).
The MDA-MB361 (provided by Dr. N. Normanno, Cancer Institute of
Naples, Italy) and the SKBR3 cell lines from human breast tumor and the A431
cell line from human epidermoid carcinoma (American Type Culture Collec-
tion, Manassas, VA) were cultured in RPMI 1640 (Life Technologies, Rock-
ville, MD). The MDA-MB453 cell line from human breast tumor (a gift of
H. C. Hurst, ICRF, London, UK) and the TUBO cell line from a BALB-neu T
mouse-derived mammary lobular carcinoma (provided by Dr. G. Forni, Uni-
versity of Turin, Italy) were grown in DMEM (Life Technologies). Media were
supplemented with 10% fetal bovine serum (20% for TUBO cells), 50 units/ml
penicillin, and 50 g/ml streptomycin (all from Life Technologies).
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Construction of the Chimeric cDNA Encoding hERB-hRNase. A cDNA
coding for HP-RNase (28) was engineered by two successive PCRs. Upstream
primers (termed A and B) were used to incorporate the NotI restriction site at
the 5 end and a spacer sequence, whereas a downstream primer (C) was used
to introduce a NotI site at the 3 end. In the first reaction, primers B and C were
used. The oligonucleotide B sequence (5-GGCCCGGAAGGCGGCAG-
CAAAGAATCTAGAGCTAAAAA-3) encodes the COOH-terminal half of
the spacer; the oligonucleotide C sequence (5-ATAAGAATGCGGCCGCA-
GAGTCTTCAACAGACG-3) contains the NotI restriction site. In the second
reaction, primers A and C were used. Oligonucleotide A (5-ATAAGAAT-
GCGGCCGCAAGCGGCGGCCCGGAAGGCGG-3) encodes the N-terminal
half of the spacer preceded by the NotI site sequence. The PCR fragment then
was digested with NotI (New England Biolabs, Beverly, MA) and cloned into
the corresponding site of pHEN2 vector (29) downstream to the sequence
encoding the available human anti-ErbB-2 scFv (26). The correct directional
insertion of the RNase gene in the NotI site was assessed by PCR using the
forward primer A in combination with a reverse oligonucleotide corresponding
to a vector sequence positioned downstream to the NotI site (5-TGAATTT-
TCTGTATGAGG-3).
Sequence analyses confirmed the expected DNA sequence. The assembled
gene then was cloned in a T7 promoter-based Escherichia coli expression
vector (pET22b).
Expression and Purification of hERB-hRNase. Cultures of E. coli BL21
(DE3), previously transformed with the recombinant pET22b() expression
vector, were grown at 37°C in LB medium containing 50 g/ml ampicillin
until the exponential phase was reached. The expression of soluble IR (hence-
forth called hERB-hRNase) was induced by addition of isopropyl--D-thioga-
lactopyranoside to a final concentration of 1 mM in the cell culture, which then
was grown at room temperature overnight. Cells were harvested by centrifu-
gation at 6000 rpm for 15 min, and the periplasmic extract was obtained as
described previously (26) and incubated with the 4-mercapto-ethyl-pyridine
HyperCel matrix (BioSepra, Cergy-Saint-Christophe, France) for 2 h at room
temperature. After extensive washes with 50 mM Tris-HCl (pH 8.0), two
additional wash steps were performed: the first with H2O and the second with
25 mM sodium caprylate in 50 mM Tris-HCl (pH 8.0). The 4-mercapto-ethyl-
pyridine HyperCel resin then was equilibrated in 50 mM Tris-HCl (pH 8.0)
before elution of the protein with 50 mM sodium acetate (pH 4.0). The sample
was immediately adjusted to pH 7.0, diluted with B-PER buffer (Pierce), and
loaded on an immobilized-metal affinity chromatography column using a
cobalt-chelating resin (TALON; Clontech, Palo Alto, CA) to achieve further
purification. Wash and elution steps were performed according to the manu-
facturer’s recommendations. The purity of the final preparation was evaluated
by SDS-PAGE, followed by Coomassie staining and Western blot analysis
with anti-HP-RNase immunoglobulins, followed by goat antirabbit horseradish
peroxidase-conjugated IgG.
RNase Activity Assays. RNase activity was tested as described previously
(30) on yeast RNA (8 mg/ml). RNase zymograms, carried out on SDS-PAGE
electropherograms, were performed as described previously (31).
Binding Assays. ErbB-2-positive SKBR3, MDA-MB361, MDA-MB453,
and TUBO cells and ErbB-2-negative A431 control cells, harvested in non-
enzymatic dissociation solution (Sigma, St. Louis, MO), were washed and
transferred to U-bottomed microtiter plates (1 105 cells/well). After blocking
with PBS containing 6% BSA, the plates were incubated with purified immu-
noagents in ELISA buffer (PBS/BSA 3%) for 90 min. After centrifugation and
removal of supernatants, pelleted cells were washed twice in 200 l of ELISA
buffer, resuspended in 100 l of the same buffer, and incubated for 1 h with
either rabbit anti-HP-RNase IgG (for the detection of hERB-hRNase) or with
murine anti-myc monoclonal antibody (for scFv detection), followed by per-
oxidase-conjugated antirabbit or antimouse IgG (Pierce), respectively, accord-
ing to the source of the primary antibody. After 1 h, the plates were centri-
fuged, washed with ELISA buffer, and reacted with 3,3,5,5-
tetramethylbenzidine (Sigma). Binding values were determined from the
absorbance at 450 nm and reported as the mean of at least three determinations
(SD  5%).
Internalization of hERB-hRNase. Cells grown on coverslips to 60%
confluency were incubated with the immunoagent (20 g/ml) for 16 h at 37°C.
Cells then were washed, fixed, and permeabilized as described elsewhere (26).
Intracellular IR was detected with a rabbit anti-HP-RNase antibody, followed
by FITC-conjugated sheep antirabbit antibody. Optical confocal sections were
taken using a confocal microscope (LSM 510; Zeiss, Oberkochen, Germany).
Cytotoxicity Assays. Cells were seeded in 96-well plates (150 l/well);
SKBR3, MDA-MB361, TUBO, and MDA-MB453 cells were seeded at a
density of 1.5  104/well, and A431 cells were seeded at a density of
5  103/well. Cell survival was expressed as percentage of viable cells in the
presence of the protein under test, with respect to control cultures grown in the
absence of the protein.
Stability of the IR. The stability of hERB-hRNase was determined by
incubating the protein at a concentration of 0.04 mg/ml in either human or
murine serum at 37°C for 24 or 48 h. At the end of incubation the samples were
tested using the analytical tests described previously.
In Vivo Antitumor Activity. All of the experiments were performed with
6-week-old female BALB/cAnNCrlBR mice (Charles River Laboratories,
Wilmington, MA). TUBO cells (5 105) were suspended in 0.2 ml sterile PBS
and injected s.c. (day 0) in the right paw. At day 10, tumors were clearly
detectable (at least 15 mm3 in volume). At day 11, hERB-hRNase, dissolved
in PBS, was administered five times at 72-h intervals peritumorally or i.p. to
two groups of five mice at doses of 1.5 mg/kg of body weight. Equimolar doses
of native HP-RNase or anti-ErbB-2 scFv were administered peritumorally to
other two groups as controls. Another group of control animals was treated
with identical volumes of sterile PBS. At day 45, blood samples were taken
and tested to obtain the main hematologic parameters. During the treatment
period, tumor volumes (V) were measured and calculated using the formula of
rotational ellipsoid V  A  B2/2 (A is axial diameter and B is rotational
diameter). All of the mice were maintained at the animal facility of the
Department of Cellular and Molecular Biology and Pathology, University of
Naples Federico II. The experiments on animals described here were con-
ducted in accordance with accepted standards of animal care and the Italian
regulations for the welfare of animals used in studies of experimental neopla-
sia. The School of Medicine Institutional Committee on animal care approved
the study.
RESULTS
Construction and Purification of hERB-hRNase. The anti-
ErbB-2 fully human IR was prepared as follows: the cDNA encoding
HP-RNase was amplified by two successive PCRs (see “Materials and
Methods”), which added a spacer sequence encoding a peptide of 11
residues designed to separate the RNase (28) and scFv moieties in the
fusion protein. The resulting product was cloned in the expression
vector pHEN2 (29), downstream to the sequence encoding the avail-
able human anti-ErbB-2 scFv (26), and in NcoI/NotI sites. The result-
ing construct encoding the IR, named hERB-hRNase, is shown in Fig.
1. It includes a 15-residue linker made up of glycine and serine
residues (SSGGGGSGGGGSGGS) interposed between VH and VL
chains, an 11-residue spacer (AAASGGPEGGS) inserted between the
antibody fragment and the RNase, and a COOH-terminal hexahisti-
dine tag. The chimeric cDNA was fully sequenced and recloned in a
T7 promoter-based E. coli expression vector (pET22b) equipped
with a pel B signal sequence for expression of hERB-hRNase as a
soluble protein in the periplasmic space.
Characterization of hERB-hRNase. The purified IR was ana-
lyzed by Western blot analysis with an anti-His and an anti-HP-RNase
Fig. 1. Schematic representation of the human immunoRNase hERB-hRNase. VH and
VL, the variable domains of heavy and light chains, respectively, of the anti-ErbB-2 single
chain variable fragment (scFv); LINKER, the 15-residue junction peptide SS(G4S)2GGS;
SPACER, the peptide AAASGGPEGGS connecting the scFv and the RNase moieties;
HP-RNase, human pancreatic RNase; and (His)6, a 6-residue His tag.
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antibody. By both analyses, an immunoreactive band of the expected
size, approximately Mr 46,000, was visualized (Fig. 2).
The fusion protein then was tested for enzymatic activity by a
zymogram developed using yeast RNA as a substrate. As illustrated in
Fig. 2, a single active band was detectable, corresponding to the size
of hERB-hRNase. The ribonucleolytic activity of the purified IR was
further tested with the acid-insoluble RNA precipitation assay (30), by
which the chimeric protein was found to have a specific activity of
950  25 units/nmol. This result was confirmed for several prepara-
tions of the recombinant fusion protein. Because the specific activity
of wild-type HP-RNase is 1100  20 units/nmol, we can conclude
that the chimeric protein retains 90% of the activity of the parental
RNase molecule.
The ability of hERB-hRNase to specifically recognize ErbB-2 was
evaluated by ELISA, performed as described in “Materials and Meth-
ods,” using SKBR3 cells from human breast cancer, which express
high levels of ErbB-2. As a control we used A431 cells from human
epidermoid carcinoma, which express the receptor at low levels. The
results, shown in Fig. 3, indicate that the IR binds with high affinity
to SKBR3 cells, whereas no significant binding to A431 cells was
detected. The apparent binding affinity of hERB-hRNase for the
ErbB-2 receptor (i.e., the concentration corresponding to half-maxi-
mal saturation) was found to be 4.5 nM, almost identical to that
obtained with the parental scFv (4 nM; see Fig. 3).
These results demonstrate that the antibody and RNase moieties
maintain their biological functions in the chimeric protein.
Internalization of hERB-hRNase by SKBR3 Cells. It has been
reported that the human anti-ErbB-2 scFv, previously isolated in our
laboratory, undergoes receptor-mediated endocytosis in SKBR3 cells
(26). To test whether the scFv in the fusion protein could provide a
useful vehicle to deliver the RNase into the cytosol, tumor target cells
were incubated with hERB-hRNase for 16 h at 37°C. After extensive
washes, cells were fixed and permeabilized as described previously
(26). Internalized IR was visualized with anti-HP-RNase antibody,
followed by sheep antirabbit FITC-conjugated antibody. As shown in
Fig. 4, a strong intracellular staining was visualized (Fig. 4B) by
confocal microscopy.
Cytotoxic Effects of hERB-hRNase on Tumor Cells. The puri-
fied hERB-hRNase then was tested for its effects on ErbB-2-positive
and ErbB-2-negative cell survival. For the latter cell type, A431 cells
from human epidermoid carcinoma were used; as antigen-positive
cells, we used SKBR3, MDA-MB361, and MDA-MB453 derived
from human breast carcinomas and TUBO cells from a BALB-neu T
mouse-derived mammary lobular carcinoma (32). Cells were plated in
the absence or in the presence of increasing concentrations of hERB-
hRNase, and after a 72-h incubation, cell survival was measured by
counting trypan blue-excluding cells.
As shown in Fig. 5, hERB-hRNase was found to be selectively
cytotoxic in a dose-dependent manner on all of the antigen-positive
cell lines tested. The values of IC50 (i.e., the concentration capable of
reducing cell viability by 50%) were found to be 12.5, 47, 52, and 60
nM for SKBR3, MDA-MB361, MDA-MB453, and TUBO cells, re-
spectively. When the IR was tested on A431 control cells, no effects
on their proliferation were observed (see Fig. 5). Moreover, no effects
on cell survival were detected when native HP-RNase was tested on
ErbB-2-positive cells at concentrations up to 1 M (i.e., at doses of
RNase up to 20-fold higher than the highest dose of RNase present in
the IR samples tested on the cell cultures). These results indicate that
(a) the RNase moiety in the IR has no effect on cell proliferation
unless driven inside the cells by the immune moiety; and (b) hERB-
Fig. 2. SDS-PAGE analyses of purified hERB-hRNase. Lane 1, hERB-hRNase eluted
from the cobalt-chelating affinity chromatography (Coomassie Blue staining); Lanes 2
and 3, Western blot analyses of the sample as in Lane 1 using anti-human pancreatic-
RNase IgGs (Lane 2) or an anti-His antibody (Lane 3); Lane 4, zymogram of the sample
as in Lane 1 using yeast RNA as a substrate.
Fig. 3. Binding tests of hERB-hRNase to ErbB-2-positive (SKBR3) and ErbB-2-
negative (A431) cell lines. SKBR3 cells (black symbols) and A431 cells (white symbols)
were tested by ELISA with hERB-hRNase (squares) or with the anti-ErbB-2 single chain
variable fragment (circles) as a control.
Fig. 4. Internalization of hERB-hRNase in SKBR3 cells as visualized by confocal
microscopy. Cells were incubated in the absence (A) or in the presence of the immuno-
RNase for 16 h (B); magnification 1:200.
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hRNase is able to finely discriminate between target and nontarget
cells and to specifically induce the death of target cells.
The stronger cytotoxicity of hERB-hRNase on SKBR3 and MDA-
MB361 cells compared with that observed on MDA-MB453 cells
could be related to their different level of ErbB-2, reported to be
sixfold lower in the latter cells (12, 33). By ELISA we confirmed a
lower level of ErbB-2 immunoreactivity in MDA-MB453 cells com-
pared with SKBR3 and MDA-MB361 cells and found a similar low
ErbB-2 content on TUBO cells (data not shown). These results indi-
cate that there is a positive correlation between the expression levels
of ErbB-2 on a particular cell type, the extent of binding of hERB-
hRNase to those cells, and their sensitivity to its cytotoxic action.
Stability of hERB-hRNase. The stability of immunoagents at
37°C is a critical factor for their potential as therapeutic agents. The
stability of hERB-hRNase in human or murine serum at 37°C for up
to 48 h was analyzed by monitoring its integrity as a protein and as
functional bioeffector. Following an incubation in serum for 24 or
48 h at 37°C, the percentage of undegraded and enzymatically active
IR was determined by Western blot analysis with anti-His tag anti-
body and zymogram analyses, respectively. By using a Phosphorim-
ager, the intensity of the electrophoretic bands obtained with treated
hERB-hRNase was expressed as the percentage of the signal given by
the untreated protein. We found that after 24 or 48 h, the percentage
of undegraded and enzymatically active hERB-hRNase was
100  5%.
The binding properties of the IR after incubation in serum were
assessed by ELISA on ErbB-2-positive cells and expressed as the
concentration corresponding to half-maximal saturation. It was found
that the protein incubated in human or murine serum conserved a
value of half-maximal saturation of 5 nM, virtually identical to that
measured for the protein before incubation (see above).
Finally, hERB-hRNase was found to fully retain its cytotoxic
activity after incubation at 37°C for up to 48 h. The IC50 values of the
incubated samples tested on SKBR3 cells (see above) were within
10% of the values measured before incubation.
These results clearly indicate that the IR is stable under the exam-
ined physiologic-like conditions.
In Vivo Antitumor Activity of hERB-hRNase. For in vivo stud-
ies, the ErbB-2-positive tumor cell line TUBO of murine origin (see
above) was used. As shown in Fig. 6, the hERB-hRNase treatment of
mice bearing TUBO tumors with five doses of 1.5 mg/kg of hERB-
hRNase injected peritumorally induced a dramatic reduction (86%) in
tumor volume. Similar results were obtained when the protein was
administered systemically by i.p. injections. This suggests that the
protein is stable in the bloodstream and is able to permeate tumor
masses. Contrarily, the anti-ErbB-2 scFv and native HP-RNase in-
jected peritumorally showed no significant effects on tumor growth
(see Fig. 6). During the treatment period, the animals did not show
signs of wasting or other visible signs of toxicity. Their main hema-
tologic parameters were those of normal mice (data not shown).
DISCUSSION
Immunotherapy has been demonstrated to be a valuable approach in
anticancer therapy. As previously indicated, ITs directed to cell sur-
face molecular targets have been shown to have a therapeutic poten-
tial. However, they also have limitations, mainly represented by
nonspecific toxicity related to vascular leak syndrome and by the
immunogenicity of their bacterial or plant toxins (8–10).
To circumvent these problems, IRs (i.e., chimeric proteins made up
of RNases fused to an antireceptor antibody or scFv) have been
prepared (13–15). These IRs were cytotoxic to tumor cells at nano-
molar concentrations. However, the choice of epidermal growth factor
or transferrin receptors as targets for the antibody, as well as the
murine origin of the antibodies used, sets a limit in the use of these
reagents as therapeutic drugs.
ErbB-2 is an attractive tumor target because of its specific local-
ization on many tumor cells of different origin, its extracellular
accessibility, and its high expression levels in many carcinomas (19,
20). Furthermore, its high expression in carcinomas has been reported
to be a clear sign of negative prognosis (21, 22).
Here, we report the construction, characterization, and antitumor
activity of the first fully human IR targeting the ErbB-2 receptor. In
this novel fusion protein, named hERB-hRNase, the human scFv and
human RNase moieties preserve their biological actions. In constrast
with previous reports (11), the IR activity as an RNase is nearly that
of the native, free enzyme. Likewise, the IR binds to target cells as
selectively and effectively as the parental, free scFv.
As for the RNase fused in the IR construct, it is mandatory, for
assigning to the IR the role and the action of an immunoprotoxin, that
the RNase per se is not a cytotoxic agent. Our work has shown that the
HP-RNase used in hERB-hRNase is not per se a cytotoxic agent,
neither in vivo nor in vitro, but becomes cytotoxic on internalization.
This may not be surprising because it has been reported that when
noncytotoxic RNases, such as RNase A, are artificially introduced
into frog ovocytes, they become powerful cytotoxic agents (34).
It is the ability of the parental scFv to be internalized by ErbB-2-
overexpressing cells fully preserved in the fusion protein, which
allows the RNase to enter the cytosol and kill target cells.
It should be noted that the scFv alone was found to inhibit the
Fig. 5. Effects of hERB-hRNase on cell survival. Dose-response curves of SKBR3 (F),
MDA-MB361 (), MDA-MB453 (Œ), TUBO (), and A431 cell lines (E) on treatment
for 72 h with hERB-hRNase.
Fig. 6. In vivo suppression of tumor growth by hERB-hRNase. Tumor growth was
followed in mice inoculated s.c with 5  105 TUBO mammary carcinoma cells. Treated
animals were injected i.p. (F) or in the peritumoral area () with hERB-hRNase at doses
of 1.5 mg/kg body weight. Control animals were treated with sterile PBS solution (),
equimolar doses of the anti-ErbB-2 single chain variable fragment (‚), or human pan-
creatic-RNase (E) administered peritumorally. Injections were repeated five times at 72-h
intervals as indicated by the arrows.
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proliferation of SKBR3 cells with an IC50 value of 200 nM (26). This
indicates that the IR, for which an IC50 value of 12.5 nM was obtained,
is a more effective anticancer agent. This result can only be attributed
to the additional toxic action of the internalized RNase because the
RNase alone has no effect on cell viability.
It may be of interest that hERB-hRNase has been found to be stable
for at least 48 h when incubated at 37°C in human or murine serum.
This feature of the IR adds to its potential as a promising antitumor
drug. Even more interesting are the results of in vivo assays of
hERB-hRNase antitumor action carried out on mice inoculated with
TUBO ErbB-2-positive tumor cells, which produce tumors similar to
the alveolar-type human lobular mammary carcinomas (35). These
experiments proved that low doses of hERB-hRNase also are effective
in vivo. Treatment of mice inoculated with TUBO cells with only five
doses of IR (1.5 mg/kg body weight) administered either peritumor-
ally or systemically strongly inhibited the growth of TUBO tumors in
mice. Such effect again can be attributed to the fusion protein as a
whole because the two moieties, the anti-ErbB-2 scFv and HP-RNase,
when administered separately to mice bearing the same tumor, were
not found to be effective in inhibiting tumor growth.
To our knowledge, hERB-hRNase is to date the first fully human IR
to be constructed and tested with satisfactory results in vitro and in
vivo. Its fully human nature, combined with its stability and its
selective cytotoxic action on target cells, could make it a precious tool
in the therapy of human mammary carcinomas.
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Summary
For analysis of multidrug resistance, a major barrier to effective cancer chemotherapy, we profiled mRNA expression of
the 48 known human ABC transporters in 60 diverse cancer cell lines (the NCI-60) used by the National Cancer Institute
to screen for anticancer activity. The use of real-time RT-PCR avoided artifacts commonly encountered with microarray
technologies. By correlating the results with the growth inhibitory profiles of 1,429 candidate anticancer drugs tested
against the cells, we identified which transporters are more likely than others to confer resistance to which agents.
Unexpectedly, we also found and validated compounds whose activity is potentiated, rather than antagonized, by the
MDR1 multidrug transporter. Such compounds may serve as leads for development.
Introduction the functions of most members of the family. Given the high
degree of similarity of ABC sequences, however, it seems plausi-
ble that additional members may also be drug exporters andThe ABC (ATP binding cassette) family of membrane transport
proteins includes the best-known mediators of resistance to may thus be associated with decreased sensitivity of cancer
cells to chemotherapy. To explore that proposition, we wantedanticancer drugs. In particular, MDR (multidrug resistance)
pumps ABCB1 (MDR1-P-gp), ABCC1-MRP1, and ABCG2-MXR to characterize ABC gene expression in a set of cancer cells
whose responses to a large number of compounds are known(Gottesman et al., 2002; Cole et al., 1992; Borst et al., 2000;
Deeley and Cole, 1997; Litman et al., 2001) actively extrude and whose molecular characteristics have been cataloged. The
natural choice was a panel of 60 human cancer cell lines (themany types of drugs from cancer cells, thereby conferring resis-
tance to those agents. More broadly, the ABC transporters ap- NCI-60) used by the Developmental Therapeutics Program
(DTP) of the National Cancer Institute (NCI) to screen 100,000pear to have evolved to defend the cell through recognition and
energy-dependent removal of a large variety of natural toxic chemical compounds since 1990. Included among the 60 are
leukemias, melanomas, and cancers of ovarian, breast, pros-agents (Sarkadi et al., 1996). Their functional significance is
suggested by the observation that they form one of the largest tate, lung, renal, colon, and central nervous system origin. Pat-
terns of drug activity across the cell lines and patterns of cellprotein families, found in various cellular membranes of organ-
isms from bacteria to mammals. Based on sequence homology, sensitivity across the set of tested drugs have been shown
to contain detailed information on mechanisms of action and48 different ABC transporters (grouped into seven subfamilies
ranging from A to G) have been defined in the human genome. resistance (Paull et al., 1989; Weinstein et al., 1992). In addition
to this pharmacological characterization, the NCI-60 cells haveTheir functions range from export of cholesterol (ABCA1) to
regulation of chloride current (ABCC7-CFTR), and they play been more extensively profiled at the DNA, mRNA, protein,
and functional levels than any other set of cells in existence.roles in the absorption, distribution, and excretion of pharmaco-
logical compounds. Therefore, if we were to measure their expression of ABC trans-
porters, it would be possible to link ABC transport function toDespite these generalizations, relatively little is known about
S I G N I F I C A N C E
Multidrug resistance of tumors is frequently associated with decreased cellular accumulation of anticancer drugs and elevated
expression of ABC transporters such as MDR1. At present, relatively little is known about the substrate specificities of most ABC
transporters. Here, we present a pharmacogenomic approach, in which we correlate expression profiles of all 48 human ABC
transporters with patterns of drug activity in the NCI-60 cell lines. The findings are used to identify candidate substrates for several
ABC transporters, as well as compounds whose toxicities are potentiated by ABCB1-MDR1. The gene expression database will serve
as a high-quality “time capsule” that can be mined to generate new hypotheses and to illuminate additional features of ABC
transporters and their functional relationships with other molecules.
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a variety of other molecular, physiological, and pharmacological of origin is moderate (see Supplemental Table S2), as indicated
by a  statistic of 0.46 (with two-tailed 95% confidence intervalfeatures of the cells.
We wished to focus, in particular, on the relationship be- 0.33–0.60). Interestingly, the two lumenal, estrogen receptor-
positive breast lines (T47D and MCF7) cluster together.tween ABC expression levels and sensitivity to drugs or drug
candidates, asking which of the transporters do (and which do This database provides valuable information on the expres-
sion patterns of both known and currently uncharacterized ABCnot) confer resistance or sensitivity to various classes of agents.
Previous transcript expression profiling of the NCI-60 using transporters. Some of them are expressed ubiquitously (e.g.,
ABCC1), whereas others are selectively expressed in particularcDNA arrays of 9000 elements (Scherf et al., 2000) and Affy-
metrix Hu6800 oligonucleotide chips (Staunton et al., 2001) cell types (e.g., ABCB5 in melanoma-derived cells; see inset in
Figure 1 and Supplemental Table S3). Langmann et al. (2003)proved useful for identification of patterns and molecular bio-
markers. However, those studies had three major limitations found high expression of ABCA2 in brain, ABCA3 in lung, and
ABCB1 and ABCC4 in kidney. When analyzed by Monte Carlowith reference to the ABC transporters: (1) only 15 and 11 of
the 48 transporters were represented in the cDNA and oligonu- permutation t test, our data show that ABCA2 is ubiquitously
expressed throughout the 60 lines (p  0.61 for each of thecleotide arrays, respectively; the total combined coverage was
only 17 of 48, and the mean correlation between the two sets nine tissues of origin), whereas ABCA3 is selectively expressed
(p  0.039) in H522M, A549, and EKVX (all of them lung cancerfor the 9 transporters represented in both was only 0.43; (2)
in part because of limited sensitivity, 64.2% and 58.5% of the lines). ABCB1 is indeed selectively expressed in the renal cancer
cell lines (p  0.0059). However, ABCC4 is only moderatelyvalues were undetectable above background for the cDNA and
oligonucleotide arrays, respectively; and (3) crosshybridization expressed in those cells (p  0.145 for each of the nine tissues
of origin). This apparent discrepancy with respect to the resultsamong close family members could be expected, especially
with the cDNA arrays, but also with the oligonucleotide arrays of Langman et al. may be due to heterogeneity of the human
tissue samples used in that study, or may reflect distinctiveinsofar as they were not designed with central focus on the
ABC transporters. Since reproducible, quantitative correlations characteristics of the cancer cells. The distribution of ABC trans-
porters on the gene dendrogram appears to be independent ofbetween expression and sensitivity were required for our study,
we chose to measure transcript expression by the “gold stan- sequence-homology categories. ABCB2 and ABCB3, known
to function as heterodimeric components of the ER transportdard” method, quantitative real-time RT-PCR, rather than the
less sensitive, less specific microarray technology. Finding such system for peptide antigen presentation, are found in different
clusters, suggesting that their reported coordinate expressioncorrelations (and confirming them in follow-up studies) demon-
strates the important role of ABC transporters in the drug resis- is disrupted in the cancer cells. Conversely, ABCG5 and ABCG8,
which also form a heterodimer, show the expected concordancetance of cancer cells. One striking result was the identification
of at least one compound whose toxicity appears to be potenti- in expression pattern across the 60 cells (see Figure 1).
ated, rather than antagonized, by ABCB1 (MDR1).
Correlation of ABC transporter mRNA levels
with drug resistanceResults and discussion
In a previous study using cDNA microarrays, the 60 cell lines
were found to cluster reasonably well by tissue of origin on theForty-eight ABC proteins are coded by the human genome
(see http://nutrigene.4t.com/humanabc.htm for a comprehen- basis of expression patterns determined for a broad range of
genes, but they did not cluster as well on the basis of patternssive database). Figure 1 shows a clustered image map (“heat
map”) (Weinstein et al., 1997) that offers a visual summary of of drug sensitivity (Scherf et al., 2000). Furthermore, there was
only a modest correspondence between the two clusterings.the patterns of ABC transporter expression across the 60 cell
lines. The complete RT-PCR results on the 48 ABC transporters Hence, cell clusters in the present study that appear similar for
both ABC transporter expression and drug activity patterns are(47 determined in this work and one previously reported [Prades
et al., 2002]) are presented in Supplemental Table S1 at http:// particularly interesting. Clusters such as that consisting of
ACHN, UO-31, HCT15, and NCI-ADR-RES fall into that cate-www.cancercell.org/cgi/content/full/6/2/129/DC1. A 49th ABC
gene, ABCC13, is predicted to encode a nonfunctional protein gory. Not surprisingly, ABCB1 (i.e., MDR1) is highly expressed
in those cells.(Yabuuchi et al., 2002) and therefore is not included in this study.
Quantitative analysis showed that the pattern of expression is Since ABCB1 (MDR1-Pgp) extrudes molecules from the cell,
the activity patterns of its substrates across the 60 cell linesmost characteristic of tissue of origin for melanoma (9 of the
10 melanoma cells cluster together on the dendrogram). The are expected to be negatively correlated with its pattern of
expression (Shoemaker, 2000; Lee et al., 1994). Figure 2 indi-one melanoma line not found in the melanoma cluster (LOX-
IMVI) is amelanotic and undifferentiated and has been shown cates that such is indeed the case for a set of 118 compounds
with putatively known mechanisms of action (Weinstein et al.,to lack transcripts characteristic of melanoma (Stinson et al.,
1992). MDA-MB435 and MDA-N were originally thought to be 1992). Reported substrates (e.g., geldanamycin, paclitaxel and
its analogs, doxorubicin and vinblastine, and bisantrene [Lee etfrom breast cancer, but their appearance within the melanoma
cluster is consistent with strong molecular profile evidence that al., 1994]), indicated by blue bars, show striking inverse correla-
tions, whereas compounds not transported by MDR1 (e.g., hy-they are melanoma-derived or at least melanoma-like (Scherf
et al., 2000; Ellison et al., 2002; Ross et al., 2000). MDA-N is droxyurea, camptothecins, methotrexate, and 5-fluorouracil) are
invariably found to be noncorrelated or positively correlated (redan ERBB2 transfectant of MDA-MB435. CNS (5/6), renal (5/8),
and ovarian (4/6) cells tend to form clusters, whereas the leuke- bars). Of the 118 compounds, only two inversely correlated
drugs, an anthrapyrazole-derivative (NSC 355644, r  0.36)mia, colon, lung, breast, and prostate cancer cell lines do not
cluster well by tissue of origin. Overall, the coherence by tissue and Baker’s soluble antifol (NSC 139105, r  0.3), have not
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Figure 1. ABC transporter gene expression in the NCI-60 human cancer cell panel
The clustered image map shows patterns of gene expression assessed by real-time RT-PCR. Red and blue indicate high and low expression, respectively.
The hierarchical clustering on each axis was done using the average-linkage algorithm with 1r as the distance metric, where r is the Pearson’s correlation
coefficient, after subtracting row and column means. The inset highlights ABC transporters characteristically expressed in melanoma cells. For more details,
see Supplemental Table S3.
previously been established as MDR1 substrates (black bars). distribution of ABCB1 was heavily right-skewed (i.e., a small
number of the cell lines expressed high levels of ABCB1 tran-However, resistance to Baker’s antifol is reversed by verapamil,
a potent inhibitor of MDR1 transport, suggesting that it is indeed script), we were concerned that the correlations obtained might
be based on the relationship of drug activity to MDR1 expressionan MDR1 substrate (Gupta et al., 1988).
To identify additional compounds that show significant in- in only a subset of the cell types. Therefore, we also computed
bootstrap distributions (based on 10,000 bootstrap samples) ofverse correlation with the expression of ABCB1, we extended
the analysis to a larger data set containing the activity patterns all correlations to obtain estimates of variability and confidence
intervals with stringent significance levels. The 18 compoundsof 1,429 compounds (Scherf et al., 2000). Since the measured
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These results support the idea that correlation of ABCB1
expression with activity patterns in the 60 cell lines can be used
to identify potential ABCB1 substrates among the 100,000
compounds tested at the NCI (Alvarez et al., 1995; Izquierdo et
al., 1996; Bates et al., 1994; Wu et al., 1992). The chemical
properties of inversely correlated compounds may also help
define the “common pharmacophore” of the structurally dissimi-
lar MDR1 substrates (Scala et al., 1997; Pajeva and Wiese,
2002; Blower et al., 2002).
ABC proteins transport a wide variety of compounds through
the lipid bilayer, and identification of transported molecules
should help us understand the physiological mechanisms and
specificities of the transporters. To identify which ABC trans-
porters and substrates may play roles in drug resistance of
cancer cells, we calculated Pearson’s correlation coefficients
for a total of 68,592 relationships (48 genes 1429 compounds;
Supplemental Table S5) using bootstrap analysis with 10,000
iterations. The analysis yielded 131 highly inverse-correlated
gene-drug pairs (Supplemental Table S6), sufficiently highly cor-Figure 2. Relationship between drug sensitivity and ABCB1 expression in the
related in the negative sense that none of their 10,000 bootstrapNCI-60 for a set of 118 drugs of putatively known mechanism of action
samples were positively correlated. This list suggests that sev-Blue bars indicate known ABCB1 substrates; red bars indicate compounds
eral ABC transporters of unknown function can, in fact, influenceshown in previous studies not to be substrates of ABCB1; black bars indicate
compounds for which data were not available from the literature. The drug response of cells to treatment. Assuming functional relationship,
names listed at the top and bottom are commonly used, representative the compounds are predicted to be substrates of the respective
agents from the classes shown by red and blue bars.
ABC transporters. To verify this hypothesis, we performed inde-
pendent followup experiments in defined systems for the most
interesting correlative findings. As examples, we will describe
here the results for two transporter drug pairs, one involvingthat survived this statistical screening share structural features
ABCC2-MRP2, the other involving ABCC11.(large size, polyaromatic backbone, amphipathic character) with
The ABCC (MRP) subfamily is comprised of nine membersthe well-known MDR1 substrates (Rabow et al., 2002; Supple-
that transport structurally diverse lipophilic anions and functionmental Figure S1 at http://www.cancercell.org/cgi/content/
as drug efflux pumps (Kruh and Belinsky, 2003). ABCC2-MRP2full/6/2/129/DC1). NSC 328426 (phyllanthoside), NSC 259968
is a canalicular efflux pump with a role in the hepatobiliary(Bouvardin), and NSC 156625 (Coralyne) have been tested in
excretion of bilirubin glucuronide as well as numerous pharma-various laboratories and shown to interact with MDR1 (Lee et
ceuticals. ABCC11, a recently identified member of the super-al., 1994; Gupta et al., 1988). The rest have not previously been
family, has been shown to mediate the ATP-dependent trans-implicated in MDR1-mediated resistance.
port of cyclic nucleotides and confer resistance to certain
nucleotide analogs (Guo et al., 2003). Of the 1429 compoundsEvidence that correlations predict drug resistance
analyzed in this study, 14 were shown by the stringent bootstrapdue to ABC transporters
criterion described above to be less active in cells that ex-To test whether our approach using the NCI-60 does, in fact,
pressed large amounts of ABCC2. One of these compoundsidentify new substrates, we used the MTT assay to test all top-
was available from DTP for followup testing (Figure 4A). Onescoring compounds that were available from DTP for follow-up
compound was less active in the presence of large amounts ofexperiments. KB-3-1, a human carcinoma cell line, and KB-V1,
ABCC11 (Figure 4C, Supplemental Figure S1, and Supplementala multidrug resistant derivative of KB-3-1 that overexpresses
Table S6). To verify whether these highly significant negativeMDR1-P-gp (Shen et al., 1986), were used for the tests. Figure
correlations indicate functional relationships, in which ABCC23 shows a typical result. When compared with the parental line,
and ABCC11 protect the cells by exporting the related com-KB-V1 cells proved resistant to NSC 363997. PSC 833, an
pounds, we compared control cells with ABCC2-transfectedMDR1 antagonist, reversed the resistance, providing evidence
or ABCC11-transfected derivatives in MTT assays. In sharpthat the observed resistance was linked to P-gp function. Fur-
contrast to the control (sham-transfected) cells, the ABCC2-ther experiments showed that KB-V1 cells were 30- to 300-fold
overexpressing MDCKII cells proved extremely resistant to NSCless sensitive than KB-3-1 cells to all 6 compounds available
641281, reinforcing the suggestion that NSC 641281 is anfor study. This resistance of KB-V1 cells was invariably reversible
ABCC2-MRP2 substrate (Figure 4B). Similarly, ABCC11-trans-by PSC 833. The intrinsic fluorescence of one of the com-
fected LLC-PK1 cells were 2- to 3-fold more resistant to NSCpounds, NSC 634791, allowed us to measure the effect of MDR1
671136 than were control, sham-transfected cells (Figure 4D),activity on its export from cells. Following incubation with NSC
suggesting that ABCC11-mediated resistance can extend to634791 for 10 min at 37C, MDR1-positive cells contained less
types of compounds other than nucleotide analogs.of the fluorescent compound than did the parental KB-3-1 cell
The real-time RT-PCR database and analytical approachline (Figure 3). The decreased accumulation was completely
presented here thus provide an unbiased method for dis-reversible by addition of PSC 833 (which had no effect on the
covering the substrate specificities of known, as well as yetparental cells), further corroborating the hypothesis that NSC
634791 is an MDR1 substrate. uncharacterized, members of the superfamily. Activity profiles
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Figure 3. Verification of novel ABCB1 substrates
by studies following up on NCI-60 correlations
A: Scatter plot showing the correlation (r) of
ABCB1 expression with sensitivity of the 60 cells
to NSC 363997 (r0.59; 99.99% two-tailed boot-
strap confidence interval 0.8488 to 0.1130).
B: MTT assay dose-response curves for treatment
of KB-3-1 parental cancer cells and the selected
resistant variant KBV1 with increasing concentra-
tions of NSC 363997. The dashed lines indicate
the same, but in the presence of 2 M inhibitor
PSC 833 (for KB-3-1, the solid and dashed lines
overlap). Values are means 	 SEM for represen-
tative experiments performed in triplicate.
C: Summary of further, analogous cytotoxicity
assays performed using the other five available
compounds. Concentrations resulting in 50% cell
death (IC50) in the absence and presence (val-
ues in parentheses) of 2 M PSC 833 are shown
in moles/liter. The effect of the MDR1-P-gp inhibitor PSC 833 on IC50 values in KB-V1 cells is expressed as a dose modifying factor, DMF  (IC50/[IC50]PSC833),
where (IC50)PSC833 is the value obtained in the presence of the inhibitor.
D: Accumulation of the intrinsically fluorescent compound NSC 634791 in MDR1-overexpressing KB-V1 cells. Representative histograms show the green
fluorescence of cells after incubation with 1.74 M NSC 634791 for 10 min at 37C in the presence (gray) or absence (black) of 2 M PSC 833.
of the 18 ABCB1 substrates were very strongly correlated with ABCD1-expression are therefore likely to be positively corre-
lated with ABCB1 expression (Supplemental Table S5).expression of the transporter. In contrast, the other two mole-
cules considered to be “MDR transporters,” ABCC1 (MRP1)
and ABCG2 (MXR or BCRP), were more weakly correlated with Positive correlations identify compounds
potentiated by ABCB1a smaller number of compounds, which did not include known
substrates. The lack of the expected correlations may partially The positive correlation between activity and ABCB1 expression
for some of the compounds in Supplemental Table S5 suggestsbe explained by the statistical limitations of the correlative ap-
proach: the sample size (n  60), the experimental uncertainty, that those compounds can inhibit growth of the cancer cells
more strongly if MDR1 is overexpressed. For some transporters,and the fact that multiple tests of significance are being done
simultaneously may contribute to false negative predictions including MDR1, several high positive correlations between
gene expression and drug sensitivity are higher than would be(hence, the “multiple testing” corrections we describe in the
text and Experimental Procedures). There are also biological expected by random sampling from a distribution of no real
underlying correlations (in the case of MDR1, for the top 10limitations: first, as is the case for almost all transcript profiling
studies, there remains uncertainty about the relationship be- positive correlations, the Benjamini-Hochberg procedure [Reiner
et al., 2003] estimates on average 3 false positive predictions).tween mRNA and protein expression, and the relationship of
both to function. As indicated in Supplemental Table S8 and Thus the toxicity of at least some of the compounds increases
systematically with higher MDR1 expression in the NCI-60. ToSupplemental Figure S2 at http://www.cancercell.org/cgi/content/
full/6/2/129/DC1, a comparison of the mRNA and protein ex- investigate that possibility, we used the MTT assay and the KB-
3-1/KB-V1 cell pair to test the top-scoring compound that waspression profiles for ABCB1 and ABCG2, respectively, indicates
that, at least for those two transporters, the real-time RT-PCR available from DTP (Figure 5A). Figure 5B shows that KB-V1
cells are 4- to 5-fold more sensitive than the parental KB-3-1.and protein expression data correlate quite well. Second, corre-
lation does not imply causality. Third, there might be functionally The finding that PSC 833 completely reversed sensitivity of KB-
V1 cells to NSC 73306 strongly suggests that the increasedrelevant differences between the RNA messages that are not
detected by RT-PCR measurements. That is, the 60 cells may sensitivity is due to the function of MDR1, not to other, nonspe-
cific properties of the KB-V1 cells.contain splice variants or SNPs that influence the substrate
specificities of the transporters (Imai et al., 2002; Honjo et al., To substantiate further that the observed potentiation of
NSC 73306 was not due to nonspecific factors arising during2002). Fourth, cofactors (e.g., conjugating enzymes) or trans-
porters (e.g., ABCC1) may be expressed discordantly in the 60 the generation of KB-V1, we repeated the MTT assays using
HeLa-transfectants in which human MDR1 is under tetracyclinecells. Fifth, the ubiquitous and consistent expression of certain
ABC transporters (e.g., ABCC1) makes it difficult to detect func- control. In these cells, addition of tetracycline suppresses tran-
scription of MDR1 mRNA, and, over a period of a few days,tional relationships through correlations. Finally, the presence
of MDR1 may mask the contribution of less potent transporters MDR1 disappears from the cells, providing a near-isogenic
model for well-controlled experiments (Aleman et al., 2003).of the same compounds. The somewhat surprising correlation
of compounds with the expression of ABCD1, a peroxisomal Figure 5C shows that the MDR1-expressing cells (MDR1-On)
are 2- to 4-fold more sensitive than are MDR1-Off cells, provid-half-transporter associated with adrenal leukodystrophy (Mos-
ser et al., 1993) (Supplemental Table S6), is probably a conse- ing strong evidence that the increased sensitivity to NSC 73306
is mediated by MDR1 function. Interestingly, NSC 73306 doesquence of the inverse correlation between the expression of
ABCD1 and ABCB1 (r  0.48, see also Figure 1 and Supple- not block MDR1-mediated transport of other molecules (data
not shown), suggesting that it might avoid the well-documentedmental Table S1). Compounds showing inverse correlation with
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Figure 5. Prediction from the NCI-60 data, followed by independent verifi-
cation, that the toxicity of NSC 73306 is potentiated, rather than inhibited,
by expression of ABCB1
A: Scatter plot showing positive correlation (r  0.54; 95% confidence
interval 0.259 to 0.713) of ABCB1 expression with sensitivity of the 60 cell lines
to NSC 73306.
B: Dose-response curves indicating that selected resistant KBV1 cells are
approximately 4-fold more sensitive to NSC 73306 than are the parental KB-
3-1 cells in an MTT assay. Dashed lines indicate the corresponding results in
the presence of 2 M PSC 833, which completely abolished the heightened
sensitivity of KBV1.Figure 4. Prediction from the NCI-60 data of new substrates for ABCC2-MRP2
and ABCC11-MRP8, then validation of the predictions by MTT assay C: Dose-response to NSC 73306 of KB HeLa cells expressing MDR1 under
tetracycline control. Cells were grown in the absence (MDR1-On) or pres-A: Scatter plot showing the correlation (r) of ABCC2 expression with sensitivity
ence (MDR-Off) of 2 g/ml tetracycline for at least seven days beforeof the 60 cells to NSC 641281 (r  0.46; 99.99% two-tailed bootstrap confi-
starting the MTT assay. Cell surface expression and function of MDR1 weredence interval 0.7987 to 0.0440).
verified prior to the assay by staining with anti-MDR1 monoclonal antibodyB: Dose-response curves for treatment of sham-transfected and ABCC2-
(MRK-16) and by a performing a functional assay based on MDR1-controlledtransfected MDCKII dog kidney cells with NSC 641281. The ABCC2-express-
accumulation of the fluorescent dye Calcein (Homolya et al., 1996) (dataing cells showed no signs of toxicity even at maximal concentrations.
not shown). The MTT assay showed an approximately 2-fold higher sensitivityC: Scatter plot showing the correlation (r) of ABCC11 expression with sensitiv-
to NSC 73306 with upregulation of MDR1-P-gp. Values are means 	 SEM ofity of the 60 cells to NSC 671136 (r  0.4; 99.99% two-tailed bootstrap
triplicate measurements.confidence interval 0.6726 to 0.0141). Note: removal of the single, high-
expressing cell line (T47D) from the analysis does not significantly reduce
the observed correlation (r  0.38; 99.99% confidence interval 0.7233
to 0.03915).
D: Dose-response curves for treatment of sham-transfected and ABCC11- in all tested cases by evidence of resistance or sensitivity in
transfected LLC-PK1 non-small cell lung cancer cells with NSC 671136.
cell lines transfected with the appropriate ABC transporters.
Although in some cases the levels of resistance were relatively
low, ample evidence indicates that even low (2- to 4-fold) levels
side effects observed in clinical trials of “classical” MDR1 inhibi- of drug resistance can have a significant impact on the clinical
tors (Kellen, 2003). Possible explanations for the increased (col- efficacy of anticancer treatment (Gottesman et al., 2002). Animal
lateral) sensitivity of otherwise resistant cells include ATP deple- models have also demonstrated decreased responsiveness to
tion (Kabanov et al., 2003) and altered activity of enzymes that chemotherapy in xenografts of a KB line selected for low levels
influence the toxicity of the compound (Bergman et al., 2003). of in vitro resistance (Horton et al., 1988). For many anticancer
The results reported in this section suggest that the pharmaco-
drugs, toxic-to-therapeutic ratios are low and, therefore, even
genomic approach presented here can be exploited to discover
a small increase in cell-based resistance can hamper chemo-such MDR1-potentiated compounds, which may serve as leads
therapy.for development of novel anticancer agents to treat resistant
The importance to cancer therapy of circumventing MDR isdisease. Studies are underway to characterize other positively
evident (Sikic, 1999). Even precisely targeted anticancer drugscorrelated compounds and to elucidate their mechanisms of
are subject to mechanisms of resistance. The real-time RT-PCRaction.
database presented here provides a means to identify (1) ABC
transporters whose expression confers drug resistance, (2)Conclusions
compounds that retain activity in cells that express MDR pro-This work demonstrates correlations between expression of
ABC transporters and response to cytotoxic drugs, confirmed teins, (3) compounds that are exported by MDR proteins, and
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with reference to the mean expression of each ABC transporter across the(4) drugs that exploit hidden vulnerabilities of MDR cells. Here,
60 cell lines.we have summarized some initial conclusions from analyses to
date. More importantly, however, the database will serve for
Drug database
many years as a high-quality “time capsule” that can be mined More than 100,000 chemical compounds have been tested in the NCI-60
by ourselves and others to illuminate additional features of the screen by the Developmental Therapeutics Program. For this study, we
ABC transporters and their complex functional relationships focused on a subset consisting of 118 compounds whose mechanisms of
action are putatively classifiable (Weinstein et al., 1992) and a larger set ofwith other molecules. In particular, these gene expression pro-
1400 compounds that have been tested multiple times and whose screeningfiles will aid studies of the physiological function of the many
data met quality control criteria described elsewhere (Scherf et al., 2000).ABC transporters whose mechanisms remain to be charac-
Both sets are available at http://discover.nci.nih.gov. The two were combinedterized.
to form a joint dataset that included 1429 compounds.
Experimental procedures
Statistical analysis
The statistical analyses were performed using the SAS software package,Purification of RNA
v8.2 (SAS Institute Inc, Cary, NC), and the R package (www.r-project.org).Using the RNeasy kit (Qiagen) according to the manufacturer’s instructions,
Two-dimensional agglomerative hierarchical cluster analysis, with averageas described previously (Scherf et al., 2000), we purified total RNA from
linkage algorithm and distance metric 1r, where r is the Pearson correlationstocks of the cell lines used in the DTP screen. Aliquots of the RNA were
coefficient, was performed using the CIMminer tool (http://discover.nci.nih.stored at 70C. The quality (purity and integrity) of the RNA samples was
gov) to group the 60 cell lines as well as 47 ABC transporters based onassessed using an Agilent 2100 Bioanalyzer with the RNA 6000 NanoLabChip
the expression profiles. The resulting matrix of numbers was displayed inreagent set (Agilent Technologies) and by assessing the ribosomal RNA
clustered image map form (Weinstein et al., 1997) as Figure 1.bands on a native agarose gel. The RNA was quantitated using a spectropho-
To determine quantitatively how well the 47 genes cluster the cell linestometer.
by their tissues of origin, we used a statistical method developed by S.
Lababidi (unpublished data). In that method, the  statistic is used to indicateQuantitative RT-PCR
how well the observed clusters correspond to the nine tissue-of-origin classi-Expression levels of 47 ABC transporters were measured by real-time quanti-
fications. For that calculation, one cell line, UK: NCI-ADR-RES, was excludedtative RT-PCR using the LightCycler RNA Amplification SYBR Green kit
because it did not clearly fit into any of the usual categories.and a LightCycler machine (Roche Biochemicals, Indianapolis, IN). Specific
To identify which genes are, on average, significantly over- or underex-oligonucleotide probes were designed for each of the ABC transporters using
pressed in cells from a given tissue of origin (in comparison with the rest ofDNAStar Primer Select (DNASTAR Inc.), and they were then synthesized at
the cell lines), we used Monte Carlo permutation t tests with 10,000 iterationsLofstrand Laboratories (Gaithersburg, MD). When possible, the amplicons
to compare, for each tissue, the within-tissue mean and the mean over allwere designed to encompass exon-intron boundaries to avoid amplification
of the other tissue types (this approach avoids the assumption of normalityof genomic DNA. The sequence of ABCA13 was not known when we assem-
and is suitable for small sample sizes).bled the PCR primers. Data reporting ABCA13 expression (Supplemental
To narrow down the list of candidates based on correlation of the geneTable S1 at http://www.cancercell.org/cgi/content/full/6/2/129/DC1) were
expression data for 48 ABC transporters and the extended list of 1429 drugtaken from Prades et al., 2002. Since the Syber Green assay detects accumu-
activities measured in 60 cell lines (both centered around zero across thelation of double-stranded DNA, we selected those primers (from a battery
cell lines as well as across the expression values or the drug activities,consisting of about 200 primers) that amplified a single product of the correct
respectively), we calculated the 95% bootstrap confidence intervals of Pear-size. A list of the primers and corresponding gene reference/accession num-
son correlation coefficients for all of the possible relationships (a total ofbers for the ABC proteins is shown in Supplemental Table S7. RT-PCR was
48  1429  68,592 correlation coefficients). The bootstrap confidencecarried out on 150 ng total RNA, in the presence of 250 nM specific primers.
intervals were calculated using the empirical percentiles method with bal-Following reverse transcription (20 min at 55C), the PCR reaction consisted
anced resampling of 10,000 iterations (Chernick, 1999). Balanced resamplingof 45 cycles of denaturation (15 s at 95C), annealing (30 s at 58C), and
forces each observation to appear exactly a number of times equal to theelongation (30 s at 72C). No-template (water) reaction mixtures were pre-
total number of iterations. By bootstrap resampling, we avoided parametricpared as negative controls.
assumptions about the distributions of the variables and incorporated possi-
ble non-normal distributional characteristics. For 10,000 bootstrap iterationsData processing
with 95% confidence interval, the component of resampling error has aDuring the PCR amplification, fluorescence emission was measured and
standard error of no more than 0.002. In recognition of the multiple testingrecorded in real time by the LightCycler. Crossing point values were calcu-
problem we preferred a stringent critical value of p  0.0001. To control thelated, using the LightCycler software package, by the Fit Points analysis
overall false positive rate, we used both a step-down procedure (Westfallmethod, with baseline fluorescence set at 1. The SyberGreen assay mea-
and Young, 1993) and a step-up procedure (Reiner et al., 2003) to adjustsures accumulation of double-stranded products, and the appearance of
for multiple testing of all 47 genes simultaneously. In the Benjamini-Hochbergprimer dimers limits quantitation at high cycle numbers. The specificity of
procedure, the p values are computed in the standard way by permutation,amplified products was verified by melting-curve analysis and agarose gel
assuming that all distributions are exchangeable: the number of values inelectrophoresis (not shown). The raw results were expressed as number of
the permuted data with correlations over a threshold, divided by the numbercycles to reach the crossing point. If the desired product was not detected,
of compounds and by the number of permutations. We calculated the mini-the corresponding value was adjusted to crossing points indicating no ex-
mum FDR (q value) at which each compound would be declared using thepression. To assess the contribution of experimental artifacts, selected cell
step-up procedure for positively correlated test statistics (again true becauselines were assessed in replicate. The average pairwise correlation of replicate
all correlations being compared are computed against the same ABC gene).expression profiles was 0.96. The reproducibility of the measurements was
In this procedure, the first q value for the largest correlation is the Bonferroni-further confirmed by cluster analyses, which showed that replicates clustered
corrected p value for that gene; then further q values are calculated as qj tightly together (data not shown).
max(pj*1429/j, qj1). This procedure limits the expected proportion of falseSince the expression levels of housekeeping genes (glyceraldehyde-3-
positives in the list 1,…j to at most qj.phosphate dehydrogenase [GAPDH], Porphobilinogen Deaminase [PBGD],
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation pro-
tein, and zeta polypeptide [YWHAZ]) were found to be highly variable among Drugs and chemicals
The compounds designated here by NSC numbers were obtained fromthe 60 cell lines (not shown; however, see Vandesompele et al., 2002), they
were not used as controls, and data were normalized with respect to the the Drug Synthesis and Chemistry Branch, Developmental Therapeutics
Program, Division of Cancer Treatment and Diagnosis, National Cancer Insti-mean expression of the transporters (excluding ABCA13). Finally, the values
were mean-centered and multiplied by 1 to indicate expression values tute. Colchicine and dimethyl sulphoxide (DMSO) were purchased from
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Overexpression of a transporter gene in a multidrug-resistant human lungSigma Chemical Co. (St. Louis, MO), and PSC 833 was provided by Novartis
cancer cell line. Science 258, 1650–1654.Pharmaceuticals Corp. (East Hanover, NJ).
Deeley, R.G., and Cole, S.P. (1997). Function, evolution and structure of
Analysis of drug sensitivity multidrug resistance protein (MRP). Semin. Cancer Biol. 8, 193–204.
Cell survival was measured by the MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-
Ellison, G., Klinowska, T., Westwood, R.F., Docter, E., French, T., and Fox,diphenyltetrazolium) assay. Cells were seeded in 100 l medium at a density
J.C. (2002). Further evidence to support the melanocytic origin of MDA-MB-of 5000 cells/well in 96-well plates, and serially diluted drug (with or without
435. Mol. Pathol. 55, 294–299.2 M PSC 833) was added the following day in 100 l medium to give the
indicated final concentration. Cells were then incubated for 72 hr at 37C in Gottesman, M.M., Fojo, T., and Bates, S.E. (2002). Multidrug resistance in
5% CO2, and the MTT assay was performed following the manufacturer’s cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48–58.
instructions (Molecular Probes, Eugene, OR).
Guo, Y., Kotova, E., Chen, Z.S., Lee, K., Hopper-Borge, E., Belinsky, M.G.,
and Kruh, G.D. (2003). MRP8, ATP-binding cassette C11 (ABCC11), is aEfflux assay
cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidinesTrypsinized cells were washed twice in phosphate-buffered saline (PBS).
2
,3
-dideoxycytidine and 9
-(2
-phosphonylmethoxyethyl) adenine. J. Biol.
5  105 cells were preincubated for 5 min at 37C in Iscove’s Modified Chem. 278, 29509–29514.
Dulbecco’s Medium (Quality Biologicals, Gaithersburg, MD) with 0.5% di-
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ABSTRACT 
The discovery of the multidrug resistance protein 1 (MDR1), an ATP-binding cassette 
transporter able to transport many anticancer drugs, represents a clinically relevant 
breakthrough in multidrug resistance.  Although the overexpression of ABC transporters 
such as P-gp/ ABCB1, MRP1/ABCC1 or MXR/ABCG2 appears to be a major cause of 
failure in the treatment of cancer, acquired resistance to multiple anticancer drugs may 
also be multifactorial, involving alteration of detoxification processes, apoptosis, DNA 
repair, drug uptake, and overexpression of further ABC transporters.  We created a 
microarray platform to evaluate relative levels of transcriptional activation among genes 
involved in various mechanisms of resistance.  In the ABC-ToxChip, a comprehensive 
set of genes important in toxicological responses (2,200 cDNA probes together with 
~18,000 oligonucleotide probes) are complemented with probes specifically matching 
ABC transporters as well as oligos representing 18,000 unique human genes.  By 
comparing the transcriptional profiles of KB-3-1 and DU-145 cells to resistant 
derivatives selected in colchicine (KB-8-5), and  9-nitro-camptothecin (RCO.1), 
respectively, we demonstrate that ABC transporters (ABCB1/MDR1 and ABCC2/MRP2, 
respectively) show dramatic overexpression, whereas the glutathione S-transferase 
gene (GST-Pi) shows the strongest decrease among the 20,000 genes studied.  The 
results were confirmed by quantitative RT-PCR and immunohistochemistry.  These 
results suggest that custom-made, dedicated microarrays will be helpful to elucidate 
mechanisms leading to anticancer drug resistance. 
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INTRODUCTION 
 
Mechanisms leading to multidrug resistance (MDR) include increased drug efflux 
(Shen et al., 1986a; Gottesman et al., 2002), decreased drug uptake (Shen et al., 
2000), recruitment of drug-processing and metabolizing enzymes (Schuetz et al., 1996), 
conjugating enzymes (Goto et al., 2002), alteration of the DNA repair activity, reduction 
of cell susceptibility to apoptosis (Reinhold et al., 2003), and mutation of specific drug 
targets (Urasaki et al, 2001).  In vitro selected cell lines most likely utilize more than just 
one of the pathways cited above (Gottesman et al., 2002).  
Tools, such as the oligo-based, cDNA-based microarrays or SAGE (Serial 
Analysis of Gene Expression, Velculescu et al., 1995) are relevant methodologies to 
screen for multifactorial mechanisms of drug resistance.  However, microarray 
technology has several inherent problems that hamper definitive interpretation.  Typical 
problems with the current technology include the necessity of validation by 
complementary technology such as further microarray analyses or RT-PCR (Lee et al., 
2003).  The lack of sensitivity could also prevent the detection of infrequent transcripts 
(Evans et al., 2002) and lead to biased conclusions.  In research aiming at the 
elucidation of mechanisms underlying acquired drug resistance, the shortcomings of 
arrays available at the time of our study originated from the low representation of genes 
of interest and the general lack of specificity of the probes.  This is especially true for 
the ABC (ATP Binding Cassette) superfamily, which has 48 members sharing high 
sequential similarity with highly divergent functions and/or specificities.  
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Like endogenous and exogenous toxic compounds, anti-cancer drugs diffuse 
through the cell membrane.  One of the most interesting features of ABC transporters is 
that these proteins can transport many substrates across the membrane, including anti-
cancer drugs, ions and peptides.  MDR1 or P-gp was the first ABC transporter found to 
confer MDR in resistant tumor samples and in vitro selected cell lines (Shen et al., 
1986b).  Using cell lines selected in various anti-cancer drugs, overexpression of further 
ABC transporters, such as ABCC1-MRP1 (Cole et al., 1992), and ABCG2- MXR-BCRP 
(Miyake et al., 1999; Doyle et al., 1998) were clearly shown to be associated with drug 
export and resistance.  In experiments performed in vitro, other members, such as 
ABCA2 and ABCB4 (MDR3) were shown to actively transport cytotoxic drugs (Laing et 
al., 1998; Smith et al., 2000).  Among the members of the MRP (ABCC) subfamily, 
MRP2 (ABCC2, cMOAT) transports GSH-S-conjugates (e.g., leukotriene C4 and 2,4-
dinitrophenyl-S-GSH), oxidized GSH (GSSG), glucuronide conjugates (e.g., 
glucuronidated bilirubin and bile salts), and sulfate conjugates of certain bile acids (e.g., 
3-sulfatolithocholytaurine), (Muller et al., 1994).  By their ability to transport nucleoside 
analogues, ABCC3-MRP3 and ABCC5-MRP5 are proteins that are thought to cause 
certain forms of drug resistance (Reid et al., 2003).  Recently, ABCC11-MRP8 has also 
been associated with anti-cancer drug export (Guo et al., 2003; Szakács et al., 2004).  
Although microarrays make possible the screening of thousands of genes in the 
same matrix, attempts aiming to address anticancer drug resistance have been biased 
in their interpretation by microarrays bearing a low number of ABC transporter 
superfamily probes (Lamendola et al., 2003).  Here, we report the design and the 
application of a dedicated ABC-ToxChip, in which we complemented a comprehensive 
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set of detoxifying genes with probes specifically matching ABC transporters.  Instead of 
using the short 25-mer probe-technology (Affymetrix, Santa Clara, CA), not optimized 
for detecting infrequent transcripts, we printed a combination of longer 70-mer oligo 
probes and 200-500 bp fragments, offering higher sensitivity due to the longer 
complementary sequences.  
Camptothecin (CPT) derivatives such as CPT-11 (Irinotecan) or Hycamtin 
(Topotecan) are increasingly used in anti-tumor therapy against colon or lung cancers 
(Kudoh et al., 1998).  9-Nitro-camptothecin (9NC) has recently been used in phase II 
studies for pancreatic cancer and is now in phase 3 clinical trials (Pantazis et al., 2003).  
Many factors, such as specific mutations in topoisomerase I, complemented by a 
general alteration of apoptotic regulation, have been proposed to explain the phenotype 
of campthotecin resistance in a prostate cancer cell line (RCO.1) selected for resistance 
to 9NC (Reinhold et al., 2003; Urasaki et al., 2001; Chatterjee et al., 2001).  To 
specifically address the role of detoxifying enzymes and ABC transporters in 
campthotecin resistance, we compared the transcriptional profiles of the parental 
prostate cancer DU145 cells and their 9NC-selected derivative cell line, RCO.1.  Here, 
we show that in RCO.1 cells, 9NC resistance is accompanied by the differential 
expression of ABCC2-MRP2 and enzymes regulating glutathione metabolism.  
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Materials and Methods 
 Taq polymerase and RT-PCR reagents were from Invitrogen (Carlsbad, CA).  
Reagents for quantitative RT-PCR were from Roche. Inc.  (Indianapolis, IN). High-
density microarrays were printed in the NIEHS facility.  9NC (Ref. C0156) was 
purchased from LKT laboratories (St. Paul, MN).  
 
Cell Lines and Cell Culture.  DU-145 and its 9NC-selected derivative, RCO.1 
cell lines were a generous gift from Dr. P. Pantazis (University of Miami, Coral Gables, 
FL).  Cells were cultured in RPMI (Invitrogen) supplemented with 10% tetracycline-
approved FBS (Hyclone Inc. Logan, UT), and 2mM L-glutamine by Quality Biological, 
Inc., (Gaithersburg, MD) at 37°C with 5% CO2.  Resistance to camptothecin analogs of 
RCO.1 was maintained with passage in camptothecin-containing media (0.1 µM) every 
three months. 
RNA Preparation.  Total RNA was purified as described in Reinhold et al. 
(2003).  For the preparation of the RNA used in the microarray analysis or RT-PCR, 
cells were cultured in non-selective media.  
 
Microarray Design.  A 20K Human Oligo/cDNA hybrid Chip, printed at NIEHS 
(NIEHS Microarray Group, National Institute of Environmental Health Sciences) was 
used for gene expression profiling experiments.  The chip contained three categories of 
probes:  
1. 96 ABC-specific probes (matching 36 ABC transporters), consisting of either 
cDNA probes developed in-house or oligo-probes obtained from Operon Technologies 
 8
(Qiagen, Valencia, CA).  To create the cDNA-probes, we performed PCR amplifications 
using specific primers on full-length cDNA sequences (ABCB1-MDR1, ABCC1-MRP1, 
ABCC2-MRP2, ABCG2-MXR, ABCC7-CFTR and ABCB11) or on cDNA prepared from 
cells rich in a given transporter (unpublished data).  We used a blast-based algorithm to 
increase specificity:  first, we aligned the targeted transporter with members of its own 
subfamily to locate a candidate region representing minimal overlap.  Specificity was 
then verified by blasting the candidate sequence against the whole non-redundant 
human database.  The probes synthesized by RT-PCR were TA cloned (Invitrogen), as 
detailed in Table 1.  ABC transporters are named using the HGNC nomenclature 
(http://nutrigene.4t.com/humanabc.htm).  When more than one probe was used for an 
ABC transporter, the probe name was chosen to match the closest Ref-Seq entry from 
the NCBI (i.e., ABCC3 (NM-003786, AJ294547.1, AJ294559.1, AJ294558.1). The 
closest exon matching the probe sequence is indicated in Table 1. 
2. 2,200 probes matching genes important in toxicological responses (cDNA 
clones from the NIEHS ToxChip version 3.0 (Nuwaysir et al., 1999).  The NIEHS set 
contains approximately 2,200 known human genes involved in pathways such as 
response to estrogens, polycyclic aromatic hydrocarbons, peroxisome proliferators, 
DNA damage, and oxidant stress, as well as genes involved in apoptosis, cell cycle, 
tumor suppression, signal transduction and transcription.  
3. 18,000 genome-wide 70mer probes obtained from Operon Technologies 
(Qiagen, Valencia, CA).  A complete listing of the two sets (Human Oligo gene-set and 
the Human TOX V1.0-set) printed on the ABC-ToxChip is available at 
http://dir.niehs.nih.gov/microarray/annereau/home.htm.  
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Gene Representation on the Microarray.  The gene ontology classification 
(http://www.geneontology.org/#ontologies) annotates each gene in three categories: 
Molecular Function, Biological Process and Cellular Component.  To search the Gene 
Ontology (GO) reference for each gene represented on our microarray, we used the 
human genome annotation (HUGO) reference converted from the Gene Accession 
number by the Source data base (http://genome-www5.stanford.edu/cgi-
bin/SMD/source/sourceSearch) and the MatchMiner database 
(http://discover.nci.nih.gov/matchminer/html/index.jsp).  Extraction of the GO annotation 
starting keyword entry was performed on the QuickGO server at EBI 
(http://www.ebi.ac.uk/ego/).  
 
 Microarray Spotting.  The oligonucleotides were resuspended in ArrayIt Spotting 
Solution Plus buffer (Telechem, San Jose, CA) and spotted at a concentration of 40 M 
onto poly-L-lysine coated glass slides using a modified, robotic DNA arrayer (Beecher 
Instruments, Bethesda, MD).  The spotting was performed in an environmentally 
controlled chamber with a temperature of 25°C at 40% relative humidity.  After printing, 
the arrays were cross linked in a Stratalinker at a power of 300 millijoules and blocked 
with succinic anhydride/1-methyl-2-pyrrolidinone (protocol available at: 
http://dir.niehs.nih.gov/microarray/methods.htm) 
 
 Microarray Hybridizations.  Each total RNA sample (25 µg) was labeled with 
Cyanine 3 (Cy3) or Cyanine 5 (Cy5)-conjugated dUTP (Amersham, Piscataway, NJ) by 
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a reverse transcription reaction using the reverse transcriptase, SuperScript II 
(Invitrogen, Carlsbad, CA), and the primer, Oligo dT (Amersham, Piscataway, NJ).  The 
fluorescently-labeled cDNAs were mixed and hybridized simultaneously on the 
microarray chip.  Each RNA pair was hybridized to a total of 4 arrays employing a fluor 
reversal accomplished by labeling the control sample with Cy3 in 2 hybridizations and 
with Cy5 in the other 2 hybridizations.  After hybridization, arrays were washed with 
Telechem wash buffers A, B, and C (Telechem International Inc., Sunnyvale, CA) for 2, 
5, and 5 minutes respectively.  The hybrid chips were scanned with an Agilent Scanner 
(Agilent Technologies, Wilmington, DE) using independent laser excitation of the two 
fluors at 532 and 635 nm wavelengths for the Cy3 and Cy5 labels, respectively.  Results 
are available at http://dir.niehs.nih.gov/microarray/annereau/home.htm.  
 
Microarray Outlier Filtering.  Raw pixel intensity images were analyzed using 
ArraySuite v2.0 extensions of the IPLab’s image processing software package 
(Scanalytics, Fairfax, VA).  This program uses methods that were developed and 
previously described by Chen et al. (2002) to locate targets on the array, measure local 
background for each target and subtract it from the target intensity value, and to identify 
differentially expressed genes using a probability-based method.  The data were filtered 
with a cut-off at the intensity level just above the buffer blank measurement values to 
remove genes having one or more intensity values in the background range.  After pixel 
intensity determination and background subtraction, the ratio of the intensity of the 
treated cells to the intensity of the control was calculated.  The ratio intensity data from 
all probes on the Human Oligo chip was used to fit a probability distribution to the ratio 
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intensity values.  The resulting probability distribution was used to calculate a 95% 
confidence interval for the ratio intensity values.  Genes having normalized ratio 
intensity values outside this interval were considered to show significant differential 
expression. 
 
Statistical Analysis and Filtering the Outliers.  For each of the 4 replicate 
arrays for each sample, lists of differentially expressed genes at 95% confidence levels 
were created and deposited into the NIEHS MAPS database (Bushel et al., 2001).  
Genes that indicated fluorescence bias or high variation were not considered for further 
analysis.  Assuming that the replicate hybridizations are independent, a calculation 
using the binomial probability distribution indicated that the probability of a single gene 
appearing on this list when there was no real differential expression was <0.00048.  The 
entire dataset is available at http://dir.niehs.nih.gov/microarray/annereau/home.htm. 
 
Identification of Relevant Biological Processes.  The GoMiner software, which 
can be downloaded at the LMB/NCI web site (discover.nci.nih.gov) offers a newly 
implemented feature—the ability to point out a biological process that has been altered.  
The algorithm uses Gene Ontology entries found in the outlier list as well as all the GO 
entries available on the chip.  The Gene Ontology database lists three structured, 
controlled vocabularies (ontologies) that describe gene products in terms of their 
associated biological processes, cellular components and molecular functions in a 
species-independent manner.  The GO entries are hierarchically linked, thus allowing 
pooling and construction of cluster genes of crossed pathways.  The bias in the gene 
 12
representation (only a part of the genome is represented on the chip) could potentially 
lead to misleading conclusions.  To evaluate the statistical weight of each emerging 
cluster, we have used the updated version of GoMiner that is now able to process 
multiple comparison analyses (Zeeberg et al., 2003, http://discover.nci.nih.gov).  The 
statistical relevance of a candidate process found to be altered with drug resistance is 
therefore calculated in comparison to the overall processes that could be theoretically 
identified. 
 
Quantitative RT-PCR.  Real time PCR was performed with a Light Cycler RNA 
SYBR Green kit (Roche Biochemicals, Indianapolis, IN).  The reaction was in a 20 µl 
final volume with 0.150 µg of purified total RNA, 4 µl PCR mix provided by the 
manufacturer, 4 µl MgCl2 (25 mM), 2.5 µl of each primer (2 µM), 0.4 µl of enzyme mix 
and DEPC-H2O.  Optimized and specific primers were designed to produce a unique 
band for the 47 ABC transporters (Szakács et al., 2004).  The reverse transcriptase 
(RT) reaction was performed at 55°C for 20 min.  cDNA generated by the RT step was 
denatured at 95°C for 20 sec.  Amplification of the cDNA was achieved in 45 cycles of 
95°C, 5 sec; 58°C, 10 sec; 72°C, 13 sec.  Fluorescence was recorded during the 
elongation phase at 72°C.  
 
Western Blots.  Following SDS-Page electrophoresis on 6% acrylamide SDS-Page 
gels (Invitrogen, Carlsbad, CA), samples (50 µg) were electro-blotted on nitrocellulose 
membranes (Invitrogen).  Membranes were saturated with a 10%, fat-free milk solution 
(Giant Foods, Inc., Landover, MD), and then incubated overnight in the presence of an 
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anti-MRP2 primary antibody (M-8316, Sigma, St-Louis, MO) at 1:1000 dilution.  An 
HRP-conjugated secondary antibody (anti-rabbit Goat IgG (Jackson ImmunoResearch 
Laboratories, Inc., West Grove, PA) was applied for 1 hour at 1:2000 dilution.  ECL was 
purchased from Amersham (Pharmacia Biotech, Inc., Little Chalfond Bucks, UK).  
For GAPDH and GST-Pi, 12% SDS-Page gels were used (Invitrogen). Primary 
antibodies were anti-GAPDH RDI-TRK-5G4-6C5 (Research Diagnostic Inc., Flanders, 
NJ) at 1:1000 dilution and anti-GST-P IgG1 at 1:1000 dilution (BD Biosciences 
Pharmingen, San Diego, CA).  The secondary antibody was Goat-IgG anti-IgG Mouse 
HRP-conjugated (Jackson ImmunoResearch Laboratories, # IR-115-035-164) at 1:2000 
dilution.  
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Results 
Creation of a Hybrid cDNA/Oligo ABC-ToxChip to Study Drug Resistance.  
The ABC-ToxChip is a dedicated microarray to study the drug resistance of cancer 
cells.  The platform contains three distinct sets of probes (Fig. 1A).  The first set of 
probes targets 36 ABC transporters (70-mer oligonucleotides, and cDNA probes).  
Specificity and sensitivity was ensured by targeting each transporter with multiple 
probes (Table 1).  Since multidrug resistance can be regarded as a detoxification 
problem, we also applied the TOX-probes (Nuwaysir et al., 1999) that cover known 
detoxification genes involved in response to estrogens, polycyclic aromatic 
hydrocarbons, peroxisome proliferators, DNA damage and oxidant stress, as well as 
genes involved in apoptosis, cell cycle, tumor suppression, signal transduction and 
transcription.  To reduce the problem of sequence reliability encountered in 
commercially available cDNA clones (Knight et al, 2001), the probes (200-500 bp) of the 
TOX-set were derived from sequence-verified plasmids originally compiled at the 
National Institute of Environmental Health Sciences (NIEHS).  To avoid the risk of a 
biased analysis inherent to highly specialized microarrays, we completed the chip with 
18,000 probes (GEN-set) targeting the human transcriptome (Operon Inc., Alameda, 
CA).  To overcome the qualitative errors found on various platforms and to rule out 
possible cross-hybridization, we verified the specificity of the cDNA and 70-mer oligo 
sequences by extensive in silico analysis (not shown).  
Of the 18,398 probes represented by 16,329 oligo probes and 2069 cDNA 
probes matching a valid gene reference, 11,813 were annotated with HUGO references, 
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using the Source / Matchminer databases (Zeeberg et al., 2003).  The cDNA, or 
detoxification set has 1,394 probes with valid GO annotations, of which 1,152 are also 
represented in the GEN-set.  The distribution of gene ontology entries proves that the 
cDNA set is indeed enriched in genes related to detoxification processes.  For example, 
genes related to drug stress and DNA repair are highly represented in the cDNA TOX 
set (1.3% and 3.3% of the total genes, respectively), as compared to the GEN-set (0.3% 
and 0.6%, respectively).  
Validation of the ABC-ToxChip Using an Established Model of Resistance.  
To identify markers of resistance or sensitivity to colchicine, we compared two cell lines 
using the ABC-ToxChip.  KB-8-5 cells were derived from parental KB-3-1 cells by 
selection in colchicine (Akiyama et al., 1985).  RNA samples from the two cell lines were 
reverse transcribed, labeled with Cy3/Cy5 and hybridized to 4 ABC-ToxChip slides.  
After filtering the data for the most reliably differentially expressed genes with a 
statistical confidence of 95%, the comparison revealed 241 statistically significant 
variations (Table S1).  Among the four cross-labeled experiments, 98 hits (40.6%) 
appeared in all 4 replicate scans.  The rest (59.4%) were significant in only 3 of the 4 
replicate slides.  
In total we identified 13 differentially expressed genes associated with colchicine 
resistance with a ratio above 2.7 (Fig. 1C).  Among the 20,000 genes, ABCB1/P-gp 
showed the highest variation (10-fold fluorescence ratio) associated with colchicine 
resistance.  Closely related members of the same subfamily (ABCB2-3-4) showed only 
moderate (about 2-fold) changes, presumably due to cross-hybridization, confirming the 
improved specificity of our dedicated microarray for ABC transporters.  To verify the 
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patterns of ABC-expression detected by the microarray analysis, we measured the 
expression of 47 ABC transporters by real time RT-PCR.  The analysis confirms that 
ABCB1 (MDR1) shows the largest variation among the ABC transporters, while the 
expression of the other members is virtually unchanged (Fig. 1B).  Comparison of KB-3-
1 cells to KB-C1, a derivative showing extreme resistance (1 ug/ml) of colchicine 
showed the highest change in the expression of the same genes (log2ratio of 6.32 and 
–4.2 for ABCB1/MDR1 and GST-Pi, respectively, data not shown). 
 Increased expression of MDR1 (ABCB1) and the glycoprotein hormone subunit 
(GPH) was revealed by several independent probes (#M29447, #M37723 and #S70585, 
#W86681 for GPH and ABCB1, respectively).  The list of further upregulated genes 
include Interleukin 8, MHC-I, COX-2 and the Interferon stimulated protein, while GST-Pi, 
Calcium-binding protein A10, Voltage gated sodium channel and EGF-like domain 5 are 
markedly downregulated in KB-8-5 cells as compared to the sensitive cell line.  We 
used the information provided by HUGO to process the ab initio and hypothesis free 
GoMiner algorithm to detect biological processes that are represented by the 
differentially expressed genes and could possibly explain mechanisms leading to 
colchicine resistance.  
Among 241 statistically significant outlier genes (see Materials and Methods), we 
identified 125 unique HUGO entries (52%). Since the dedicated design of the 
microarray can introduce a bias in analysis, with, for example, an overrepresented class 
of detoxifying genes printed, we evaluated the significance of the results in the light of 
the global representation of the GO ontology annotation entries.  The GoMiner analysis 
indicates that expression of genes found to be altered by selection for colchicine 
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resistance is linked to antigen presentation and carbohydrate metabolism (P<0.0001). In 
Table S2, we present the statistically relevant biological processes that can be 
associated with colchicine resistance. In Table S3, we present the genes that belong to 
the altered gene ontology categories related to antigen presentation, carbohydrate 
metabolism, transport and oxydoreduction.  
Application of the ABC-ToxChip to Study 9-nitro-camptothecin Resistance.  
We next turned our attention to RCO.1, a prostate cell line selected in 9NC, where 
mechanisms leading to the resistant phenotype have not been fully understood. This 
cell line was created by selecting parental DU-145 cells in 0.1 µM 9-nitro-camptothecin 
(Urasaki et al., 2001).  RCO.1 presents a unique profile of multidrug resistance with a 
selective resistance to camptothecin analogs, NB-506 (an inhibitor of topoisomerase I) 
and cisplatin, while being sensitive to drugs known to be exported by ABCB1-MDR1 or 
ABCC1-MRP1 (Chatterjee et al., 2001).  Several laboratories have attempted to 
elucidate this atypical profile of resistance:  a mutation of topoisomerase I, preventing 
the binding of camptothecin analogs (Chatterjee et al., 2001) and an alteration of the 
apoptotic pathway (Chatterjee et al., 2001; Reinhold et al., 2003) have been proposed 
as explanations.  However, an exhaustive analysis of ABC transporters or genes 
involved in detoxification has not been reported to date.  To explore the role of ABC 
transporters and other detoxifying genes in 9NC resistance, we compared the mRNA 
expression profiles of DU-145 and RCO.1 cells using the ABC-ToxChip.  Total cellular 
RNA was extracted from both cell lines.  Since the phenotype of acquired 9NC 
resistance is stable without the pressure of selection, RNA was collected from cells 
cultured in drug-free medium.  Microarray experiments were performed as described 
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previously for the KB cells.  To control for labeling differences, reactions were carried 
out in quadruplicate, and the fluorescent dyes were switched.  
The list of the most significant differentially expressed genes is shown in Figure 
1C and in Table S4.  Among the 20,000 genes, ABCC2-MRP2 shows one of the highest 
variations associated with 9NC resistance.  First named the canalicular multispecific 
organic anion transporter (cMOAT), ABCC2-MRP2 is a 190-kDa phosphoglycoprotein 
localized in the canalicular (apical) membrane of hepatocytes.  It is involved in the 
transport of organic anions, including sulfated and glucuronidated bile salts.  
Overexpression of MRP2 has been suggested to confer resistance to anti-cancer drugs 
such as cisplatin, anthacyclines, and methotrexate, and animal models have shown 
reduced hepatic transport of camptothecins (Horikawa et al., 2002).  
Gamma-glutamylcysteine synthetase (GCS), also known as glutamate cysteine 
ligase, a key enzyme in glutathione metabolism, was coordinately up-regulated with 
MRP2, in keeping with the findings that MRP2 exports glutathione conjugates 
(Paulusma et al., 1996).  In contrast, despite its general up-regulation in cancer cells, 
the expression of GST-Pi, catalyzing the conjugation of glutathione to electrophilic 
carcinogens, was significantly reduced in RCO.1 cells, as it was in the colchicine-
selected KB cells.   
Additional changes which might contribute to the pattern of drug resistance in 
RCO.1 cells were also observed.  The up-regulation of various histones in the selected 
cells may provide means for the cells to adapt to the 9NC-mediated DNA insult.  Further 
changes associated with drug resistance include reduction in the tumor-associated 
antigen L6 (transmembrane super family 4 or TM6).  TM6 is also found to be down-
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regulated in cisplatin-resistant cells (KB/cDDP) (Higuchi et al., 2003), indicating that the 
loss of TM6 expression is potentially associated with resistance to camptothecin and 
cisplatin.  Of the genes presented in Table S4, the decreased expression of GST-Pi, 
NKT4 and Interleukin-4 in RCO.1 cells was also observed by an independent 
microarray analysis (Table 2), which however failed to detect the overexpression of 
ABCC2-MRP2.  
Although 85 of the 125 outliers (68%) have a HUGO reference, the GoMiner 
algorithm did not suggest specific biological processes to be significantly linked to 
camptothecin resistance.  (See tables S5 and S6 for the biological processes and their 
associated genes linked to camptothecin resistance.)  
We next sought to determine whether the differential expression of ABCC2-
MRP2 and GST-Pi could be confirmed by quantitative RT-PCR.  The results show that 
among the 47 ABC transporters, ABCC2-MRP2 is overexpressed in the resistant cell 
line, while the expression of the other members is unchanged (Fig. 2A).  Since mRNA 
levels may not reflect protein expression, due to modulation of translation or inhibition of 
protein processing, we analyzed the expression of MRP2 and GSTPi at the protein 
level.  Fig. 2C shows that the protein expression of these two genes follows the pattern 
predicted by the RNA analyses:  In the RCO.1 cells, GST-Pi is down-regulated and 
ABCC2-MRP2 is up-regulated as compared to the parental line. 
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Discussion 
In this report, we present a new microarray design and analysis to study 
multifactorial drug resistance.  We have designed and synthesized probes to match 36 
of the 48 ABC transporters to print them on a platform enriched in genes involved in 
detoxification, as well as a general set of 18,000 human gene probes (the ABC-
ToxChip).  To increase at the same time sensitivity and specificity for genes involved in 
drug resistance, we combined on the same chip both cDNA and oligos probes.  This 
approach provides an example of how existing microarray platforms may be modified to 
target a gene family with high sensitivity and specificity to study multidrug resistance of 
cancer.  In this study, we confirm that overexpression of ABCB1 is a principal 
component of the genetic changes underlying colchicine resistance.  KB-8-5 cells 
express ABCB1-MDR1 at a moderate level, comparable to that found in clinical 
samples.  We had made several earlier attempts to identify the molecular signature of 
colchicine resistance, using a 9K cDNA microarray platform (UniGemV2, Advanced 
Technology Center, NIH, Gaithersburg, MD).  The UniGemV2 chip failed to identify the 
overexpression of ABCB1-MDR1 and suggested, incorrectly, that the main outlier is 
ABCB2, a protein closely related to ABCB1 (not shown).  ABCB2-TAP1 is a component 
of the ER transport system for peptide antigen presentation and is not believed to play a 
role in the efflux of cytotoxic compounds, and, in fact, was not actually overexpressed in 
KB-8-5 cells.  
Analysis of a prostate cancer cell line (RCO.1) indicated the potential role of 
ABCC2/MRP2 in 9NC resistance.  Previous studies have shown that the resistance of 
RCO.1 cells was also due to a mutation in the Topoisomerase 1 gene (Urasaki et al., 
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2001) and to a defect in apoptosis pathways (Reinhold et al, 2003; Chatterjee et al., 
1996), suggesting that resistance to camptothecin is multifactorial.  Previous attempts to 
elucidate mechanisms leading to campthotecin resistance included microarray analyses 
of parental DU145 cells and RCO.1 cells (Reinhold et al., 2003), using a UniGem 
microarray.  Despite the high expression of ABCC2/MRP2 in the resistant cells (Fig. 
1C), it’s overexpression wasn’t detected in these earlier studies.  Taken together, these 
findings suggest that the specific targeting of ABC transporters in dedicated, custom-
made arrays may improve the specificity and sensitivity of earlier generation 
microarrays.  Typical shortcomings of microarray platforms may be attributed to 
imperfect clone annotation as well as the lack of specificity of probes targeted at 
overlapping or homologous sequences of closely related proteins, such as ABCB1 and 
ABCB2.  These considerations prompted us to create our own, dedicated microarray 
platform.  In order to ensure specificity, we designed probes uniquely matching the 
target transporters.  The ABC-ToxChip analysis of cells selected in colchicine and 9NC 
demonstrate the elevated expression of ABCB1 and ABCC2, respectively.  Since gene 
expression levels obtained by even the most carefully designed microarrays must be 
validated by independent methods, we also designed specific primers for the human 
ABC transporters (Szakács et al, 2004).  The quantitative RT-PCR data confirmed the 
pattern of ABC transporter expression and suggested that there are no further ABC 
transporters differentially expressed in the cells analyzed in this study.  Through the 
systematic analysis of ABC transporters and other genes of detoxification, our data 
provide novel information about the effect of 9NC selection on gene expression.  
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While the GoMiner algorithm did not identify major biological processes linked to 
9NC resistance, the list of differentially expressed genes may provide some insight into 
mechanisms underlying (or accompanying) resistance.  An interesting example is 
Radixin, which is overexpressed in the 9NC selected cell line.  Radixin belongs to the 
ERM (Ezrin-Radixin-Myosin) protein complex, and is involved in localization of integral 
membrane proteins.  Radixin -/- mice have Dubin-Johnson-like symptoms (Kikuchi et al, 
2002), because MRP2 is not properly localized to the plasma membrane.   
 The coordinated expression of phase II (conjugating) and phase III (efflux) 
systems has been shown to improve cellular detoxification (Morrow et al., 2000).  We 
found significant changes in the expression of two glutathione metabolism-related 
genes.  GST-Pi is involved in coupling electrophilic drugs to reduced glutathione, and 
GCS is the rate-limiting enzyme for glutathione synthesis.  Neither GST-Pi mRNA nor 
the protein is detectable in the resistant cell line.  This observation is striking given the 
association of high GST-Pi levels found in several resistant tumors and cell lines (Liu et 
al., 2001; Tew, 1994).  In contrast, gamma glutamate cysteine synthetase (GCS) is 
overexpressed in the camptothecin resistant cells, as shown both by oligo and cDNA 
probes (see Fig. 1C).  The changes in GST-Pi, GCS and ABCC2 expression suggest a 
putative “metabolic switch” necessary for resistance.  As shown in Fig. 2B, these 
enzymes play a role in the pathway of glutathione-mediated detoxification. Consistently, 
two further genes belonging to the “Cysteine metabolism” ontology group (Table S4) 
show differential expression (cystathioneine gamma-lyase and glutamate cyteine-ligase, 
Table S6).  
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Camptothecin resistance has been associated with the elevated expression of 
ABCG2-MXR (Brangi et al., 1999), which was observed in a sub-line of the human 
ovarian cancer cell line, A2780, selected against an analog of camptothecin:  DX-8951f 
(van Hattum et al., 2002).  Our results do not show elevated ABCG2 expression in 
RCO.1 cells, and suggest that ABCC2 may be involved in part of the resistant 
phenotype.  Consistent with our findings, previous studies have reported MRP2 as a 
detoxifying transporter for camptothecin in animal models (Arimori et al., 2003) and cell 
lines transfected with antisense MRP2 (Koike et al., 1997).  Since resistance of RCO.1 
against 9NC was shown to be partially mediated by mutations in topoisomerase I, we 
speculate that the elevated expression of ABCC2 may play a role during the initial steps 
of the selection process.  This early adaptation may provide the background for the 
evolution of further resistance mechanisms, such as mutation of topoisomerase 1 or 
loss of the expression of other topoisomerase(s) 1 genes (Urasaki et al., 2001). 
 Retroviral transfer of ABCC1 (MRP1) has been shown to result in decreased 
intracellular glutathione levels and increased sensitivity to BSO (Rappa et al., 2003). 
Furthermore, in vitro reversal of MRP1-mediated resistance and in vivo potentiation of 
the cytotoxicity of doxorubicin in MRP1-overexpressing tumors by BSO were previously 
reported (Rappa et al., 2003).  In an analogous fashion, consistent with the capacity of 
ABCC2 to export glutathione conjugates (Konig et al., 1999), RCO.1 cells also proved 
hypersensitive to BSO treatment (data not shown).  It is conceivable that the 
coordinated expression of MRP2 and GCS occur as the cells adapt to the cytotoxic 
stress.  Since the maintenance of glutathione levels is critical for the survival of the 
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cells, overexpression of GCS may represent an adaptive response compensating for 
the loss of intracellular glutathione in the RCO.1 cells. 
In conclusion, we have used a novel ABC-ToxChip to show the overexpression 
of two ABC transporters in two different cellular models of drug resistance.  In both 
cases, ABC transporter overexpression occurs at the level of transcription and is 
prominent when compared to the pattern of expression of 18,000 other genes.  Our 
results reinforce our interest in following the expression of ABC transporters as specific 
markers of acquired drug resistance.  The ABC-ToxChip should be a helpful tool to 
assess the role of ABC transporters, and how their expression is linked to other 
detoxification genes in various pathophysiological processes, such as drug resistance, 
not only in tissue culture models, but in clinical samples as well. 
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TABLE 1   
 
ABC probes printed on the ABC-ToxChip 
 
Probea         ABC                 Gene bank       Matching        Probea        ABC                Gene bank          Matching 
                    transporterb      identifierc           exon                                transporterb      identifierc             exon 
 
OLIGO ABCA1 NM-005502.1    OLIGO ABCC3 NM-003786.2    
CDNA ABCA1 XM-050009.5   cDNA  ABCC3 AJ294547.1 exon 3 
OLIGO ABCA2 AF178941.1   cDNA  ABCC3 AJ294559.1 exons 20-23 
OLIGO ABCA3 NM-001089.1     cDNA  ABCC3 AJ294558.1 exon 19 
cDNA  ABCA3 XM-028843.2   cDNA  ABCC3  NM-020038.1     
OLIGO ABCA4 NM-000350.1    OLIGO ABCC4 NM-005845.1    
cDNA  ABCA4 Y15644.1 exon 10  cDNA  ABCC4 XM-036453.1   
cDNA  ABCA4 Y15676.1 exon 42  cDNA  ABCC4 AF071203.1  
cDNA  ABCA5 NM-018672.1      cDNA  ABCC4 U66686.1  
cDNA  ABCA5 XM-057257.3   cDNA  ABCC4  AF071202.1  
OLIGO ABCA8 NM-007168.1    OLIGO ABCC5 NM-005688.1    
cDNA  ABCA12 NM-015657.1      cDNA  ABCC5 BC007229.1  
OLIGO ABCB1 NM-000927.2     cDNA  ABCC5 AF146074.1  
cDNA  ABCB1 M29426.1 exon 4  cDNA  ABCC5 AB005659.1  
 cDNA  ABCB1 M37723.1 exon 6  cDNA  ABCC5 XM-002914.6  
 cDNA  ABCB1 XM-029059.2   OLIGO ABCC6 NM-001171.2    
 cDNA  ABCB1 M29447.1 exon 28  cDNA  ABCC6 AF076622.1  
OLIGO ABCB2 NM-000593.2     cDNA  ABCC6 AF168791.1  
 cDNA  ABCB2 U07198.1 exon 4,  cDNA  ABCC6 NM-001171.2   
 cDNA  ABCB2 S70260.1  OLIGO ABCC7 NM-000492.2    
 cDNA  ABCB2 NM-000593.3      cDNA  ABCC7 M55109.1 exon 4 
OLIGO ABCB3 NM-000544.2     cDNA  ABCC7 M55032.1 exon 19 
 cDNA  ABCB3 XM-165824.1   cDNA  ABCC7 XM-004980.4  
OLIGO ABCB4 NM-018850.1    OLIGO ABCC8 NM-000352.2    
 cDNA  ABCB4 XM-167466.1  OLIGO ABCC9 NM-005691.1    
 cDNA  ABCB5 XM-166496.1      cDNA  ABCC11 NM-032583.2  
OLIGO ABCB6 NM-005689.1     cDNA  ABCC12 NM-033226.1  
 cDNA  ABCB6 BC000559.1  OLIGO ABCD1 NM-000033.2    
 cDNA  ABCB6 XM-050891.4      cDNA  ABCD1  BC025358.1  
OLIGO ABCB7 NM-004299.2    OLIGO ABCD2 NM-005164.1    
cDNA  ABCB7 XM-032877.2     OLIGO ABCD3 NM-002858.2    
OLIGO ABCB8 XM-032165.2     cDNA  ABCD3 BC009712.1  
 cDNA  ABCB8 XM-032165.5  OLIGO ABCD4 NM-005050.1    
OLIGO ABCB10 NM-012089.1     cDNA  ABCD4  NM-020326.1  
 cDNA  ABCB10 XM-001871.4     OLIGO ABCE1 NM-002940.1  
OLIGO ABCB11 NM-003742.1     cDNA  ABCE1 XM-003555.9  
OLIGO ABCC1 NM-019902.1    OLIGO ABCF1 NM-001090.1  
 cDNA  ABCC1 AF022824.1 exon 2  cDNA  ABCF1 BC016772.1  
 cDNA  ABCC1 AF022826.1 exon 4 OLIGO ABCF2 XM-039075.1  
 cDNA  ABCC1 AF022830.1 exon 8  cDNA  ABCF2 BC001661.1  
 cDNA  ABCC1 AF022853.1 exon 31   cDNA  ABCF3 NM-018358.1  
 cDNA  ABCC1 AJ003198.1  OLIGO ABCG1 NM-004915.2  
 cDNA  ABCC1 NM-019902.1    cDNA  ABCG1  XM-032950.3  
 cDNA  ABCC1 AF022830.1 exon 8 OLIGO ABCG2 NM-004827.1  
OLIGO ABCC2 XM-050760.1     cDNA  ABCG2 XM-032424.1  
 cDNA  ABCC2 AJ132306.1 exon 23  cDNA  ABCG2 AF098951.2  
 cDNA  ABCC2 AJ245627.1 exon 26  cDNA  ABCG4 lo XM-012099.8  
 cDNA  ABCC2  U63970.1  
 
 cDNA  ABCG8 NM-022437.1  
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aOligo indicates that the probe is a single-stranded, 70 mer oligonucleotide; cDNA indicates the 
probe is a fragment of double-stranded DNA amplified by PCR. 
bABC transporters are named using the HGNC nomenclature 
(http://nutrigene.4t.com/humanabc.htm).  
c The probes are named after the closest matching RefSeq entries (National Center for 
Biotechnology Information (NCBI), e.g., C3 (NM-003786, AJ294547.1, AJ294559.1, AJ294558.1).  
The exon most closely matching the sequence is indicated. 
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TABLE 2  
Differentially expressed genes identified by two independent microarray analyses (ATC-DU-145 
versus RCO.1) 
 
Clone ID HCNG 
reference 
Gene description Ratio R/Sa 
Reinhold et al., 
2003 
Ratio R/Sa 
Present studyb 
       
266146 CYP24A1 Cytochrome P450 XXIV 12.66 NA (1.91) 
429091 H2A1 Histone 2A like protein (H2A-I) 6.93 NA (2.70) 
376370  EGR-Early Growth response protein 5.22 1.94( NA ) 
209156 DAD1 Defender against cell death 2.29 NA (1.91) 
774710 GSTP1 Glutathione-S-tranferase Pi 0.12 0.12 ( 0.03) 
810859 NK4 Natural killer cells protein-4 0.13 NA (0.25) 
328692 IL8 Interleukin 8 0.13 NA (0.26) 
840683 CIN Cytokine inducible nuclear protein 0.23 NA (0.45) 
 
aRelative expression, resistant versus sensitive (R/S)  
bRelative expression based on oligo and cDNA probes. Results based on cDNA probes are shown in 
parentheses.  NA, not applicable. 
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Figure Legends 
 
Fig. 1. Creation and application of the ABC-ToxChip.  A, Details of a scan of the ABC-
ToxChip . The section shown is one of the 32 blocks printed. The platform has 4 x 8 
such blocks, each containing 625 (25 x 25) slots, yielding in total 20,000 probe-slots 
available for printing. The upper part of the block contains the oligo-set, and the lower 
part bears the cDNA probes matching the detoxification set. The probes specifically 
matching the ABC transporters are printed in the lowest row. B, Quantitative RT-PCR to 
follow transcriptional changes of ABC transporters and GST-Pi. Crossing point values of 
amplification for 47 ABC transporters and GST-Pi in the two samples are shown in a 
scatter plot. Deviations greater than 2 cycles are considered significant. Results 
demonstrate activation of MDR1 and downregulation of GST-Pi with colchicine 
resistance. C, Significant outliers (>2.7 fold) identified by the microarray experiments. 
ABC transporters appear as major outliers in both analyses, suggesting their strong 
contribution to the MDR phenotype. Genes where the variation was confirmed by more 
than one probe are indicated in grey. Arrows point out the most drastic changes 
discussed in this paper (i.e. GST and ABC transporters).  OL and cD refer to oligo and 
cDNA probes, respectively. n defines the number of experiments (out of 4 replicates) 
where gene expression is found significantly altered. C.R. (calibrated ratio) indicates the 
fold of difference of expression between the resistant cell line versus the parental cell 
line.  
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Fig. 2.  Overexpression of ABCC2 and downregulation of GST-Pi with 9NC selection.  
A, Confirmation of the overexpression of ABCC2, and down-regulation of GST-Pi with 
9NC selection by quantitative RT-PCR. Crossing point values of amplification for 47 
ABC transporters and GST-Pi in the two samples are shown in a scatter plot.  B, 
Illustration of the role of ABCC2, GST and GCS in the glutathione-related detoxification 
pathway. The concentration of glutathione is regulated by its metabolism (GSH–GSX, 
GSH-GSSG) and biosynthesis, catalyzed by GST and GCS, respectively, and the 
activity of ABCC2.  C, Correlation between the mRNA and protein levels. The symbols 
S and R correspond to the sensitive (ATC-DU-145) and resistant cell line (RCO.1), 
respectively. The signal for GST-Pi in the resistant cell line was below the level of 
detection.  
 
 
 
 
AcD
NA
O
lig
o
s
KB-3-1 versus KB-8-5 ATC-DU-145 versus RCO.1
Gene ID n Description of up-regulated genes C.R. Gene ID n Description of up-regulated genes C.R.
OL M29447 3 Human P-glycoprotein [MDR1] gene, exon 28 14.8 OL U70312 3 EGF-like repeats and discoidinI-like domains 3 12.50
OL S70585 4 Glycoprotein hormone, alpha polypeptide 13.5 OL AJ132306 4 HSA132306 MRP2  gene, exon 23"" 12.32
cD W86681 4 Glycoprotein hormone, alpha polypeptide 13 cD 376184 4 Insulin-like growth factor binding protein 3 6.88
OL M37723 3 Human MDR1/P-glycoprotein gene, exon 6 11.3 OL M38591 4 S100 calcium-binding protein A10 5.79
OL M29426 3 Human P-glycoprotein [MDR1] gene, exon 4 9.39 cD 308366 3 Folate receptor 1  5.13
cD W45324 4 Interleukin 8 7.19 OL J02763 4 S100 calcium-binding protein A6 4.65
OL X15422 3 Mannose-binding lectin 2 4.5 OL X60484 3 H4 histone family, member E 4.37
OL X58536 4 Major histocompatibility complex, class I, C 3.86 OL U05598 4 Aldo-keto reductase family 1, member C2 4.27
OL AF071596 4 Immediate early response 3 3.83 OL AB032261 4 Stearoyl-CoAdesaturase 4.07
OL M80469 4 MHC class I HLA-J gene, exons 1-8 3.74 OL U28369 3 Sema domain, immunoglobulin domain  3B 3.90
OL M12758 4 MHC class I HLA-A24 gene, exons 4,6-8 3.19 OL M30704 4 Amphiregulin 3.35
cD R80217 4 Cyclo oxygenase 2 2.99 cD 203721 4 Glutamate cysteine ligase , catalytic 3.01
OL M13755 4 Interferon stimulated protein 2.98 OL M76231 3 Sepiapterin reductase 2.96
OL X05908 4 Annexin A 1 2.82
Gene ID n Description of down-regulated genes C.R. Gene ID n Description of down-regulated genes NCBI C.R.
OL M38591 3 S100 calcium-binding protein A10 0.37 OL Y11307 3 Cysteine-rich, angiogenic inducer, 61 0.36
cD AA040702 4 Phosphoglyceratemutase 1 [brain] 0.36 OL X04741 3 Ubiquitin carboxyl-terminal esterase L1 0.35
OL AF225985 3 Sodium channel, voltage-gated, type I 0.36 cD 110503 4 Fos Related Antigen 1 0.35
cD R33755 4 Glutathione-S-transferase-Pi 0.35 cD 484963 4 Metallothionein from cadmium treated cells 0.33
OL AB011542 3 EGF-like-domain, multiple 5 0.35 OL M24283 3 Intercellular adhesion, human rhinovirus receptor0.32
OL U12472 3 Glutathione-S-transferase-Pi 0.06 OL M90657 4 Transmembrane 4 super family member 1 0.32
OL S52784 3 Cystathionase 0.31
cD 328692 4 Interleukin 8 0.26
OL AJ270993 4 Homeobox B6 0.25
OL M59807 3 Natural killer cell transcript 4 0.25
OL X16172 4 Human HOX-2.5 gene for homeodomain protein 0.17
cD 136235 4 Glutathione-S-transferase-Pi 0.12
OL U12472 4 Glutathione-S-transferase-Pi 0.03
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